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Abstract 
 
Adenosine to inosine editing of RNA is a widespread posttranscriptional mechanism 
increasing the variety of the transcriptome in metazoa. Adenosine deamination is performed 
by adenosine deaminases that act on RNA (ADARs). A to I editing can change codons or 
splice patterns and lead to a higher diversity in protein isoforms. Additionally ADARs play an 
important role in miRNA biogenesis, stability and choice of their silencing target. 
Most known coding editing substrates are the transcripts of proteins expressed in the central 
nervous system like: glutamate receptors, serotonin 2C receptor or gamma-aminobutyric acid 
type A receptor. Not surprisingly, changes in editing patterns at some of these sites are linked 
to neurodegenerative diseases like: schizophrenia, depression or ALS (amyotrophic lateral 
sclerosis) and also to brain tumours. It is important to learn how the activity of ADARs is 
controlled in attempt to cure some of these diseases. 
Although much is known about function and activity of the enzymes, regulation of A to I 
editing is not well understood so far. Some ADAR isoforms are regulated at the 
transcriptional level but an increasing amount of evidence suggests other mechanisms of 
regulation in addition. 
The aim of this thesis was answering some of the open questions concerning the regulation of 
ADAR activity. A functional yeast in vivo editing system was developed and successfully 
employed in identification of cellular enhancers of RNA editing. In this screen the protein 
DSS1 could be identified as strong enhancer of editing. The properities of this protein were 
confirmed in the mammalian context on various editing substrates proving the functionality of 
the developed screening system. 
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Zusammenfassung 
 
Adenosin Deaminierung von Ribonukleinsäure (RNA) ist ein weitverbreiteter Mechanismus 
auf posttranskriptioneller Ebene, der zu einer massiven Zunahme der Variabilität des 
Metazoentranskriptoms führt. Die A zu I Editierung wird von sogenannte Adenosin 
Deaminasen (ADARs = adenosine deaminases that act on RNA) durchgeführt. Diese 
Deaminierungen führen zu Veränderungen von Kodons und Spleißmustern und bewirken 
dadurch eine Steigerung der Zahl von Protein-Isoformen. Zusätzlich spielen ADARs eine 
wichtige Rolle in der Biogenese, Stabilität und der Zielmolekülauswahl von mikroRNA 
(miRNA) Molekülen. 
Die meisten bekannten kodierenden Substrate für ADARs sind Transkripte von Proteingenen, 
die im Zentralnervensystem exprimiert werden. Darunter fallen z.B.: Glutamatrezeptoren, der 
Serotonin 2C Rezeptor oder Gamma-Aminobutiryl-Säure Typ A Rezeptor. Nicht 
überraschend sind Veränderungen im Editierungsmuster einiger dieser Zielsequenzen mit 
neurodegenerativen Erkrankungen verbunden, wie z.B. Depression, Schizophrenie oder ALS 
(Amyotrophe laterale Sklerose) sowie Hirntumoren. Daher ist es entscheidend mehr über die 
Aktivitätskontrolle von ADARs zu erfahren, um etwaige Therapieansätze zu entwickeln. 
Die Funktionen und Aktivitäten von Deaminasen sind sehr gut bekannt, Mechanismen der 
Regulation von A zu I Editierung sind bisher jedoch noch sehr wenig untersucht. Die 
Regulation einiger ADAR Isoformen passiert auf transkriptioneller Ebene, es gibt aber 
zunehmend Hinweise darauf, dass es noch weitere Regulationsmechanismen gibt. Die 
Aufklärung einiger solcher Regulationsmechanismen war das Hautpziel dieser 
Dissertationsarbeit. 
Zu diesem Zweck wurde ein in vivo Editing System in Hefe entwickelt, mit dessen Hilfe es 
möglich war, zelluläre Verstärkermoleküle im RNA-Editierungsprozess zu identifizieren. Das 
Protein DSS1 wurde dabei als besonders aktiver Verstärker isoliert. Die Eigenschaften von 
DSS1 wurden anschließend in einem Expressionssystem im Säugerhintergrund an 
unterschiedlichen Editierungssubstraten bestätigt, wodurch auch die Funktionalität des neu 
entwickelten Screening Systems bewiesen werden konnte. 
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1 Introduction
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1.1 Eucaryotic RNA processing 
 
The beginning of the new millennium has coincided with the completion of the human 
genome sequence, an event that brought a very surprising outcome. Suddenly a human 
genome of 100.000 predicted genes shrunk to only to 23.000 confirmed ones (Venter, Adams 
et al. 2001; 2004). It brought down the amount of protein coding fragments of the genome to 
1.5% of its size and rose a few fundamental questions. How is the complexity of the human 
organism achieved with such a small number of protein coding genes? What makes such a 
significant differences between organisms if the difference in number of protein-coding genes 
is not enough to create it? These questions have opened the door for many scientist and many 
already old but neglected findings to surface. At last the central dogma of genetics stating: 
one gene = one polypeptide has fallen. The eyes of the scientist worldwide has turned towards 
non-coding RNAs and RNA modifications as the true agents behind the complexity of the 
human transcriptome and proteome. 
In contrary to prokaryotic messenger RNA eukaryotic mRNA is transcribed from 
genomic DNA as an unfinished product. It has to undergo three main processes before it can 
be translated into a protein, which are; 5’-capping, 3' polyadenylation, and RNA splicing. 
Already these processes being studied in the late 60s and 70s of the last century gave us 
insights on how a diversity in the transcriptome can be introduced. RNA splicing is the most 
remarkable of these RNA processing mechanisms discovered already 30 years ago (Chow, 
Gelinas et al. 1977). It occurs in all eukaryotic pre-mRNA containing coding regions (exons) 
and non-coding (introns) which are removed during the splicing process. Not every intron is 
spliced-out with the same efficiency and additionally many times also the exons are being cut 
out along with them. These occurrences introduce diversity among proteins. In addition to 
alternative splicing, various promoters and polyadenylation sites generate diversity in protein 
expression. Moreover, different kinds of single nucleotide modifications, and RNA editing 
contribute to protein diversity (Karijolich, Kantartzis et al. 2010). 
 
1.2 RNA modifications 
 
Beside the well known and understood post-transcriptional RNA modifications like 7-
methylguanosine (m7G) cap and poly-adenosine tail additions to 5’ and 3’ ends of mRNA, 
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respectively, or CCA trinucleotide addition to tRNA there are many other chemical nucleotide 
modifying processes. These kinds of RNA modifications are widespread, very common in 
cellular RNA and have been known already for decades. 
Over 100 different RNA modifications have been characterized to date with the largest 
number of them found in tRNA, followed by rRNA (Grosjean, Auxilien et al. 1996). A few 
main characteristics of these modifications are interesting and striking. They are introduced in 
a very site-specific manner and are widely conserved across phylogenetic lineages. Even 3-
10% of all proteins spanning from bacteria to higher eukaryotes are devoted to RNA 
modifications what would highly suggest an important function of single one of them 
(Anantharaman, Koonin et al. 2002; Ferre-D'Amare 2003). 
RNA particles containing the most nucleotide modifications are tRNAs, where up to 80 
different types of modifications affect 25% of all nucleotides. Most abundant are; 
dihydrouridine (D) and pseudouridine (Ψ) with secondary structures like D loop and TΨC 
loop named after them respectively (Bjork, Ericson et al. 1987). Most of the modifications 
present in rRNA particles are methylations at over 100 sites in higher vertebrates, from which 
80% are 2´-O-ribose methylations. Additionally, up to 100 uridines in human pre-rRNA are 
converted into pseudouridines (Ψ). Interesting is that in case of rRNA all modifications are 
performed by the RNA-guided nucleotide modification mechanism, where snoRNAs (small 
nucleolar RNAs) containing segments precisely complementary to conserved regions in 
rRNA. The snoRNAs guide proteins, that are the second constituent of the snoRNP particle, 
performing the modification reaction (Decatur and Fournier 2003). 
 
1.3 RNA editing 
 
Another posttranscriptional RNA modification is RNA editing. RNA editing alters 
information transcribed from DNA via a more or less precise change in a single or several 
nucleotides within an RNA molecule. It is widespread in all eukaryotic organisms and 
depending on the organism it involves different molecular mechanisms like: insertion or 
deletion of nucleotides or base modification. Some of the RNA editing function as a repair or 
correction mechanism of the information encoded in DNA and some simply introduce 
additional diversity to the pool of the proteins possibly offering organisms a higher 
complexity. RNA editing may alter codon information, introduce or destroy a stop codon, or 
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change a translation product of the mature mRNA. By creating or destroying a splice site or 
regulatory sequence editing can alter splicing or the effectiveness of it. RNA editing may also 
simply alter the stability of the RNA particle and its tertiary structure (Gott and Emeson 2000; 
Bass 2002). In addition, RNA editing can affect RNAi pathways in major ways (Nishikura 
2006). 
 
1.3.1 Deletion and insertion RNA editing 
 
Deletion and insertion RNA editing was the first type of editing discovered. In the 
1980s in the cytochrome oxidase gene coxII of Trypanosoma brucei the first example of 
uridine insertion was found, with four of them frame shifting the whole transcript in a way 
that gives rise to a functional protein (Benne, Van den Burg et al. 1986). Most mitochondrial 
mRNAs of kinetoplastid protozoa often undergo extensive RNA editing, by which precursor 
mRNA sequence is changed by the insertion, and less frequently, the deletion of uridine 
nucleotides (Us). This can create methionine translation initiation codons, correct frameshift 
mutations, or even give rise to new open reading frames (Feagin, Abraham et al. 1988; 
Maslov and Simpson 1992; Alfonzo, Thiemann et al. 1997). 
The edited mRNAs are translated into components of the oxidative phosphorylation 
system and are essential for functioning of the mitochondria. To achieve this, the 
mitochondrial genome consists of 50 identical 22kb large mitochondrial DNA (maxicircle) 
and of 10000 heterogeneous 1kb small mitochondrial DNA (minicircle). Pre-mRNA is 
encoded by maxicircles whereas minicircles encode 50-70nt trans-acting guide RNAs 
(gRNAs) (Stuart, Schnaufer et al. 2005). Guide RNAs encode the proper protein information 
and by its 5’-anchor complementary sequence binding to pre-mRNA downstream of the 
editing site guide the process. The information about inserted or deleted uridines is placed in 
the middle of gRNAs (Blum and Simpson 1990; Simpson, Sbicego et al. 2003). Editing is 
catalyzed by multiprotein complexes that have been largely characterized. Editing occurs by a 
series of coordinated catalytic steps: cleavage, insertion or deletion and ligation. Uridines are 
either added by a TUTase in insertion editing or removed by an ExoUase in deletion editing 
(Stuart, Schnaufer et al. 2005). 
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1.3.2 Ribonucleotide deamination 
 
Right after the discovery of editing in Trypanosoma brucei evidences of different kind 
of editing resurfaced in higher eukaryotes. A year later C to U editing was discovered in mice 
and at the end of the 1980s A to I editing discovery in Xenopus leavis eggs followed (Bass 
and Weintraub 1987; Rebagliati and Melton 1987). Both of these RNA modifications are 
based on ribonucleotide deamination, cytidine to uracyl in the former and adenosine to 
inosine in the latter. This type of editing is widespread and common in all higher eukaryotes. 
 
1.3.2.1 Cytidine to Uridine RNA editing 
 
The discovery of transcripts of apoliprotein B (ApoB) being edited more than 20 years 
ago in the mouse intestine was the first observed example of RNA editing in vertebrates 
(Chen, Habib et al. 1987; Powell, Wallis et al. 1987). ApoB is a component of the plasma 
lipoproteins and is necessary for transport of cholesterol and triglycerides in it (Chan 1992). 
There are two forms of ApoB: long ApoB100 and short ApoB48 isoforms. Expression of 
ApoB48 is a result of C to U deamination of C
6666
 in the mature transcript which creates a 
premature stop codon (CAA to UAA). 
In humans this deamination occurs only in the small intestine but not the liver and 
therefore ApoB48 is expressed only in the former tissues (Greeve, Altkemper et al. 1993). 
ApoB100 is required for assembly of VLDL complex (very low density lipoprotein) required 
for the transport of endogenously synthesized cholesterol and triglycerides in the blood 
stream. VLDL is later metabolized to IDL (intermediate-density lipoprotein) and then to LDL 
particles (low density lipoprotein). Increased plasma level of LDL is coupled with higher risk 
for coronary heart disease. LDL is removed from blood stream by LDL receptors via the C-
terminus of ApoB. ApoB48 generated in small intestine lacks this C-terminus and is 
necessary for synthesis of chylomicrons, large lipoprotein complexes of the intestines. These 
huge particles cannot be converted into LDL particles and, therefore, represent lower risk 
factor for acquiring cardiovascular disease (Herz and Willnow 1995; Chang, Olin et al. 1998). 
Additional two known substrates of C to U editing are: neurofibromatosis type 1 (NF1) 
and eukaryotic translation initiation factor 4 gamma 2 (eIF4G2) mRNAs. NF1 RNA editing 
generates a translational termination codon at position 3916 that is predicted to truncate the 
protein product. The translational repressor eIF4G2 undergoes C to U editing at multiple sites, 
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with the creation of stop codons, that in turn reduce protein abundance (Yamanaka, Poksay et 
al. 1997; Cichowski and Jacks 2001). 
A protein responsible for the deamination of these substrates is a cytidine deaminase 
APOBEC1 (ApoB mRNA-editing enzyme catalytic polypeptide 1), which performs a very 
specific reaction, in case of mRNA of ApoB one of the largest proteins known, 1 nucleotide 
in 14000 (Teng, Burant et al. 1993; Chang, Olin et al. 1998). In order to perform such a task it 
needs cis-acting sequences and trans-acting factors, a mooring sequence downstream of 
editing site and 5’ and 3’ efficiency elements (Backus, Schock et al. 1994; Hersberger and 
Innerarity 1998). Additionally APOBEC1 is not able to facilitate the reaction alone and needs 
in addition an auxiliary protein factor and APOBEC1 complementation factor (ACF) to form 
a functional editosome (Mehta, Kinter et al. 2000; Lellek, Welker et al. 2002). APOBEC1 
carries out the same type of reaction as described later for ADARs (adenosine deaminases that 
act on RNA) but the specificity of it is quite different. Although it is necessary for APOBEC1 
deamination for RNA to form a double stranded stem, the deamination still occurs on single 
stranded RNA (Hersberger, Patarroyo-White et al. 1999) [Fig. 1.1]. Additionally, C to U 
RNA editing of endogenous ApoB in vivo is largely confined to spliced and polyadenylated 
nuclear transcripts (Lau, Zhu et al. 1994).  
 
 
 
APOBEC1 belongs to a large family of cytidine deaminases consisting of 11 members. 
Most of them are facilitating ssDNA cytidine deamination like: hypermutations introduced in 
the negative strand of the human immunodeficiency virus (HIV) DNA, which are mediated by 
Fig. 1.1: Editing of APOB mRNA by 
APOBEC1 (from (Keegan, Gallo et al. 
2001)). APOBEC1 binds complexed with 
ACF to folded APOB mRNA. It is not known 
if the protein binds in monomeric or dimeric 
state. Essential for editing specificity are: 
Mooring sequence and 5’ and 3’ efficiency 
elements. 
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the two APOBEC family members: APOBEC3F and APOBEC3G and mutations introduced 
in VDJ region of immunoglobulin (Ig) gene by activation-induced (cytidine) deaminase (AID) 
(Muramatsu, Kinoshita et al. 2000; Chen, Lilley et al. 2006). 
 
1.3.2.2 Adenosine to inosine RNA editing 
 
The second type of RNA-editing by deamination is a similar process to cytidine 
deamination, which is conversion of adenosine to inosine, an atypical nucleoside [Fig. 1.4]. 
This type of editing is the most common one, found in many RNAs starting from yeast and 
ending in humans. The substrates of this reaction are mostly imperfect double stranded 
regions where an adenosine deaminase performs flipping of the target adenosine and its 
deamination. Inosine does not possess adenosine’s base-pairing abilities to uridine on the 
opposing strand but to cytidine instead. It causes two most important implications of this kind 
of deamination; unwinding of the double stranded region and reading inosine by cellular 
machinery as guanosine (Keegan, Gallo et al. 2001; Bass 2002; Nishikura 2009). Up till now 
editing events have been found in both coding and non-coding regions of protein-coding 
genes, in viral transcripts, in tRNAs and in miRNAs (Cattaneo, Schmid et al. 1988; Polson, 
Bass et al. 1996; Morse, Aruscavage et al. 2002; Athanasiadis, Rich et al. 2004; Blow, Futreal 
et al. 2004; Kim, Kim et al. 2004; Levanon, Eisenberg et al. 2004; Luciano, Mirsky et al. 
2004; Li, Levanon et al. 2009). 
Two groups of adenosine deaminases editing adenosines on RNA have been discovered. 
First, ADATs (adenosine deaminases that act on tRNA/tRNA-specific adenosine deaminase) 
are a protein family responsible for numerous tRNA editing events (Keller, Wolf et al. 1999; 
Gerber and Keller 2001). These events are often present in the first anticodon position 
(wobble position 34) in a number of tRNAs in higher eukaryotes and yeast, but also in 
tRNA
Arg2
 of prokaryotes and chloroplasts. It introduces more flexibility in the process of 
codon triplet recognition (Sprinzl, Horn et al. 1998). Additionally, another common editing 
site is known, N
1
-methylinosine (m
1
I37) found at position 37 of tRNA
Ala 
(A37), adjacent to the 
anticodon. This atypical base is achieved by adenosine deamination occurring first being 
followed by the methylation of the inosine (Grosjean, Auxilien et al. 1996). 
The first enzyme of this family discovered was ADAT1 performing A37 tRNA
Ala
 site 
deamination, in Saccharomyces cerevisiae (Tad1p/scADAT1) and subsequently in human, 
mouse and Drosophila melanogaster (Gerber, Grosjean et al. 1998; Maas, Gerber et al. 1999; 
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Keegan, Gerber et al. 2000; Maas, Kim et al. 2000). Another two deaminases from this 
family, which were able to deaminate adenosine at position A34 of tRNA, were discovered 
shortly afterwards. These two enzymes form a catalytically active heterodimer in contrast to 
ADAT1. Unlike ADAT1, ADAT2
 
and ADAT3 yeast knock-out strains are lethal, indicating 
the importance of this editing mechanism. Unlike other adenosine deaminases, ADATs do not 
contain an RNA binding motif, suggesting that the deaminase domain directly recognizes its 
substrate (Gerber and Keller 1999; Gerber and Keller 2001; Keegan, Gallo et al. 2001). Out of 
three ADAT family members only ADAT1 is present in mammals. ADAT1 is different in 
size, structure and mode of interaction with tRNA from ADAT2 and ADAT3. Additionally, 
only mammalian ADAT1 has the ADAR-like deaminase domain containing a loop insertion 
in between second and third zinc-chelating residues. A homologue of yeast ADAT2 is also 
present in Escherichia coli called tadA (Keegan, Leroy et al. 2004; Nishikura 2009). 
The second family of adenosine deaminases are ADARs (adenosine deaminases that act 
on RNA) that are thought to have evolved from the ADAT family through the acquisition of 
double-stranded RNA-binding domains (dsRBDs) and slight alterations of the primary 
structure in the catalytic (deaminase) domain. These deaminases, their structure and function 
are described in further chapters of this work. 
 
1.4 Adenosine deaminases that act on RNA (ADARs) 
 
A to I deamination of adenosines in double stranded RNA is catalysed by the ADAR 
(adenosine deaminase that act on RNA) family of adenine deaminases. Since their first 
discovery in Xenopus leavis they have been characterized in many other metazoa: mammals, 
birds, frogs, flies and worms (Bass and Weintraub 1987; Rebagliati and Melton 1987; Bass 
and Weintraub 1988; Kim, Wang et al. 1994; Herbert, Lowenhaupt et al. 1995; Lai, Drakas et 
al. 1995; O'Connell, Krause et al. 1995; Melcher, Maas et al. 1996; Gerber, O'Connell et al. 
1997; Hough and Bass 1997; Palladino, Keegan et al. 2000; Slavov, Clark et al. 2000; Slavov, 
Crnogorac-Jurcevic et al. 2000). 
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1.4.1 Discovery of ADARs 
 
ADARs activity was discovered in year 1987 in Xenopus leavis independently by two 
research groups, who described the phenomenon as RNA unwinding or helicase activity (Bass 
and Weintraub 1987; Rebagliati and Melton 1987). In the performed experiments, silencing in 
activated eggs failed as an effect of the single-stranded RNA used. It did not reanneal due to 
conversion of up to half of the adenosines in dsRNA to inosine by an adenosine deaminase 
acting on RNA. The unwinding observed was an effect of A-U base pairs being converted to 
I-U mismatches destabilizing RNA duplexes (Bass and Weintraub 1988; Wagner, Smith et al. 
1989; Polson, Crain et al. 1991). Shortly thereafter the responsible enzyme was found in 
Xenopus leavis and subsequently in human and in cattle (Hough and Bass 1994; Kim, Wang 
et al. 1994; O'Connell and Keller 1994). The discovered enzyme was named differently by 
both laboratories; dsRAD (dsRNA adenosine deaminase) and DRADA (dsRNA adenosine 
deaminase). In 1996 another two enzymes were cloned, RED1/DRADA2 (dsRNA-specific 
editase 1/dsRNA adenosine deaminase 2) and catalytically inactive RED2 (Melcher, Maas et 
al. 1996; Melcher, Maas et al. 1996). To avoid complications names of these adenosine 
deaminases were unified in mammals to ADAR1, ADAR2 and ADAR3 respectively (Bass 
1997). 
 
1.4.2 Members of the ADAR family 
 
As already mentioned ADARs are widespread and highly conserved in all metazoa. In 
mammals three members of the family are present: ADAR1, ADAR2 and ADAR3. One 
member homologous to ADAR1 was discovered in frog and chicken and numerous members 
were found in fishes (Herbert, Lowenhaupt et al. 1995; Hough and Bass 1997; Slavov, Clark 
et al. 2000; Slavov, Crnogorac-Jurcevic et al. 2000; Jin, Zhang et al. 2009). In invertebrates 
ADAR members were also characterised. In Drosophila melanogaster one member dADAR, 
in Caenorhabditis elegans two: ADR-1 and ADR-2 and also two splicing isoforms of 
sqADAR2 in squid (Palladino, Keegan et al. 2000; Tonkin, Saccomanno et al. 2002; 
Palavicini, O'Connell et al. 2009). Additionally, recent findings have shown presence of two 
ADARs; ADAR1 and ADAR2 in sea urchin and sea anemones (Jin, Zhang et al. 2009). 
ADARs in contrast to ADATs are absent in Protozoa, Yeast and Plants (Jin, Zhang et al. 
2009). 
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Insects have lost one of ADARs during evolution and that’s why Drosophila 
melanogaster has only one member of ADAR family termed dADAR with more similarities 
to mammalian ADAR2 than to ADAR1 (Palladino, Keegan et al. 2000) [Fig. 1.2]. dADAR is 
nearly exclusively expressed in the central nervous system of embryos and in the brains of 
adult flies (Palladino, Keegan et al. 2000; Ma, Gu et al. 2001). It consists of two dsRBDs 
(dsRNA binding domains) and a C-terminal catalytic deaminase domain. It forms dimers on 
its substrates and the dimerisation occurs through contacts between the N-terminus and the 
first dsRBD (Gallo, Keegan et al. 2003). A striking majority of its targets localize to the 
nervous system with mRNAs of voltage- and ligand-gated ion channels genes, as well as the 
members of the synaptic release complex being edited (Hoopengardner, Bhalla et al. 2003). 
Like its vertebrate homologue ADAR2, mRNA of this protein is self-edited creating a 
negative auto-regulation mechanism, leading to the synthesis of the protein isoform with the 
reduced deamination activity (Palladino, Keegan et al. 2000; Keegan, Brindle et al. 2005). 
Loss of dADAR activity leads to severe behavioral defects in the adult fly including loss of 
coordination, seizures, and temperature-sensitive paralysis (Palladino, Keegan et al. 2000; 
Jepson and Reenan 2009). 
In C. elegans, two ADAR proteins are present but are so different from vertebrate 
ADARs, that it’s hard to distinguish, how the proteins are related. Both of the enzymes have a 
C-terminal catalytic domain but while ADR-1 has two dsRBDs, ADR-2 has only a single 
dsRBD [Fig. 1.2]. Both of them are necessary for A to I editing in worms (Hough, Lingam et 
al. 1999; Tonkin, Saccomanno et al. 2002; Keegan, Leroy et al. 2004). Similar to substrates in 
D. melanogaster, identified substrates are important for the functionality of the nervous 
system and a knock-out of adr-1 and adr-2 leads to defects in behavior in chemotaxis assays 
(Morse, Aruscavage et al. 2002; Tonkin, Saccomanno et al. 2002). Surprisingly these defects 
can be rescued by mutations in the rde-1 or rde-4 genes that are involved in RNAi, suggesting 
an interplay of the RNAi and RNA-editing machineries (Tonkin and Bass 2003). 
In mammals, there are three proteins that belong to the ADAR family: ADAR1, 
ADAR2 and ADAR3 [Fig. 1.2]. ADAR1 is a long ubiquitously expressed protein consisting 
of three important structural elements. Z-DNA binding domain (ZBA) composed of the Zα 
and Zβ moieties is placed N-terminally and is thought to play a role in guiding ADAR1 to the 
active transcription sites where, due to unwinding, the DNA adopts a Z-like helical 
conformation (Herbert and Rich 2001). The central part of the proteins comprises three 
distinctively different dsRNA binding domains (dsRBD) docking the protein to double-
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stranded RNA during the deamination reaction. The catalytic deaminase domain responsible 
for the reaction can be found at the C-terminus of ADAR1. Two isoforms of ADAR1 are 
known in mammals: a full-length one, 150kDa in mass and a shorter N-terminally truncated 
one of 110kDa. The shorter version of ADAR1 doesn’t contain the Z-DNA binding domain 
(Patterson and Samuel 1995; George and Samuel 1999). Three promoters driving ADAR1’s 
translation are known (Wang, Zeng et al. 1995; Weier, George et al. 1995; Liu, George et al. 
1997). One of them is interferon inducible giving rise to the full-length version (ADAR1-i), 
that starts at methionine 1. It predominantly localizes to the cytoplasm where the 150kDa 
protein is implicated in viral RNA editing (Wong, Sato et al. 2003). Beside of its prime target, 
viral RNA, also transcripts of infected organism are edited more frequently during infection 
and inflammation (Yang, Luo et al. 2003). Two other promoters are constitutive ones 
directing synthesis of the shorter isoform (ADAR1-c), which starts translation from 
downstream methionine at position 296. This version predominantly localizes to the nucleus 
(Patterson and Samuel 1995; George and Samuel 1999). Additionally two alternative splice 
variants that are differentially expressed in different tissues have been reported. In comparison 
to full-length ADAR both splice variants contain a deletion of 26 amino acids at the exon 7-
intron 7 junction, which lies between the dsRBD3 motif and the catalytic domain. The third 
variant has an additional deletion of 19 amino acids at the intron 5-exon 6 junction which lies 
between the dsRBD2 and dsRBD3 motifs. These splice site variants retain the dsRBDs 
functionally intact, and all three of the ADAR variants encode active enzymes that possess 
comparable deaminase activity (Liu, George et al. 1997). The picture may get even more 
complex if taking into account ADAR1 Intracellular localization studies performed in mouse 
lymphocytes during acute inflammation. Still unknown inflammatory regulatory mechanism 
in lymphocytes increases the number of ADAR1 isoforms. More than a dozen different 
ADAR1 cDNAs were found in spleens harvested from endotoxin-challenged mice. One of the 
variants is 80kDa ADAR1, in which by alternative splicing the whole exon 2 comprising 1.4 
kb is deleted. This event results in a deletion of the entire Z-DNA binding domain, the NLS, 
and the entire dsRBDI. The translation of p80 starts at a methionine 519 producing a 
predominantly cytoplasmic protein (Yang, Nie et al. 2003). Additionally numerous C-terminal 
truncated versions of ADAR1 have been detected (Nie, Zhao et al. 2004). 
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Fig. 1.2: ADAR and ADAT family members (adapted from (Keegan, Leroy et al. 2004; Nishikura 2009)). 
From ADAR family three mammalian members are shown: ADAR1 in its long and short isoform, ADAR2 
and ADAR3. Invertebrate members are represented by two squid ADAR2 isoforms, D. melanogaster 
ADAR and C elegans ADR-1 and ADR-2. ADAR family shares C-terminal catalytic domain (light blue) 
and found either N-terminally or centrally dsRNA binding domains (purple). Unique to some members, 
N-terminal motifs, are Z-DNA binding domain (green) and R- or RG-rich regions (magenta and red 
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respectively). Known regions bearing nuclear localisation signal are also presented (dark blue). ADAT 
family is represented by only one known mammalian member ADAT1, S. cerevisiae ADAT1, ADAT2 and 
ADAT3 and E. coli tadA. ADATs contain the deaminase domain homologue to the one from ADARs but 
lack dsRNA binding domains. Insertion of a loop in the catalytic domain in mammalian ADAT1, present 
also in all ADARs, is also indicated (grey). 
 
ADAR2 is a smaller than ADAR1 with only 80kDa. It exhibits a high level of structural 
similarity to ADAR1, 31% sequence identity with the catalytic domain being the most 
conserved one (Melcher, Maas et al. 1996). ADAR2 lacks the Z-DNA binding domain of 
ADAR1 and contains only two dsRBDs N-terminally and a catalytic domain C-terminally. 
ADAR2 exhibits a putative N-terminal NLS which is responsible for the nuclear localization 
of the protein with its characteristic nucleolar accumulation (Desterro, Keegan et al. 2003; 
Sansam, Wells et al. 2003). In contrast to ADAR1 being ubiquitously expressed, ADAR2 is 
present in most tissues but expressed predominantly in the brain (Paul and Bass 1998). 
Initially, four different splice variants of ADAR2 were detected. All of them were a 
combination of two alternative splicing events. One of them shows an inclusion/exclusion of 
an Alu cassette encoding 40-aa in the core of the deaminase domain. The second results in 
creation of two different C-termini, one long (29-aa) and another short (2-aa). All of them are 
expressed at different ratios and are active at comparable levels (Gerber, O'Connell et al. 
1997; Lai, Chen et al. 1997). Recent findings have introduced more variety to what is known 
about existing ADAR2 variants. An additional functional promoter was found upstream of 
ADAR2. A transcript emerging from this promoter adds an additional 49-aa long, highly 
conserved exon termed exon 0. This new alternative splice form of ADAR2 including exon 0 
harbours a stretch of positively charged residues that are highly similar in sequence, length 
and relative position to the so-called R-domain of ADAR3. This variant of ADAR2 is 
expressed, at lower levels than ADAR2 lacking exon 0, differently in various tissues with the 
highest expression rates in hippocampus, colon and the brain (Maas and Gommans 2009). 
Also a novel alternatively spliced exon, located within intron 7 of ADAR2 was discovered. 
Exon 7a is highly conserved in the mammalian ADAR2 gene. It has stop codons in all three 
frames and is down regulated by NMD. The level of exon 7a inclusion differs between 
different human tissues, with the highest levels of inclusion in skeletal muscle, heart and 
testis. In the brain, where the level of editing is known to be high, the level of exon 7a 
inclusion is low (Agranat, Sperling et al. 2010). If the high number of various splicing 
variants of ADAR2 was not enough, from experiments in rat we know that ADAR2 can edit 
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its own mRNA at position -1 in intron 4 converting AA into AI and creating in that way a 
typical 3’ splice site (AG). Introduction of a frame shift and a C-terminal truncation directs 
the protein to NMD, which serves most probably as an auto regulatory negative feedback 
loop(Rueter, Dawson et al. 1999; Dawson, Sansam et al. 2004). 
The last known member of mammalian ADAR gene family is the 81kDa ADAR3 
protein. It shows an exclusive brain expression pattern, particularly in the amygdala and the 
thalamus (Mittaz, Antonarakis et al. 1997). It is 50 % identical to ADAR2 in sequence, with 
two dsRBDs and a conserved deaminase domain. Interestingly, an additional N-terminal 
arginine-lysine-rich sequence (R-domain) of ADAR3 has been identified on its N-terminus as 
a single-stranded RNA binding domain (Chen, Cho et al. 2000). ADAR3 is, however, 
believed to lack any catalytic activity, firstly because no substrate of it has been identified so 
far and, secondly, because it is unable to edit any of the known ADAR1 or ADAR2 
substrates. Even though it is not capable of performing the catalysis, ADAR3 could bind 
potential and serve as a negative regulator of the two enzymatically active ADARs (Melcher, 
Maas et al. 1996; Chen, Cho et al. 2000).  
Additional ADAR-like proteins discovered in vertebrates are catalytically inactive 
ADAD1/TENR (adenosine deaminase domain-containing protein 1/testis nuclear RNA-
binding protein) and ADAD2/TENRL (adenosine deaminase domain-containing protein 
2/testis nuclear RNA-binding protein-like). TENR is expressed in the male germline and has 
only one dsRBD. TENR is missing a key glutamate residue in the active site of the deaminase 
domain and also lacks zinc-chelating residues (Hough and Bass 1997; Connolly, Dearth et al. 
2005). TENRL is expressed in the brain (McKee, Minet et al. 2005). 
 
1.4.3 Evolution of the ADAR family 
 
The putative ancestors of ADARs are ADATs. It is believed that ADATs evolved into 
ADARs by adding dsRBDs to a deaminase domain resembling that from ADARs. ADATs  
are  an older family of proteins, with members present in all eukaryotes, and a bacterial 
orthologue tadA also discovered. In comparison, ADARs are only present in metazoa. The 
highest homology between the catalytic domain of ADAR and ADAT is presented by 
ADAT1. Mammalian ADAT1 acquired additional loop in the catalytic domain, that is not 
present in yeast ADAT1. That indicates, that ADAT1 is an ancestor of ADARs and itself has 
evolved from ADAT2, which is older having its homologue already in E. coli tadA (Gerber, 
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Grosjean et al. 1998; Maas, Gerber et al. 1999; Keegan, Gerber et al. 2000; Maas, Kim et al. 
2000; Wolf, Gerber et al. 2002; Keegan, Leroy et al. 2004). It appears that the ancestors of 
ADATs are the cytidine deaminases acting on mononucleotides (CDAs) or on RNAs 
(CDARs) but not the adenosine deaminases acting on mononucleotides (ADAs) (Kim, Wang 
et al. 1994; Gerber and Keller 1999; Gerber and Keller 2001). Only the former group of 
proteins has the ability to dimerize, which is crucial for ADATs and seems to be also 
important for ADARs (Betts, Xiang et al. 1994; Lau, Zhu et al. 1994; MacGinnitie, Anant et 
al. 1995; Cho, Yang et al. 2003; Gallo, Keegan et al. 2003). ADARs seem to be present in all 
metazoa with high conservation levels in all vertebrates (Hough, Lingam et al. 1999; Slavov, 
Clark et al. 2000; Slavov, Crnogorac-Jurcevic et al. 2000). The recent discovery of 
homologues of ADAR1 and ADAR2 in sea urchin and sea anemones, primitive metazoa, 
would suggest an origin of both proteins already in early metazoa. ADAR3 might have 
evolved more recently by duplication and mutation of ADAR2 gene in mammals. Although a 
homologue of ADAR3 is very well conserved in fish genomes suggesting that the protein is 
older and conserved in all chordate but other groups have lost it on the way. Furthermore also 
either ADAR1 or ADAR2 might have been frequently lost during the course of evolution. 
Insects lack ADAR2 for example. Additionally until now only ADAR1 homologues were 
found in frogs and ADAR2 homologues in squid (Keegan, Leroy et al. 2004; Jin, Zhang et al. 
2009). 
 
1.4.4 Domain architecture 
 
All proteins belonging to either ADAR or ADAT family contain a catalytic deaminase 
domain in their C-terminus, which is the most conserved part of the protein, but show greater 
variation in their central and N-terminal regions. The deaminase domain is always placed in 
C-terminal part of the protein and bears high homology to the catalytic centers of DNA 
methyltransferases and cytidine deaminases that act on RNA (CDARs) (Kim, Wang et al. 
1994; Hough and Bass 1997). It consists of all characteristic three deaminase motifs (I - III), 
with four or five highly conserved amino acids surrounding each of the cysteines and 
histidines, that bind zinc and are required for the catalysis of hydrolytic deamination (Keegan, 
Leroy et al. 2004) [Fig. 1.3]. 
All ADARs contain in their central region dsRNA binding domains (dsRBDs) but the 
number and structure of them differs. While ADAR1 contains three double-stranded RNA-
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binding domains, only two dsRBDs can be found in ADAR2 and ADAR3. A typical dsRBD 
of ADARs is a roughly 65 amino acid long motif forming a characteristic α β β β α formation 
(Ryter and Schultz 1998). They are involved in the substrate recognition and binding, but also 
serve as modulators of the intracellular trafficking in case of ADAR1 (Eckmann, Neunteufl et 
al. 2001; Strehblow, Hallegger et al. 2002; Valente and Nishikura 2007; Fritz, Strehblow et al. 
2009). 
 
 
 
Fig. 1.3: ADAR2 catalytic domain (from (Macbeth, Schubert et al. 2005)). (A) Ribbon model of human 
ADAR2 catalytic domain. The active-site zinc ion is represented by magenta sphere. Regions that share 
structural similarity with CDA and tadA are shown (cyan and dark blue). C-terminal helical domain 
making contacts with IP6 is also shown (red and IP6 as sticks under the zinc ion). (B) Residue interactions 
at the active site. Shown are: the zinc ion, coordinating residues (H394, C451, C516), the nucleophilic 
water (blue sphere) and the proposed proton shuttling residue, E369. The hydrogen bond, that connects 
the active site to the IP6 is also indicated. 
 
The biggest differences between the three proteins are in their N-termini. The 
interferon-inducible isoform of ADAR1 (ADAR1-i) harbors two left-handed Z-DNA binding 
domains (Z and Z) in its N-terminus. Structural analyses have shown that each domain 
builds up a helix-loop-helix structure similar to the one found in DNA-binding proteins, and 
can bind left-handed, supercoiled DNA Z-helix in vitro (Herbert, Alfken et al. 1997; Schade, 
Turner et al. 1999; Schwartz, Rould et al. 1999). The cocrystal structure of Zα complexed to 
Z-DNA showed that one monomeric Zα domain binds to one strand of double-stranded DNA 
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and a second Zα domain binds to the opposite strand with 2-fold symmetry with respect to 
DNA helical axis. Recent findings support an active B-Z transition mechanism, in which the 
Zα first binds to B-DNA and then converts it to left-handed Z-DNA, a conformation that is 
then stabilized by the additional binding of a second Zα (Kang, Bang et al. 2009). Although 
this type of DNA is not well investigated yet, experimental evidence points to the existence of 
Z-DNA in living mammalian cells and its conserved role in processes such as gene regulation, 
nucleosome positioning, chromatin remodeling and recombination (Zhao, Bacolla et al.; 
Wang and Vasquez 2007). It was speculated that this atypical DNA structure might be present 
in transcriptionally active sites, which led to the proposition that the ZBDs direct ADAR1-i 
there but the evidence is still missing to support such a hypothesis (Herbert, Alfken et al. 
1997). It has been demonstrated in Xenopus leavis, that the ZBDs are dispensable for 
chromosomal localization (Eckmann and Jantsch 1999). Furthermore, there are hypotheses 
suggesting the importance of ZBDs for viral dsRNA binding in the cytoplasm, required for 
hyperediting in the antiviral response(Herbert, Alfken et al. 1997; Brown, Lowenhaupt et al. 
2000). In addition to that ADAR1 harbors a RG-rich region in front of the ZBDs (O'Connell, 
Krause et al. 1995). ADAR3 in contrast contains a N-terminal arginine/lysine-rich sequence 
(R-domain), which has been identified as a single-stranded RNA binding domain (Chen, Cho 
et al. 2000). 
Each ADAR contains an NLS sequence directing the proteins into nucleus. ADAR2 and 
ADAR3 exhibit an NLS in the N-terminus in front of dsRBDs. On the other hand the NLS of 
ADAR1 is a non-canonical one embedded in its third dsRBD with a nuclear localization 
function independent of RNA-binding activity (Eckmann, Neunteufl et al. 2001). Shuttling of 
ADAR1-i is performed thanks to a typical leucine-rich N-terminal nuclear export signal 
(NES), which overlaps with the N-terminal part of the Z-DNA binding domain, Z  (Poulsen, 
Nilsson et al. 2001). The constitutively expressed version of ADAR1 is also able to shuttle 
between the nucleus and cytoplasm. This movement is also mediated by dsRBD3, although 
this time due to RNA-dependent interactions between the dsRBD and exportin 5 (Fritz, 
Strehblow et al. 2009). 
 
1.4.5 Mechanism of deamination 
 
ADARs, thanks to their catalytic deaminase domain, are able to perform RNA editing, 
via the well-characterized conversion of adenosine (A) to inosine (I) by hydrolytic 
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deamination. The reaction mechanism consists of a nucleophilic attack of an activated water 
molecule at the C6 of the purine ring in an intermediate step. Subsequently, an ammonia 
molecule is released, resulting in a stable inosine moiety (Bass and Weintraub 1988; Wagner, 
Smith et al. 1989) [Fig. 1.4]. The architecture of the active site of the catalytic domain is 
defined by highly conserved amino acid residues: histidine H394, glutamic acid E396 and two 
cysteine residues C451 and C516 obtained from crystallography studies of catalytic domain of 
ADAR2 and are involved in coordination of a zinc ion (Macbeth, Schubert et al. 2005). 
Similar to most metalloenzymes also in ADARs, a water molecule is activated by the zinc ion, 
enabling the nucleophilic attack (Lai, Drakas et al. 1995). This kind of geometry of the 
catalytic center has also been observed in cytidine deaminases and E. coli TadA, a member of 
the ADAT2 family. 
The site of the nucleophilic attack during the ADAR reaction is buried in the major 
groove of the dsRNA. Due to its inaccessibility, ADARs are thought to employ a base-
flipping mechanism to bend the target adenosine out of the dsRNA A-helix (Stephens, Yi-
Brunozzi et al. 2000). Interestingly, the dsRBDs of ADARs might facilitate this 
conformational change through enhancement of the RNA duplex flexibility (Yi-Brunozzi, 
Stephens et al. 2001). The catalytic zinc centre is located in a deep pocket surrounded by the 
positively charged residues, making it an ideal binding surface for the negatively charged 
dsRNA [Fig. 1.3]. 
An essential element of the active site of the enzyme is one molecule of inositol 
hexakisphosphate (IP6). This cofactor is deeply buried in the active site [Fig. 1.7]. Its presence 
was confirmed in ADAR2 and ADAT1 and it seem to be necessary for proper folding of the 
catalytic domain and activity of ADARs (Macbeth, Schubert et al. 2005). Beside of IP6 no 
other cofactors are needed for ADARs activity in vitro (Polson, Crain et al. 1991; O'Connell, 
Gerber et al. 1997). 
Like for ADATs the formation of homodimers between single ADAR molecules were 
studied and it seems that like in the case of their distant relatives this process takes place and 
that dimerisation is required for proper editing (Cho, Yang et al. 2003; Gallo, Keegan et al. 
2003). It has been shown that ADAR1 and ADAR2 are the ones that undergo homo and 
heterodimerisation but not ADAR3, which could explain its inactivity (Gallo, Keegan et al. 
2003) Whether dimerisation of the protein molecules requires RNA is still unknown, although 
the studies suggest, that the interactions take place on a protein-protein level. The region 
required for dimerisation is still not known even though the dsRBD regions seem to play a 
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pivotal role (Chilibeck, Wu et al. 2006; Poulsen, Jorgensen et al. 2006; Valente and Nishikura 
2007). Although, many studies indicate requirement of dimerisation for deamination reaction 
there are also some that contradict these findings indicating otherwise. In few experiments it 
was shown that active ADARs may exist as monomers in solution (O'Connell and Keller 
1994; Macbeth, Lingam et al. 2004). Additionally N-terminal deletions and later also 
expression of catalytic domain fragment of hsADAR2, that have shown its functionality leave 
rather a little maneuver for possible dimer formation (Macbeth, Lingam et al. 2004; Macbeth, 
Schubert et al. 2005). Also the specific binding of dsRBDs of rADAR2 to GluR-B R/G site 
would suggest rather a 1 to 1 ratio of the enzyme and the substrate (Stefl, Xu et al. 2006). 
 
 
 
 
 
Fig. 1.4: Deamination of adenosine to 
inosine by ADAR (from (Nishikura 
2009)). A simplified hydrolytic 
deamination of adenosine to inosine 
is shown. The reaction consists of 
nucleophilic attack of an activated 
water molecule at the C6 and an 
ammonia molecule is release. 
Adenosine base-pairs with uridine, 
whereas inosine, as if it was 
guanosine, with cytidine. 
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1.4.6 Substrate recognition and specificity of ADARs 
 
ADARs are enzymes binding to dsRNA and edit adenosines within it. Both inter- or 
intramolecular dsRNAs of >20 base pairs, which are two turns of dsRNA helix, can serve as a 
substrate (Nishikura, Yoo et al. 1991). ADARs exhibit a wide range of specificity and are able 
of both quite different tasks; they can edit very specifically, one base in hundreds or lead to 
random conversion of many adenosines until reaching a state of roughly 50% of them being 
edited (Nishikura, Yoo et al. 1991; Polson and Bass 1994). An explanation to this remarkably 
different editing extents lays in the structure of ADARs but also in the RNA conformation. 
A typical dsRNA forms an A-form helix, which in contrast to the B-form helix of DNA 
has a deep and narrow major groove, making the only place where an enzyme could come in 
contact with bases fairy inaccessible. In fact, dsRBDs are proven to bind the phosphodiester 
backbone of RNA and are sequence-independent (Bycroft, Grunert et al. 1995; Kharrat, 
Macias et al. 1995; Nanduri, Carpick et al. 1998; Ryter and Schultz 1998). dsRBDs of 
ADARs bind tightly to any dsRNA sequence, which can be an explanation for the more 
random editing events. However, recent findings have shown that in a few cases dsRBDs may 
bind in very specific way to certain editing substrates including nonhelical regions, that flank 
dsRNA. This indicates, that some dsRBDs may possess intrinsic binding selectivity. NMR 
structures of two dsRBDs of ADAR2 have demonstrated, that dsRBD1 recognizes a 
conserved pentaloop of the GluR-B R/G stem-loop, whereas dsRBD2 recognizes two bulged 
bases adjacent to the editing site, demonstrating RNA structure-dependent recognition by the 
ADAR2 dsRBDs (Stephens, Haudenschild et al. 2004; Stefl, Xu et al. 2006). 
Still selective editing depends on something different than the specificity of dsRBDs. 
To understand this kind of deamination one has to remember the specificity of ADARs 
towards dsRNA and not ssRNA and also that dsRNA fragment is rarely perfectly base-paired 
(Bass and Weintraub 1987). We also know that by deaminating adenosines in A-U base-pair 
are converted into a less stable I-U mismatch. Experiments performed on perfect dsRNA have 
shown that editing is introducing more instability into a dsRNA particle by slowly unwinding 
it. As the reaction proceeds less and less adenosines are perfect targets for ADAR 
deamination which causes a halt of hyperediting of perfectly base-paired dsRNA at 50-60% 
(Nishikura, Yoo et al. 1991; Polson and Bass 1994). Most of the selectively edited substrates 
are not forming perfectly base-paired dsRNA. They contain internal bulges and loops, which 
seem to be the answer to the selectivity of ADARs. Even a long dsRNA stretch but 
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interrupted by bulges may cause ADAR to see RNA as a series of shorter helices, in which 
maybe only one or two adenosines present themselves as good editing substrates  (Lehmann 
and Bass 1999). These findings led to the conclusion, that the only way to make ADAR bind 
in register and edit selectively is to make a duplex very short or to enclose editing sites 
between two mismatches creating only one possible way for the enzyme to bind (Lehmann 
and Bass 2000; Ohman, Kallman et al. 2000) [Fig. 1.5]. 
 
 
 
Fig. 1.5: Selectivity of ADAR deamination (from (Bass 2002)). ADARs (green) reacting with four different 
substrates are shown: perfectly double-stranded long and short fragments and double-stranded fragments 
interrupted with mismatches or loops. ADAR deaminating dsRNA introduces I-U mismatches decreasing 
stability of RNA fragment. Reaction stops after editing up to 50-60% of the adenosines shown on 
hyperedited long RNA fragment. Selective editing is only achieved by editing of shorter fragments or 
longer ones interrupted with mismatches and loops, which divide long fragment into a series of shorter 
dsRNA fragments. 
 
Although these results help to understand how ADAR substrate selectivity can be 
obtained they still do not explain why ADARs exhibit slight preferences of one adenosine 
over others. Additionally the exchange of the deaminase domains between ADAR1 and 
ADAR2 resulted in the substrate specificity typical for the enzyme whose deaminase domain 
was part of the protein chimera (Wong, Sato et al. 2001). So even if targeted binding of 
dsRBDs to dsRNA may be the major factor positioning proper adenosine in vicinity of the 
active site, like in the case of the GluR-B R/G site, it seems that also the architecture of the 
active site dictates the choice of the base being edited (Stefl, Xu et al. 2006). Evidence from 
in vivo and in vitro experiments on endogenous and also synthetic substrates have revealed a 
certain neighbourhood preference of the base  adjacent to the edited adenosine and of the 
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pairing partner on the other strand. These preferences would encompass additional bases that 
beside the edited adenosine interact with the active site of the enzyme. Studies with Xenopus 
and human ADAR1 show that the enzyme targets adenosines further than three nucleotides 
from the 5’ terminus and eight from the 3’ terminus with a 5’ neighbour preferences of U = A 
> C > G (Polson and Bass 1994; Riedmann, Schopoff et al. 2008). ADAR2 on the other hand 
deaminates as close as three nucleotides from either terminus with 5’ and 3’ neighbouring 
preferences, which are; U ≈ A > C =G and U = G > C = A respectively (Lehmann and Bass 
2000; Ohman, Kallman et al. 2000; Riedmann, Schopoff et al. 2008). Also the studies 
concerning preferences of ADARs towards a certain pairing partner in the editing 
complementary site indicate major role of the active site in this choice. In both mammalian 
ADAR1 and ADAR2 a mismatch at the editing site is preferred in comparison to A-U base-
pairing. Most efficiently edited is adenosine in A-C mismatch followed by A-A and A-G 
mismatches (Wong, Sato et al. 2001). In the studies on Alu elements the most often base 
opposite the edited adenosine was uracil, followed by cytosine. This is mostly due to uracil 
being a usual base-pairing partner of adenosine. Nonetheless, the frequency of C opposite an 
edited A is about three times higher than expected by the natural occurrence of C residues 
opposite A residues (Riedmann, Schopoff et al. 2008). Very similar neighbourhood 
preferences only confirm that ADAR1 and ADAR2 have overlapping but distinct substrate 
specificities with certain substrates being edited exclusively by one enzyme to some, where 
the edited state is an effect of the redundancy of the enzymes (Maas, Melcher et al. 1996; 
Melcher, Maas et al. 1996; Lai, Chen et al. 1997). 
 
1.5 Substrates of ADAR 
 
Initially editing events were detected as A to G changes in cDNA and mostly restricted 
to coding ones. Only in recent years when more sophisticated computational methods for 
genome-wide identification were implicated, a real landscape of A to I editing was revealed. 
A large number of predicted editing sites (~15000 sites in ~2000 genes) was found to be 
localized in non-coding regions, in inversely oriented Alu and SINE elements in comparison 
to less than 100 recoding events in human genes (Hoopengardner, Bhalla et al. 2003; 
Athanasiadis, Rich et al. 2004; Blow, Futreal et al. 2004; Kim, Kim et al. 2004; Levanon, 
Eisenberg et al. 2004; Ohlson and Ohman 2007; Gommans, Tatalias et al. 2008; Li, Levanon 
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et al. 2009). Substrates of ADARs obtained in these screens may be divided in three major 
groups. Firstly, the coding substrates, which in mammals, as well as in flies and worms are 
located in the central nervous system (CNS) where ADAR-mediated RNA editing regulates 
important functional properties of neurotransmitter receptors (Maas, Kawahara et al. 2006) 
[Fig. 1.6]. Furthermore, another important role for ADARs in mammals is thought to be 
editing and hyperediting of viral dsRNA as a defense mechanism against infections. Finally, 
in recent years the effects of adenosine deamination in the non-coding substrates, most 
notably the microRNA precursors, emerged as a significant regulatory mechanism in RNA 
interference (Nishikura 2006; Ohman 2007). 
 
1.5.1 Most known coding substrates 
 
A typical coding editing substrate forms a hairpin structure, ranging from the shortest 
known stem-loops of ~60-70 nucleotides like in the case of Gabra-3 I/M and GluR-B R/G 
stem-loops to few with editing site and its editing complementary sequence (ECS) in a 
distance of a kb in length like in case of GluR-5 and GluR-6 substrates (Seeburg, Higuchi et 
al. 1998; Ohlson, Pedersen et al. 2007). In most cases the double stranded region is formed 
between an exonic region with edited adenosines in the vicinity of a splicing site and an 
intronic ECS like in case of GluR-B and serotonin receptor 2C editing sites [Fig. 1.5]. This 
implies that editing must occur before splicing, when the intron is cut out (Higuchi, Single et 
al. 1993; Lomeli, Mosbacher et al. 1994; Herb, Higuchi et al. 1996; Burns, Chu et al. 1997; 
Niswender, Sanders-Bush et al. 1998; Laurencikiene, Kallman et al. 2006; Schoft, Schopoff et 
al. 2007). Editing in coding regions may lead to a change of the codon and therefore of the 
information carried by mRNA. The proximity of editing sites to splicing sites may also 
influence splicing dynamics or even its course (Bass 2002; Schoft, Schopoff et al. 2007) The 
most prominent and best described targets of ADARs are found in the central nervous system. 
They are the pre-mRNAs encoding subunits of the glutamate receptor, the serotonin 2C 
receptor in mammals, potassium, sodium and chloride channels in Drosophila or potassium 
channel in squids (Melcher, Maas et al. 1996; Burns, Chu et al. 1997; Patton, Silva et al. 
1997; Seeburg, Higuchi et al. 1998; Lehmann and Bass 2000) (Burns, Chu et al. 1997; Patton, 
Silva et al. 1997; Palladino, Keegan et al. 2000; Reenan, Hanrahan et al. 2000). 
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L-glutamate is the major excitatory neurotransmitter in the vertebrate central nervous 
system. It serves the glutamate-gated ion channels in mediating rapid excitatory transmission 
and synaptic plasticity (Greger and Esteban 2007). Glutamate-gated ion channels belong to 
heterotetrameric cation channels which consist of three main subtypes: AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxasolepropionic acid) receptors, NMDA (N-methyl-D-aspartate) 
receptors and kainate receptors, all concentrated at postsynaptic sites. AMPA receptors, that 
are mostly Ca
2+
-impermeable and displaying extraordinarily fast kinetics, are responsible for 
the primary depolarization in glutamate-mediated neurotransmission. They exhibit an 
enormous diversity in their electrophysical properities, that comes from various subunit 
compositions and the modifications introduced through RNA splicing and RNA editing. Four 
subunits, termed GluR1-GluR4 or, alternatively, GluR-A–GluR-D in different constellations 
form the channel. Most studied editing sites are present in the GluR-B subunit pre-mRNA 
(Seeburg, Higuchi et al. 1998) [Fig. 1.6]. Editing of the GluR-B Q/R site is performed by 
ADAR2 and the binding platform for the enzyme is formed between exon 11 and ECS located 
in the downstream intron (Higuchi, Single et al. 1993). Editing of this site was shown to be 
essential. Here, RNA editing leads to conversion of a glutamine (Q) codon (CAG) into an 
arginine (R) codon (CGG) with 99.9 % efficiency. The biological impact of this conversion is 
dramatic, with the residue found deep in the ion channel in the second transmembrane domain 
taking part in the receptor´s central channel formation. Assemblage of Q/R site-edited 
Fig. 1.5: Typical substrate of ADAR editing (from 
(Keegan, Gallo et al. 2001)). A duplex RNA, that is 
recognized by ADARs, is formed between the editing site 
and ECS that is often located in downstream intron. The 
enzyme binds through the dsRNA binding domains. 
 
 25 
 
subunits into the receptor significantly lowers the channel´s Ca
2+
 permeability (Sommer, 
Kohler et al. 1991). Editing at this site has also been shown to decrease the rate of receptor 
assembly and its transport to the synaptic membranes in cultured hippocampal neurons 
(Greger, Khatri et al. 2002; Greger, Khatri et al. 2003). Unlike GluR-B Q/R site in case of 
R/G site both versions, edited and unedited, coexist introducing more diversity. Editing of this 
site is not essential and plays a more subtle role in neuronal modulation. Deamination occurs 
at up to 80 % efficiency in three out of four AMPA receptor subunits (GluR-B, -C and –D). It 
is located in exon 13, at position -2 with respect to the 5´ splice site of intron 13. Also in this 
case a vital change in the codon occurs, with an arginine (R) codon (AGA) turned into a 
glycine (G) codon (GGA). This site exhibits varying editing levels during development and its 
physiological role is to alter calcium ion permeability and therefore increased recovery rates 
from desensitization (Kohler, Burnashev et al. 1993; Lomeli, Mosbacher et al. 1994). Besides 
editing in AMPA receptor subunits B, editing sites are present also in subunits C and D and 
also in kainate receptor subunits GluR-5 and GluR-6 (Seeburg, Higuchi et al. 1998). 
Serotonin (5-hydroxytryptamine) is a neurotransmitter interacting with a large family of 
receptors to elicit signaling events that are crucial for proper neurotransmission. Serotonin 
binding to its transmembrane receptor is involved in several physiological functions, like 
production of cerebrospinal fluid, and behavioral processes such as: sleep regulation, appetite 
or pain for instance (Maas and Rich 2000). The human 5-hydroxytryptamine receptor subtype 
2C (5-HT2CR) is ubiquitously distributed throughout the central nervous system and is a 
member of G protein-coupled receptor superfamily that stimulates phospholipase to produce 
phosphates and diacylglycerol starting signaling cascades in the cell (Hoyer, Clarke et al. 
1994). Five different editing sites have been detected within the 5-HT2CR transcript, which 
allow five different distinct amino acid changes [Fig. 1.6]. All five editing sites (A,B,C,D and 
E) are situated within the pre-mRNA segment encoding the second intracellular loop of 5-
HT2CR, a receptor domain important for G-protein coupling (Niswender, Sanders-Bush et al. 
1998). While editing at sites A and B is accomplished by ADAR1, site D is deaminated by 
ADAR2. The C and E sites may be efficiently edited by both proteins (Wang, O'Brien et al. 
2000). Experiments have revealed, that out of twenty four possible, at least seven isoforms in 
rat and twelve in humans are expressed resulting from alternative editing at five different sites 
by ADARs, which coexist on different levels depending on a part of brain examined (Burns, 
Chu et al. 1997; Niswender, Copeland et al. 1999). The receptor isoform whose pre-mRNA is 
edited at all five sites carries amino acid substitutions at positions 156, 158 and 160, where 
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the genomic DNA-encoded isoleucine, asparagine and isoleucine (I,N and I) are converted 
into valine, glycine and valine (V,G and V), respectively. Amino acid substitutions result in 
decreased G-protein coupling and less efficient triggering of the phospholipase C signaling 
cascade. The ligand affinity is also affected. The unedited version exhibits the highest and the 
fully edited version the lowest affinity for the neurotransmitter, while partially edited isoforms 
show intermediate affinity (Burns, Chu et al. 1997; Niswender, Sanders-Bush et al. 1998). 
Mutant mice with the knocked-in pre-edited (VGV) receptor version were showing elevated 
energy expenditure and loss of fat mass due to constitutive activation of the sympathetic 
nervous system (Kawahara, Grimberg et al. 2008). 
Recently, editing in a third group of central nervous system receptors was reported in 
the mouse, namely in the gamma-aminobutyric acid type A (GABAA) receptor subunit α3 
(Gabra-3) [Fig. 1.6]. This receptor is the member of the Cys-loop ligand-gated ion channel 
superfamily and conducts chloride ions (Cl
-
) upon GABA-mediated activation. Editing of 
adenosine found in exon 9 within a short stem-loop structure leads to I/M (isoleucine to 
methionine) amino acid substitution in the transmembrane domain 3 in the subunit α3 of the 
five-subunit GABAA receptor changing its electrophysiological properties. Both ADAR1 and 
ADAR2 mediate adenosine deamination in this case on developmentally dependent levels; 50 
% of transcripts are edited in newborn mice at day 2, while those in adult mouse brain are 
edited to almost 100% (Ohlson, Pedersen et al. 2007). 
Also mammalian potassium channel mRNAs are edited with Kv1.1 as an example [Fig. 
1.6]. This editing event leads to expression of an isoform, that recovers faster from 
inactivation of the receptor and reduces ability of the receptor subunits to tetramerize (Bhalla, 
Rosenthal et al. 2004). 
Most coding substrates known in invertebrates and vertebrates are concentrated in the 
CNS. In Drosophila melanogaster transcripts of three different ion channels are edited: α1 
subunit of Na
2+
-channel (para), α1 subunit of Ca2+-channel (cac) and α1 subunit of 
neurotransmitter-gated chloride channel (GluCl-α1) with still unknown implications although 
knock-out of dADAR causes locomotion and behavioral disorders (Smith, Peixoto et al. 1998; 
Semenov and Pak 1999; Palladino, Keegan et al. 2000; Reenan, Hanrahan et al. 2000; 
Keegan, Brindle et al. 2005). Editing sites in sodium channel are found throughout the whole 
mRNA and include codon changes in transmembrane and intracellular domains (Palladino, 
Keegan et al. 2000). 
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In squid on the other hand the voltage-gated Kv2 potassium channel mRNA is targeted 
at multiple sites. Editing of two mostly edited sites affects channel closure upon repolarization 
(Patton, Silva et al. 1997). 
Additional new targets in transcripts of coding genes were identified by different 
screens over the last years (Levanon, Eisenberg et al. 2004; Levanon, Hallegger et al. 2005; 
Ohlson and Ohman 2007; Gommans, Tatalias et al. 2008; Li, Levanon et al. 2009). Many of 
these editing sites were found in receptors, ion channels, and proteins involved in synapse 
function, trafficking, or membrane organization. The novel targets CyFip2 (cytoplasmic 
FMR1 interacting protein 2), Filamin A (Flna), and Filamin B (Flnb) are involved in different 
steps of actin reorganization. CyFip2 is part of WAVE complexes and within these complexes 
regulates actin nucleation (Takenawa and Suetsugu 2007). Flna and Flnb, however, are key 
regulators of orthogonal branching of actin filaments (Popowicz, Schleicher et al. 2006). 
Editing in Flna and Flnb is highly conserved in both proteins in a homologous region located 
at position -2 relative to a conserved 5`splice site.  
Actin reorganization is essential for cell motility and migration and is an important 
determinant in dendritic spine and synapse formation (Dillon and Goda 2005; Popowicz, 
Schleicher et al. 2006). Another target protein for RNA editing, IGFBP7, has a proposed 
function in glioma cell growth and migration (Jiang, Xiang et al. 2008). Additional target 
proteins with functions in cell migration and/or adhesion are RSU-1, PTK2 (FAK), CRB2 and 
TRO (Li, Levanon et al. 2009). Numerous editing events were discovered also in proteins of 
less known function like Blcap (bladder cancer-associated protein) a protein differentially 
expressed in bladder cancer (Gromova, Gromov et al. 2002; Clutterbuck, Leroy et al. 2005; 
Levanon, Hallegger et al. 2005) [Fig. 1.6]. 
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Editing substrate Protein 
product 
Editing 
enzyme 
Effect 
GluR-B 
 
glutamate 
receptor 
subunit B 
Q/R site 
ADAR2 
R/G site 
ADAR1 
and 
ADAR2 
Q/R 
ion 
permeability of 
channel 
R/G 
ligand 
desensitiza 
-tion recovery 
rate 
 
GluR-5 
 
glutamate 
receptor 
subunit 5 
ADAR2 ion 
permeability of 
channel 
GluR-6 
 
glutamate 
receptor 
subunit 6 
ADAR2 ion 
permeability of 
channel 
5-HT2CR 
 
Serotonin 
receptor 
2C 
subtype 
sites A, B 
ADAR1 
site D 
ADAR2 
sites C, E 
ADAR1 
and 
ADAR2 
G protein 
interactions 
Gabra-3 
 
gamma-
aminobut
yric acid 
type A 
receptor 
subunit 
α3 
ADAR1 
and 
ADAR2 
trafficking of 
the receptor 
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Kv1.1 
 
Kv1.1 
potassiu
m ion 
channel 
ADAR2 channel 
inactivation 
kinetics 
Blcap 
 
bladder 
cancer 
associate
d protein 
ADAR1 unknown 
ADAR2 
 
ADAR2 ADAR2 expression of 
inactive splice 
variant 
HDV antigenome 
 
hepatitis 
delta 
virus 
antigen 
ADAR1 expression of 
large or small 
antigen 
 
Fig. 1.6: Table of few coding substrates of ADARs (adapted from (Maydanovych and Beal 2006)). 
Sequences of editing sites of: GluR-B, GluR-5, GluR-6, 5-HT2CR, Gabra-3, Kv1.1, Blcap, ADAR2 and 
HDV antigenome are shown. Additionally data about protein product of each mRNA, enzyme editing 
particular site and biological effects of editing are provided. 
 
1.5.2 Viral substrates 
 
Shortly after ADARs were discovered a viral RNA isolated from the brain of a patient 
who died suffering a persistent measles virus infection gave indication of ADAR being 
responsible for changes in the viral RNA sequence (Cattaneo, Schmid et al. 1988). The 
editing of viral RNAs occurred promiscuously with up to 50 % of all adenosines modified. 
One of the pre-mRNA also found nonselectively deaminated is encoding the matrix protein of 
the measles virus, which is crucial in viral budding. This prevents the progression of the lytic 
cycle and forces the virus to remain in the persistent infection state (Sheppard, Raine et al. 
1985). This alterations in cDNA sequences consistent with the ADAR enzymatic activity and 
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its neighboring preferences have been reported for many viruses afterwards. Beside of 
measles virus such hypermutation has been discovered in viral RNA isolates of host cells 
invaded by parainfluenza virus 3, respiratory syncytial virus and vesicular stomatitis virus 
(Murphy, Dimock et al. 1991; Rueda, Garcia-Barreno et al. 1994; Kumar and Carmichael 
1997; Bass 2002). All of the above mentioned pathogens belong to the group of 
paramyxoviruses whose perfectly double stranded RNA genome requires an RNA-dependent 
RNA polymerase for the transcription into an mRNA. Another similarity among them is the 
exclusively cytoplasmic replication cycle. The obvious candidate to perform editing on such a 
substrates was (Bass 2002)the full-length isoform of ADAR1, ADAR1-i, which is transcribed 
from a promoter region containing an interferon-stimulated response element (ISRE) (George 
and Samuel 1999). Like most genes whose activation is triggered through interferon 
signaling, from the beginning ADAR1-i has been implicated in the cellular antiviral defense 
mechanism. Interferon synthesis is induced by dsRNA, a byproduct of the replication cycles 
of many RNA viruses, as the ones mentioned above, serving as the first line in defense against 
these viruses (Sen 2001; Sen and Sarkar 2007).  
A limited number of viruses, however, have already adapted to ADAR1 activity and 
take advantage of the ADAR-mediated RNA editing. Most of these viruses use ADARs as a 
switch between early and late stages in their cycle. For example, during the late stage 
infection with the polyoma virus, newly synthesized giant multimer transcripts with 
complementary regions to early short transcripts form double-stranded regions, leading to the 
hyperediting of the latter. While the hyperedited early transcripts become export-incompetent, 
the late ones reach the cytoplasm and give rise to proteins fundamental for the transition from 
early to late stage infection. In the nucleus, such hypermutated RNAs, like the polyoma virus 
early transcripts, are anchored to the nuclear matrix by the inosine-specific RNA-binding 
protein p54
nrb
, which forms a complex with the splicing factor PSF and the inner nuclear 
matrix protein matrin 3, thereby preventing escape of the promiscuously edited messages 
from the nucleus and, subsequently, their translation to the non-functional proteins (Kumar 
and Carmichael 1997; Zhang and Carmichael 2001). 
There are also selective editing events described for viral RNAs, like in hepatitis delta 
virus (HDV) [Fig. 1.6], a subviral human pathogen that requires hepatitis B virus (HBV) for 
packaging. Its antigenome forms an imperfect double stranded structure interrupted with 
numerous bulges and loops. It encodes a single open reading frame, giving rise to hepatitis 
delta antigen (HDAg). Due to ADAR-mediated RNA editing, two forms of this protein are 
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expressed. The shorter form is expressed constitutively, while the adenosine deamination 
within the amber (UAG) stop codon gives rise to tryptophane (UGG) codon at the amber/W 
site, resulting in the extension of the open reading frame by additional 19 amino acids 
(Polson, Bass et al. 1996). The shorter protein (HDAg-S) plays a role in the viral genome 
replication, while the longer isoform (HDAg-L) leads to the replication inhibition and 
promotes the assembly of new viral particles (Ryu, Bayer et al. 1992). 
Recently, also ADAR1-i was shown to stimulate human immunodeficiency virus
 
type 1 
(HIV-1) replication by using both editing-dependent and
 
editing-independent mechanisms. 
Over-expression
 
of ADAR1 in HIV-1 producer cells increases viral protein accumulation
 
in 
an editing-independent manner. ADAR1-i has been shown to reverse the protein kinase R 
(PKR) inhibition of HIV expression. Additionally, ADAR1 associates with HIV-1 RNAs and 
edits adenosines in
 
the 5' untranslated region (UTR) and the Rev and Tat coding
 
sequences. It 
is believed ,that just like polyoma virus and HDV, HIV-1 has adapted in a way to make use of 
specific RNA editing activity
 
of the host cell (Clerzius, Gelinas et al. 2009; Doria, Neri et al. 
2009). 
 
1.5.3 Non-coding substrates 
 
Recent developments in the field of RNA editing indicate that mRNA recoding at 
specific sites may not be its sole function. Extensive bioinformatics screening for novel 
ADAR substrates revealed a completely new set of putative ADAR targets in non-coding 
regions such as introns and 5’- and 3’UTRs. Strikingly, the majority of editing sites were 
localized to SINE and LINE elements. Additionally, microRNA precursors Were identified as 
editing targets (Hoopengardner, Bhalla et al. 2003; Athanasiadis, Rich et al. 2004; Blow, 
Futreal et al. 2004; Kim, Kim et al. 2004; Levanon, Eisenberg et al. 2004; Ohlson and Ohman 
2007; Gommans, Tatalias et al. 2008; Li, Levanon et al. 2009). 
In primates, up to 85% of pre-mRNAs may be edited. This can be explained by the 1.4 
million copies of Alu elements in the human genome that comprise just over 10,5 % of the 
entire genome (Jurka 2004). Alu elements rarely occur alone. Presence of two or three Alus in 
inverted orientation leads to their base-pairing and thus allows their editing (Morse, 
Aruscavage et al. 2002; Athanasiadis, Rich et al. 2004; Levanon, Eisenberg et al. 2004). It 
was determined that 90 % of newly discovered editing events reside in one of the members of 
Alu family indicating more global implication of their editing. These editing events can cause 
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creation or elimination of splicing signatures and affect the alternative splicing of Alu-derived 
exons, but can also serve as a global regulatory mechanism in controlling RNA stability, 
export, splicing or translation (Athanasiadis, Rich et al. 2004; Levanon, Eisenberg et al. 2004; 
Lev-Maor, Sorek et al. 2007; Chen and Carmichael 2008; Chen and Carmichael 2009). It is 
also hypothesized, that RNA editing might influence this evolutionary process (Mattick and 
Mehler 2008). 
miRNAs are synthesized from a dsRNA precursors  which can serve as substrates for 
RNA editing. They are processed in two steps. Firstly a pri-miRNA, a short hairpin structure 
enclosed in a larger untranslated RNA transcript is cleaved in the nucleus by the 
microprocessor complex, consisting of Drosha and DGCR8, to 60-70 nucleotide long pre-
miRNA. Pre-miRNA is exported to the cytoplasm and cleaved subsequently into a 20 to 22 
nucleotide long siRNA-like duplex by Dicer-TRBP (transactivating response RNA-binding 
protein). One of both strands may serve as a mature miRNA. After integration into the 
miRNA induced silencing complex (miRISC) and binding to partially complementary targets 
in 3’UTRs miRNAs may block translation of the transcript or guide it for destruction (Bartel 
2004; Kim 2005). Several studies indicate that all steps of miRNA biogenesis and miRNA 
function may be affected by A to I editing (Nishikura 2006; Ohman 2007; Nishikura 2009). 
Editing of certain adenosines in miRNA sequence may lead to inhibition of cleavage by 
Drosha and Dicer or change their substrate specificity (Scadden 2005; Yang, Chendrimada et 
al. 2006; Kawahara, Zinshteyn et al. 2007; Kawahara, Zinshteyn et al. 2007). 
 
1.5.4 Other implications of editing 
 
Recoding of gene information creating higher diversity in proteome is not the only 
implication of A to I editing performed by ADARs in the coding genes. One of the possible 
function of editing is affecting alternative splicing. Firstly, in more direct way a splice site 
may be destroyed by editing 3’ acceptor splice site (AG – IG = GG) or created by editing 
future 3’ acceptor site or 5’ donor site (AA – AI = AG or AU – IU = GU respectively). Till 
now only few examples of this occurrence were discovered. One of them is the self-editing of 
mammalian ADAR2 pre-mRNA.. Editing converts AA dinucleotide into AI which is read as 
AG dinucleotide typically found at 3’ splice sites. This new event causes incorporation of 47 
nucleotide long intronal insertion, a frameshift and a production of only 88aa long 
polypeptide lacking dsRBDs and the catalytic domain. This process is clearly a negative 
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feedback loop, which in a tight way controls ADAR2 expression (Rueter, Dawson et al. 
1999). Another example is the editing of the same process of creation of 3’ splice site in 
intron of nuclear prelamin A recognition factor (NARF) gene. There the editing site is formed 
as an effect of folding two inversely repeated Alu elements. Thanks to this event a stop codon 
is eliminated and an intronic Alu is exonized (Lev-Maor, Sorek et al. 2007). 
Less direct influence of ADARs on splicing comes from the fact that most of the 
platforms for editing are composed of exonic fragment and intronic fragment folding back to 
form a double-stranded structure. Edited adenosines are present ranging from one to few 
nucleotides from the splice sites. Such a pattern, which had to have implications on splicing 
inspired many scientific investigations. Looking only on most known mammalian editing 
substrates shows the importance of it. Editing at both the Q/R and R/G site is having a crucial 
influence on splicing of GluR-B pre-mRNA. Reduced editing levels at Q/R site cause aberrant 
retention of the downstream intron 11 (Higuchi, Maas et al. 2000; Schoft, Schopoff et al. 
2007). On the other hand, the R/G site is situated only one nucleotide upstream of the 5´ 
splice site of intron 13  and influences the mutually exclusive flop and flip incorporation of 
exon 14 and exon 15, respectively (Schoft, Schopoff et al. 2007; Penn and Greger 2009). Also 
splicing of intron 5 of serotonin receptor 2C is affected by editing. Three alternative 5’ splice 
sites are known at this junction. Only the first splice site following the editing sites and not 
the second or the upstream one lead to formation of a functional full-length protein. 
Completely unedited transcripts tend to be spliced with the upstream splice site resulting in 
truncated, non-functional protein. Most of the transcripts, which are edited in at least two 
editing sites are spliced from the proper splice site though. This process may be again an 
example of a control mechanism, which prohibits expression of the protein from completely 
unedited transcript (Wang, O'Brien et al. 2000; Flomen, Knight et al. 2004; Marion, Weiner et 
al. 2004). 
Exonic and intronic regions of the pre-mRNA fold together to form a substrate for 
ADAR editing and splicing. This gives the possibility to interfere between these two 
processes. It also suggests a possible interplay between the two events and also a system that 
regulates it. In vitro studies on GluR-B editing sites have shown that editing can both 
stimulate and repress splicing efficiency. Lack of editing inhibits splicing at the Q/R site. 
Editing of both the Q/R nucleotide and an intronic editing hotspot are required to allow 
efficient splicing (Schoft, Schopoff et al. 2007). On the other hand the presence of an edited 
nucleotide at the R/G site reduces splicing efficiency of the adjacent intron facilitating 
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alternative splicing events occurring downstream of the R/G site (Schoft, Schopoff et al. 
2007). However, the same site was found in vivo to efficiently edit and splice without 
interference, suggesting that the two RNA processing events are somehow coordinated (Bratt 
and Ohman 2003). The answer to this dilemma may lie in the interaction of ADAR2 with 
CTD of RNA polymerase II. CTD may work as a landing pad for different factors depending 
on the nature of the transcript coordinating the RNA processing events, enhancing or 
inhibiting RNA editing or splicing (Laurencikiene, Kallman et al. 2006).  
Also evidence for nuclear retention due to A to I editing has been reported with p54
nrb
 
protein playing a pivotal role. A model, based on the 3’UTR of the mouse cationic amino acid 
transporter 2 (CAT2) transcript postulates, that p54
nrb
 binds to edited inverted SINE repeats 
present in the 3’UTR leading to their sequestration to nuclear speckles. During stress CAT2 
mRNA (CAT-RNA) is posttranscriptionally cleaved and de novo polyadenylated to allow the 
production of a functional protein (Zhang and Carmichael 2001; Prasanth, Prasanth et al. 
2005). Discovery of abundance of editing events in Alu repeats in human genes rose a 
possibility of a global regulation system directing all 3’UTR edited transcripts for nuclear 
retention. However, while some reports confirm this theory others show that the presence of 
double stranded structure in 3’UTRs and their editing has no effect on nuclear export. This 
raises doubt that inversely oriented repeats may influence nuclear retention of edited 
transcripts (Chen, DeCerbo et al. 2008; Hundley, Krauchuk et al. 2008). It was also reported 
that inosine-containing dsRNAs are reduced due to a lower abundance of the transcript and 
that such transcripts are likely to be found in a stress-granule-like-complex. This suggests that 
ADARs may take part in stress induced gene silencing via extensive mRNA editing and 
formation of stress granules in the cytoplasm (Scadden 2007). 
A possible involvement of ADARs in heterchromatic gene silencing has also been 
proposed. ADAR1 and inosine containing RNA were found to form complexes with vigillin, 
the Ku86-Ku70 heterodimer, and RNA helicase A. Vigillin localizes to heterochromatin and 
the whole complex is involved in the phosphorylation of a set of targets important for 
heterochromatin silencing. Although these findings may hint to a role of  ADAR1 in this kind 
of silencing a definitive proof is still missing (Wang, Zhang et al. 2005). 
Besides ADARs editing miRNA there seems to be a more global interplay between A to 
I editing and RNAi (Nishikura 2006; Nishikura 2009). This revelation comes as no surprise 
considering that both processes rely on the presence of dsRNA. Studies of adr-1 and adr-2 
null mutant worms indicate an equilibrium between ADAR and Dicer activities. 
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Caenorhabditis elegans lacking A to I editing activity shows chemotaxis defects. These 
defects can be rescued by the absence of RNAi components. Although the precise process has 
not been discovered it seems, that expression of the genes involved in chemotaxis are 
controlled by the balance between editing and dicing (Tonkin and Bass 2003). Since dsRNAs 
are both substrates of ADARs and Dicer an antagonistic competition for substrate scenario 
was suggested in which editing of dsRNA would reduce the RNAi efficacy (Bass 2000; 
Nishikura 2006). It seems that Dicer is able to distinguish dsRNA containing I – U wobble 
pairs. dsRNA extensively edited (up to 50%) becomes resistant to Dicer cleavage (Scadden 
and Smith 2001). Inosine-containing dsRNA may be later degraded in the cytoplasm by a 
RISC-associated component, Tudor staphylococcal nuclease (Tudor-SN), which shows 
specificity towards A to I edited RNAs (Scadden and Smith 2001). However, the moderately 
edited dsRNA may be processed by Dicer to esiRNA (endoribonuclease-prepared siRNAs) 
the substitution of only one adenosine with inosine could reduce the efficacy of RNAi. 
Editing of targets of siRNA leads to generation of less esiRNA and also nonfunctional edited 
siRNA (Zamore, Tuschl et al. 2000). Additionally, an editing-independent way of 
antagonizing RNAi has been reported. Cytoplasmic ADAR1-i is induced by the presence of 
viral, dsRNA. Also introduction of siRNAs to the cell induces increased ADAR1-i expression 
as a response (Hong, Qian et al. 2005). It was reported that cytoplasmic ADAR1-i binds very 
tightly to siRNAs sequestering the RNA and therefore limiting its potency by decreasing its 
functional concentration (Yang, Wang et al. 2005). 
Recently it was shown that ADAR1-i takes part in the regulation of gene expression. It 
binds to NF90/ILF3 (nuclear factor 90/NFAR/Interleukin enhancer-binding factor 3), which is 
a protein known to stimulate gene expression at the transcription and translation levels in 
vertebrates. ADAR1-i stimulates and regulates NF90-mediated gene expression and may be 
involved in translation control by facilitating interactions between the NF90 proteins and the 
dsRNA components of highly structured mRNAs (Nie, Ding et al. 2005). 
 
1.6 Biological implications of A to I editing 
 
Changes in the information stored in the genome can be achieved in few several ways: 
through gene mutations, deletions, duplications, but also through alternative splicing and 
RNA-editing. However, the former group represents permanent changes hardwired in the 
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genome while the latter occurs posttranscriptionally, at the RNA level. Alternative splicing 
and RNA editing has an advantage of a regulation possibility, causing its occurrence and 
therefore its implications ranging from low to high levels. This kind of control allows many 
different isoforms of one protein to exist simultaneously enriching its possible function, what 
seems to be most important in central nervous system where most known coding substrates of 
A to I editing were discovered. Different editing levels of diverse substrates differentially 
distributed in various brain subregions varying throughout developmental stages contribute in 
fine-tuning of neurotransmission and evolution of higher functions. It is naturally anticipated 
that malfunctions in editing would lead to diseases in human connected with learning, 
memory, thinking and behavior. In order to elucidate syndromes connected to ADARs 
malfunction knock-out animals in several species were obtained and studied showing, that the 
role of ADAR-mediated RNA editing became increasingly important during the course of 
evolution. Not surprisingly also some neurodegenerative diseases were linked to ADAR 
malfunctions. ADARs also seem to play an important role in tumorogenesis (Bass 2002; 
Maas, Kawahara et al. 2006; Nishikura 2009; Skarda, Amariglio et al. 2009). 
 
1.6.1 Phenotype of mutant animals 
 
Inactivation of ADAR genes has severe consequences in all tested systems. However it 
seems that the importance of A to I editing varies between invertebrates and vertebrates. In 
the former loss of ADAR activity leads to behavioral defects while loss of ADAR is lethal in 
mice for example(Bass 2002). Despite their viability, knock-outs of both adr-1 and adr-2 
genes in C. elegans show aberrant chemotaxis (Tonkin, Saccomanno et al. 2002; Ohta, 
Fujiwara et al. 2008). A knock-out of the Drosophila melanogaster dADAR gene causes 
mostly behavioral and motoric phenotype in flies. The adult specimens lacking dADAR 
exhibit various defects including: temperature-sensitive paralysis, locomotor discoordination 
and tremors and, finally, changes in grooming and mating behavior, all intensifying with age. 
Detectable anatomical defects are: changes observed in retina and liaisons in all areas of the 
brain (Palladino, Keegan et al. 2000). These findings suggest important but non-essential role 
of ADARs in invertebrates affecting integrity and function of central nervous system. 
In contrast to invertebrate ADAR deletions, mammals show more severe phenotypes. In 
the case of ADAR1 locus deletion, heterozygosity leads to birth of apparently completely 
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healthy mice. On the other hand, homozygous deletion leads to early embryonic death around 
day E11.5. Death occurs as an effect of halted developmental processes, distorted fetal liver 
structure and widespread programmed cell death the liver and hematopoietic lineage (Wang, 
Khillan et al. 2000; Wang, Miyakoda et al. 2004). This phenotype is most probably due to 
inappropriate induction of interferon signaling pathways and apoptosis of hematopoietic 
progenitor cells. This role of ADAR1 is attributed to the editing of as yet unidentified target 
involved in the interferon-induced cellular response (Hartner, Schmittwolf et al. 2004; 
Hartner, Walkley et al. 2009). 
Also heterozygous ADAR2 knock-out mice are viable and appear normal. Their 
homozygous mutant counterparts, however, die few weeks after birth, between postnatal days 
0 and 20, exhibiting frequent epileptic seizures. This phenotype is a consequence of 
underediting at exclusively ADAR2-targeted Q/R site of the GluR-B pre-mRNA. This 
underedited site, normally edited up to 99,9%, is giving rise to a subunit incorporated in 
receptors with increased Ca
2+
 permeability in hippocampal neurons, leading to hippocampal 
neurodegeneration. Interestingly ADAR2 null mice mutants can be rescued by introducing 
mutation in GluR-B Q/R site mimicking its ’edited’ state, which suggests that ADAR2 knock-
out lethality is only due to underediting of this site (Higuchi, Maas et al. 2000). 
Additionally, mutant animal models with permanently altered editing patterns of 
specific substrates have been created. Heterozygous mutant mice harboring an editing 
incompetent GluR-B allele that lacks editing complementary sequence (ECS) for GluR-B Q/R 
site were created. Importance of editing at this site was presented by increased Ca
2+
 
permeability leading to epileptic seizures and premature death by 3 weeks of age (Brusa, 
Zimmermann et al. 1995). Mutant mice harboring hyper and hypo-edited alleles of serotonin 
receptor 2C (5-HT2CR) were generated. Surprisingly not the latter, editing-blocked allele-
expressing mice have shown a abnormal growth but the former, fully-edited allele-expressing 
mice. These mice had drastically reduced fat mass in spite of compensatory hyperphagia 
connected with constant excitation of sympathetic nervous system and consequent increase in 
energy expenditure. This finding show an importance of all editing variants of 5-HT2CR and 
additionally would indicate a possibility of existence of yet unknown mechanism controlling 
fat metabolism and energy expenditure via 5-HT2cR mRNA editing (Kawahara, Grimberg et 
al. 2008). 
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1.6.2 Neurodegenerative diseases linked to ADAR 
 
Most known and well studied examples of diseases linked to ADAR dysfunction are 
neuronal and neurodegenerative diseases. A possible connection between such a diseases and 
the most known editing substrates was made: amyotrophic lateral sclerosis (ALS) and 
epilepsy to underediting at the GluR-B Q/R and schizophrenia and depression to reduced or 
disregulated editing at 5-HT2CR editing sites (Maas, Kawahara et al. 2006). 
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease mostly fatal 1-
5 years after the onset (Cleveland and Rothstein 2001). In ALS motor neurons degenerate 
causing characteristic symptoms: muscle weakness, muscle atrophy, spasticity and eventually 
paralysis and respiratory failure. Glutamate excitotoxixity contribute to the pathology of ALS 
with elevated glutamate levels in 40% of sporadic ALS cases suggesting prolonged activation 
of glutamate gated channels, to which GluR-B belong. Prolonged exposure to Ca
2+
 ions is 
causing damage to motor neurons end eventually leads to their death (Spreux-Varoquaux, 
Bensimon et al. 2002). There may be many reasons of increased level of synaptic glutamate 
but increased permeability of GluR-B receptors due to underediting of GluR-B Q/R site is one 
of them. Decreased levels of editing at that site, ranging from 60-100% has been shown 
among few ALS patients (Kawahara, Kwak et al. 2003; Kawahara, Ito et al. 2004; Kawahara 
and Kwak 2005; Kwak and Kawahara 2005). 
A role of underediting of GluR-B Q/R site in epilepsy has also been proposed. Epilepsy 
is a neurological disorder characterized by recurrent, unprovoked seizures (Delorenzo, Sun et 
al. 2005). Changes in receptor subunit expression, channel density and posttranscriptional 
regulation of AMPA-type glutamate receptors have been observed in epilepsy patients and 
animal models (Feldmeyer, Kask et al. 1999). As mentioned before phenotype of GluR-B 
editing deficient mouse models exhibit seizures resembling epilepsy (Brusa, Zimmermann et 
al. 1995; Feldmeyer, Kask et al. 1999; Higuchi, Maas et al. 2000). Comparison of models not 
expressing GluR-B, also resulting in higher permeability, and expressing unedited version of 
it show epileptic phenotype only in case of the second one suggesting that this phenotype may 
be connected with gating kinetics, channel conductance or its assembly and trafficking 
(Greger, Khatri et al. 2002; Greger, Khatri et al. 2003). 
Until now no specific A to I editing target has been connected to a psychiatric disorder. 
such as schizophrenia or depression (Abdolmaleky, Thiagalingam et al. 2005). However, 
considering the role that serotonin plays in the central nervous system, it is believed that 
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reduced or disrupted ADAR activity could play a role in this kind of psychiatric disorders. 
Members of serotonin receptor (5-HTR) family are believed to play a major role in 
psychological and behavioral processes such as: emotion, appetite and sexual behavior. 5-
HT2cR is the only G protein-coupling receptor that is edited (Burns, Chu et al. 1997). There 
are few evidences of changes in editing pattern among suicide victims with documented 
chronic major depression. In comparison with healthy individuals, these patients had 
overedited E and C sites and an underedited D site. Since all of the affected sites are ADAR2 
targets, altered function of this protein seems to be a likely cause of the symptoms (Gurevich, 
Tamir et al. 2002). Moreover, studies on mice and rat models have shown that the treatment 
with the antidepressant, serotonin-selective reuptake blocker, fluoxetine leads to exactly 
reverse changes in editing frequency at E, C and D sites when compared to the suicide 
victims, implying one of the possible mechanisms of action for this type of medication 
(Iwamoto, Nakatani et al. 2005). Unfortunately results regarding schizophrenia are not that 
clear with few reports claiming no difference in editing levels in patients diagnosed witch the 
disease and one showing increased level of expression of unedited version (INI) of 5-HT2cR 
(Niswender, Herrick-Davis et al. 2001; Sodhi, Burnet et al. 2001; Dracheva, Elhakem et al. 
2003; Iwamoto and Kato 2003). 
In addition to studying glutamate R-B and serotonin 2C receptors expression levels of 
ADAR2 and RNA editing were studied in trisomy 21 (Down’s syndrome) since Human 
ADAR2 is located on this chromosome. However, no effect of gene dosage was observed on 
the expression level of ADAR2 and consequently no impact on RNA-editing levels was 
observed (Kawahara, Ito et al. 2004). 
 
1.6.3 ADAR in cancer 
 
It was clear that ADAR, proteins that may change information carried by mRNA and 
affect many other processes, may take part in tumorigenesis. Misregulation of the editing 
pattern or editing levels of many vital substrates could lead to cellular instability and therefore 
to formation of tumors. Most of the tumors connected with misregulation of ADAR editing 
are the tumors of the brain (Skarda, Amariglio et al. 2009). 
Underediting of GluR-B Q/R editing site was found in glioblastoma multiforme 
(astrocytoma grade IV), a common and most aggressive type of primary brain tumor in 
humans, involving glial cells and accounting for 52% of all parenchymal brain tumor cases 
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and 20% of all intracranial tumors (Maas, Patt et al. 2001; Iacob and Dinca 2009). 
Overexpression of Ca
2+
-impermeable (R) versions of the receptors in the tumor cells inhibited 
cell locomotion and induced apoptosis. In contrast overexpression of Ca
2+
-permeable (Q) 
versions of the receptor facilitated migration and proliferation of the tumor cells. Formation of 
this type of malignant gliomas may be due to downregulated expression of ADAR2 in 
proliferating cells (Ishiuchi, Tsuzuki et al. 2002). It was additionally demonstrated that high 
calcium permeability of AMPA receptors influences migration by activating the Akt pathway, 
that plays a key role in multiple cellular processes such as glucose metabolism, cell 
proliferation, apoptosis, transcription and cell migration (Ishiuchi, Yoshida et al. 2007). 
Also another type of malignant gliomas has been studied, many types of pediatric 
astrocytomas (type I-IV) and also here a correlation between ADAR2 activity and tumor 
mailgnancy has been detected (Cenci, Barzotti et al. 2008). Underediting of GluR-B Q/R site 
in pediatric astrocytomas (92-100%) is not as severe as in their adult counterparts (70-95%). 
Overexpression of ADAR2 leads to a decrease in malignant cell behavior. Indeed ADAR2 
overexpression slows down the cell cycle during S-G2 transition. In this type of tumor cells 
ADAR2 is expressed at normal level but ADAR1-c and ADAR3 are overexpressed leading to 
the assumption that higher concentrations of ADAR1 and 3 may influence the activity of 
ADAR2 (Cenci, Barzotti et al. 2008). 
Beside the tumors originating from glial cells in the CNS other examples of 
cancerogenic processes connected to ADAR malfunctions are known. In patients with acute 
myeloid leukemia (AML) an aberrant editing event has been discovered. In comparison to 
healthy patients a transcript of tyrosine phosphatase PTPN6 (SHP-1), a tumor suppressor, 
isolated from CD34
+
 and CD117
+
 lymphocytes is edited at one of the splice branch points. 
This event leads to an expression of a non-functional protein. The alternative splicing due to 
this editing event decreases also in patients with remissions (Beghini, Ripamonti et al. 2000). 
Recent bioinformatic approaches discovering editing in Alu element have also shown a 
global hypoediting process occurring in numerous tumor tissues. Beside brain tissues editing 
levels were decreased in prostate, lung, kidney and testicular tumors. Downregulation of all 
three, ADAR1, ADAR2 and ADAR3, was detected, which correlated significantly with 
malignancy of the tumors. However one of the known editing substrates of ADAR1, Blcap 
(bladder cancer-associated protein) Y/C editing site, was at the same time edited at higher 
level in the brain (Paz, Levanon et al. 2007). 
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1.6.4 Other diseases 
 
Another disease has been found associated with ADAR1 malfunction: Dyschromatosis 
symmetrica hereditaria is a pigmenting genodermatosis (reticulate acropigmentation of dohi, 
symmetrical dyschromatosis of the extremities) present primarily in Japan and China, but has 
also been found to affect individuals from Europe, India, and the Caribbean, characterized by 
progressively pigmented and depigmented macules, often mixed in a reticulate pattern, 
concentrated on the dorsal extremities (Tomita and Suzuki 2004). The disease is an effect of 
numerous mutations occurring in front of methionine 296 of ADAR1, which cause expression 
of aberrant or truncated versions of ADAR1-i but don’t influence expression of ADAR1-c. 
Twelve missense, nine frameshifts, eight nonsense and three splice site mutations discovered 
up to date cause only a mild heterozygous dominant phenotype not affecting mental or 
physical condition of the patients. It is speculated that numerous expressed aberrant variants 
of ADAR1 may quench wild-type ADAR1 activity by heterodimerizing with it forming a 
non-functional complex (Miyamura, Suzuki et al. 2003; Zhang, He et al. 2004; Cui, Wang et 
al. 2005; Gao, Wang et al. 2005). 
Also a possible link between RNA editing and type 2 diabetes has been proposed. Mice 
chronically fed a high-fat diet exhibit an elevated level of ADAR2, but not ADAR1, 
transcripts and therefore elevated editing levels of primary ADAR2 substrates, such as: 
ADAR2 and GluR-B transcripts in pancreatic islets and β-cell lines. These insulin-secreting 
cells play a central role in glucose metabolism and homeostasis responding to fluctuations of 
blood sugar levels by adequate insulin secretion. Additionally expressed in this cell line 
ionotropic glutamate receptors are responsible for insulin secretion. It still remains to be 
determined whether ADAR2 has any influence on insulin secretion (Gan, Zhao et al. 2006). 
 
1.7 Regulation of ADAR 
 
A poorly understood chapter of A to I editing is the regulation of ADAR activity. 
Activity of ADARs is regulated throughout developmental and in a tissue specific manner 
(Paul and Bass 1998; Jacobs, Fogg et al. 2009; Nishikura 2009; Tan, Huang et al. 2009). The 
activity of the enzyme depends on substrate specificity of it and is controlled by: alternative 
splicing, localization and dimerisation (Gerber, O'Connell et al. 1997; Lai, Chen et al. 1997; 
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Liu, George et al. 1997; Tan, Huang et al. 2009). Also sumoylation of ADAR1, a cofactor of 
ADAR2 and interaction between ADAR and  the C-terminal domain (CTD) of polymerase II 
were discovered. (Desterro, Keegan et al. 2005; Macbeth, Schubert et al. 2005; 
Laurencikiene, Kallman et al. 2006) Until now no other factors that influence ADAR activity 
were found and it is not known whether such factors exist. 
 
1.7.1 Developmental und tissue-specific expression of ADARs 
 
All three members of ADAR family are developmentally controlled. Experiments in 
mice have shown that ADAR1 and ADAR2 are expressed at embryonal stage day 10 (E10.0) 
with the highest editing level in embryonic heart (Wang, Khillan et al. 2000; Reymond, 
Marigo et al. 2002; Wang, Miyakoda et al. 2004). At this stage expression of ADAR1 is 
downregulated by miRNA-1 (Lim, Lau et al. 2005). Start of expression of ADARs at this 
early developmental stage perfectly coincides with embryonal lethality of homozygous knock 
outs of ADAR1 in mice at E12.5 (Hartner, Schmittwolf et al. 2004). From that point on the 
expression level of ADAR1 mRNA stays constant while ADAR2 expression increases in the 
brain to reach its peak in the adult, as shown in the rat model (Hang, Tohda et al. 2008). 
However a better studied mouse model shows increase of expression of both proteins through 
development, with both enzymes widely distributed in brain around birth (Jacobs, Fogg et al. 
2009). 
Analyses of expression of ADAR1 and ADAR2 have also shown a tissue specific 
expression of ADARs (Kim, Wang et al. 1994; O'Connell, Krause et al. 1995; Melcher, Maas 
et al. 1996; Paul and Bass 1998). Measured total inosine level in most tissues perfectly 
correlate with ADARs expression, that follows the pattern: brain>lung>heart>skeletal muscle 
(Paul and Bass 1998). Many studies performed on specific editing substrates have confirmed 
this finding (Nishimoto, Yamashita et al. 2008; Riedmann, Schopoff et al. 2008). Expression 
of ADARs in the brain appears at E15.0, with expression of ADAR1 higher than ADAR2, and 
reaches its peak at P21 in the adult mouse. The highest levels of RNA editing have been 
detected in the thalamus and hypothalamus and the lowest levels in cortex and hippocampus 
with editing levels about 50% lower than on the average in the rest of the brain. ADARs are 
not only differentially expressed in different tissues but also cell specific. Both ADAR1 and 
ADAR2 are detectible in neurons but not in astrocytes, for example (Paupard, Friedman et al. 
1997; Jacobs, Fogg et al. 2009). 
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Not surprisingly also editing levels of most known coding substrates change during 
development. Editing in mice starts to be detectible at low levels at day E15 followed by a 
rapid increase until just after birth (P0-P2). This is followed by a slow increase until P21 
when editing levels of most of the substrates reach their maximum. On the other hand there 
are some editing sites that stay at the same editing level throughout development from day 
E15 till the adult mouse. The most extreme example is the GluR-B Q/R site with editing at 
E15 already over 90% and increasing only minimally in development. Also C and E editing 
sites of 5-HT2CR show this pattern (Bass 2002; Du, Davisson et al. 2006; Ohlson, Pedersen et 
al. 2007; Daniel and Ohman 2009; Jacobs, Fogg et al. 2009). 
However in many cases expression of ADARs does not correspond to editing of certain 
substrates. GluR-B Q/R site and D site of 5-HT2CR are edited at embryonal day 15 of mouse 
embryos to 90% and 50% respectively, when ADARs are barely detectable (Jacobs, Fogg et 
al. 2009). Additional studies have shown that expression of ADAR2 does not correspond 
temporally and spatially throughout development with its prime substrates (Hang, Tohda et al. 
2008) (Liu, Emeson et al. 1999; Seeburg 2000). Also editing of the K/E site of CyFip2 nicely 
correlates with ADAR2 expression and in many tissues. However, in lung and leukocytes 
editing is not detectable although ADAR2 levels are high (Nishimoto, Yamashita et al. 2008). 
In malignant gliomas hypoediting of GluR-B Q/R and 5-HT2CR sites was detected with no 
significant change in expression of ADAR2 (Maas, Patt et al. 2001). Similar results were 
obtained from pediatric astrocytomas, also suggesting that abnormal overexpression of 
ADAR1 and ADAR3 may form heterodimers with ADAR2 sequestering it (Cenci, Barzotti et 
al. 2008). A global decrease of Alu element editing was shown in different types of tumors 
due to a general decrease of ADAR expression. However Blcap that is exclusively edited by 
ADAR1 showed a higher editing activity in tumors versus controls in brain, oral cavity and 
lung (Paz, Levanon et al. 2007).  
 
1.7.2 Regulation of ADAR activity 
 
Today, already a few ways are known how expression and activity of ADARs can be 
regulated (Tan, Huang et al. 2009). 
One mode of regulation is represented by self-editing of ADAR2 transcript. The editing 
of rat ADAR2 occurs in 6 different positions in intron 4 and exon 5. Editing in intron 4 
converts AA dinucleotide into AI, which is read as AG a canonical 3’ splice site [Fig. 1.6]. It 
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results in addition of 47 nucleotides to exon 5 generating a frameshift. This results in 
synthesis of a truncated non-functional protein (Rueter, Dawson et al. 1999). Transgenic mice 
lacking ADAR2 self-editing activity have elevated editing levels of some ADAR2 substrates 
indicating editing of ADAR2 mRNA being a negative feedback loop mechanism, in which 
ADAR2 regulates its own expression (Feng, Sansam et al. 2006).  Interestingly in Drosophila 
melanogaster editing occurs in the catalytic domain changing the properties of the dADAR 
(Palladino, Keegan et al. 2000). 
Widespread regulation of ADARs occurs on a level of alternative splicing, as an effect 
all of them occur in many isoforms. Existence of alternative splicing variants results in 
differential tissue- and developmental-specific expression of them and also different activity. 
Two additional ADAR1 variants contain deletions, either one or two, between catalytic 
domain and dsRBD3 and dsRBD2 and dsRBD3 changing distances between them. All 
variants are ubiquitously expressed, but splice variant containing both deletions at the same 
time is expressed at the lower level that the variants with only one deletion (Liu, George et al. 
1997). The various splice variants of ADAR1 are active enzymes, with comparable specific 
activity. All three human ADAR1 variants possess editing activity for the A, B, and C editing 
sites of 5-HT2CR but were inactive for the D site. These results indicate that the two deletions 
in ADAR1 mRNA do not significantly affect the site-selectivity for editing the 5-HT2CR RNA 
substrate. However, they displayed differential activities towards these sites resulting in 
different editing levels (Liu, Emeson et al. 1999). Also editing of GluR-B R/G site shows 
differences in activity (Liu and Samuel 1999). 
Also four known classical human ADAR2 splicing variants are expressed in a different 
manner. The variants with Alu cassette inclusion in the catalytic domain are expressed at the 
higher level (Lai, Chen et al. 1997). Additionally the presence of Alu cassette in the sequence 
in human version of the protein reduces catalytic activity of ADAR2 by 50% (Gerber, 
O'Connell et al. 1997). Also newly discovered splicing variant containing exon 0 is expressed 
in a tissue-specific manner, with the highest level in mouse cerebellum (Maas and Gommans 
2009) Also an inclusion of a novel alternatively spliced exon 7a, located within intron 7 of the 
human ADAR2 gene, is more prominent in some tissues with the highest levels of inclusion 
in skeletal muscle, heart and testis. In the brain, where the level of editing is known to be 
high, the level of exon 7a inclusion is low (Agranat, Sperling et al. 2010). Overall the 
evidence presented indicate, that different splice variants of ADAR1 and 2 are differentially 
expressed and possess different activities. 
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As presented earlier the evidence about homodimerisation of ADARs is not clear and 
sometimes contradictory (O'Connell and Keller 1994; Cho, Yang et al. 2003; Gallo, Keegan et 
al. 2003; Macbeth, Lingam et al. 2004; Macbeth, Schubert et al. 2005). Although it is known, 
that homodimerisation happens but most probably is not essential for the editing reaction it is 
still not sure if ADARs could heterodimerise. However, some evidence could indicate this 
process. For example, an overexpression of ADAR1 in pediatric astrocytoma could inhibit 
editing activity of ADAR2. This and the finding that ADAR1 can be precipitated along with 
ADAR2 suggest that this kind of complexes could be formed (Cenci, Barzotti et al. 2008). 
Unfortunately these results were obtained without RNAse treatment and one cannot dismiss 
RNA acting as a bridge between the proteins. A reduction in ADAR activity was also 
observed in Drosophila when active and inactive versions of dADAR were expressed (Gallo, 
Keegan et al. 2003). Although this findings may be still an effect of competitive binding of 
ADARs to substrate the possibility of yet another ADAR regulation system exist. One could 
imagine various splice variants of ADARs with different editing activities affecting each other 
via formation of dimers. Also catalytically inactive ADAR3 could form heterodimer 
sequestering active ADARs. 
Also cellular localization has a great influence on ADAR activity. Both ADAR1 
isoforms, ADAR1-i and ADAR1-c can shuttle from nucleus to the cytoplasm with the former 
being predominantly cytoplasmic and the latter nuclear. ADAR2 and ADAR3 are 
predominantly nuclear (Eckmann, Neunteufl et al. 2001; Poulsen, Nilsson et al. 2001; 
Desterro, Keegan et al. 2003; Fritz, Strehblow et al. 2009). ADARs are localized to the 
compartments where they are needed most. ADAR1-i in the cytoplasm as a response to viral 
infection and ADAR1-c and ADAR2 in the nucleus to perform post-transcriptional editing on 
mRNA. It was shown that high abundance of RNA in the nucleolus may tether ADAR1 and 
ADAR2 to this compartment. That would explain characteristic nucleolar localization of 
ADAR2. The process is reversed via inhibition of rRNA synthesis or overexpression of an 
editing substrate. Only when editing substrates accumulate in the nucleoplasm ADAR2 is 
released from the nucleoli (Desterro, Keegan et al. 2003; Sansam, Wells et al. 2003). It was 
also demonstrated that although both ADAR2 and ADAR1 are present in nucleolus, only 
ADAR2 is able to edit a substrate expressed from Pol I in this compartment (Vitali, Basyuk et 
al. 2005). 
One of the most obvious processes affecting enzyme activity are also post-translational 
modifications. Human ADAR1 has been found to be sumoylated. An ubiquitin-like protein 
 46 
 
SUMO, which can affect protein localization, stability and activity modifies ADAR1 at lysine 
418, which lies between the Z-domain and the first dsRBD. Upon this modification, activity 
of the enzyme is substantially reduced. This suggest an important role of SUMO in control of 
ADAR1 activity (Desterro, Keegan et al. 2005). Although many possible phosphorylation 
sites for ADARs have been predicted until now no such modification was reported (Blom, 
Sicheritz-Ponten et al. 2004). 
Additionally any change in structure of dsRNA and modification to RNA in vicinity of 
the editing site could affect editing activity. Possibilities are infinite starting with proteins 
binding to RNA, changing allosteric properties of the editing site, unwinding of RNA by 
helicases to modification of the RNA backbone or bases. Since both A to I editing and 
splicing are taking part post-transcriptionally and most of the known editing substrates are 
formed in between an exon and an intron this two processes compete for the same substrate. 
The moment splicing occurs cutting out the intron harboring the ECS editing cannot occur 
(Bratt and Ohman 2003). A single modification at the editing site can also influence editing 
level of this site. A 2’-O-methylation C editing site of 5-HT2CR is guided by C/D snoRNA 
MBII-52 and results in complete inhibition of editing at that site without affecting a nearby D 
editing site (Yi-Brunozzi, Easterwood et al. 1999; Vitali, Basyuk et al. 2005). 
 
1.7.3 Interactors of ADARs 
 
Even less is known about RNA, proteins or small molecules that would bind to ADARs 
modulating their activity. A crystallographic study of the catalytic domain of ADAR2 has 
revealed the presence of a small molecule buried deep in the active site of the enzyme. 
Inositol hexakisphosphate (IP6) serves as a cofactor of the protein and is essential for its 
function, which was proven by expressing ADAR2 in a yeast strain deficient in the last step of 
IP6 synthesis. It seems that this molecule is acquired during ADAR2 folding. Since IP6 was 
also found bound to ADAT1, but not ADAT2 and ADAT3, it seems that its function is 
conserved and it will be found also bound to other ADARs (Macbeth, Schubert et al. 2005) 
[Fig. 1.7]. IP6 is an abundant molecule implicated in many cellular functions including: RNA 
export, DNA repair, endocytosis and chromatin remodeling (York, Odom et al. 1999; 
Hanakahi and West 2002; Hoy, Efanov et al. 2002; Shen, Xiao et al. 2003; Steger, Haswell et 
al. 2003). It also serves as a cofactor of deoxyhemoglobin and clathrin adaptor complex (AP2) 
(Arnone and Perutz 1974; Collins, McCoy et al. 2002). Interestingly IP6 is affecting AMPA 
 47 
 
receptors via increasing presence of GluR-A and GluR-B subunits in the functional receptor 
(Valastro, Girard et al. 2001). Also connection of IP6 to serotonin receptor 2C allows us to 
raise some speculations about its role in regulation of ADAR editing. This type of receptor 
upon excitation activates a phospholipase C a first agent in the cellular response cascade. A 
cell membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) is cleaved into 
diacylglycerol and inositol 1,4,5-triphosphate (IP3), which subsequently is phosphorylated to 
form IP6. Since 5-HT2cR is a substrate of editing it poses a possibility of a feedback loop. In 
presence of increased stimulation by serotonin more IP6 and therefore ADAR2 is produced, 
which by more active editing of the receptors transcript lets only receptors less sensitive to the 
ligand to be expressed (Macbeth, Schubert et al. 2005).  
 
 
 
It was also reported that ADAR2 interacts with the C-terminal domain (CTD) of 
polymerase II. Thus changes in pol-II phosphorylation and associated factors could act as 
developmental modulators of editing. Although the CTD is required for successful splicing in 
general it showed not to be the case for splicing of ADAR2 intron 4 at either the normal 3’ 
splice site or the alternative site created by editing. Surprisingly, the CTD is required for 
efficient co-transcriptional auto-editing of ADAR2 intron 4, which would implicate an 
important role of the CTD in site-selective RNA editing by ADAR2 and in coordination of 
editing with alternative splicing. Expression of polymerase II without a CTD has gravely 
reduced ADAR2 editing. The CTD of polymerase II could serve as a landing pad for different 
factors depending on the nature of the transcript. Either CTD directly binds ADAR2 or one of 
CTD-associated factors is (Laurencikiene, Kallman et al. 2006). 
Fig. 1.7: Stereo image of IP6 buried in binding site of 
ADAR2. (from (Macbeth, Schubert et al. 2005)) The zinc 
ion (magenta sphere) and E396 residue are coordinating 
the nucleophilic water (aqua sphere). Underneath Ip6 
molecule is visible (yellow sticks) interacting with 
conserved residues (green) of active site via hydrogen 
bonds, which in case of W523 and W687 are mediated by 
water. 
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Also the already known relationship between RNA editing and life cycles of few 
viruses presented some candidates of molecules, that interact with A to I editing. In the life 
cycle of previously mentioned hepatitis B virus (HBV) ADAR1 induces a switch between 
expression of two variants of hepatitis delta antigen (HDAg). The editing at this site cannot 
occur before replication of the genome is not completed because the expression of HDAg-L 
leads to the replication inhibition. It was discovered that HDAg inhibits editing at amber/W 
site not allowing this site to be edited completely. However since it is believed that HDAg can 
bind to HDV RNA the inhibition of editing occurs most probably via interference by binding 
near or at the editing site (Polson, Ley et al. 1998). 
Another viral molecule inhibiting ADAR1 activity is a small and highly structured 
regulatory RNA expressed by Adenovirus, VAI RNA (Ma and Mathews 1996). It 
accumulates in high concentrations at the late times after viral infection and antagonizes IFN-
induced antiviral response (Soderlund, Pettersson et al. 1976; Kitajewski, Schneider et al. 
1986). Its main target is RNA-dependent protein kinase PKR (Samuel 1991). It was shown 
that VAI RNA can also inhibit the activity of endogenous and overexpressed ADAR1 (Lei, 
Liu et al. 1998). Most probably VAI RNAis competing with other substrates for dsRBDs of 
ADAR1 or binds to ADAR changing its conformation to a less favorable one. 
Another factor, this time a protein, inhibiting ADAR1 activity is E3L protein expressed 
from DNA of vaccinia virus. Vaccinia virus (VACV or VV) is a large, complex, enveloped 
virus belonging to the poxvirus family. E3L is a short 190 amino acid-long protein bearing a 
Z-DNA binding domain and one dsRBD important for viral replication and inhibition of IFN-
induced antiviral response (Beattie, Tartaglia et al. 1991; Chang, Watson et al. 1992; Chang 
and Jacobs 1993; Davies, Chang et al. 1993; Chang, Uribe et al. 1995; Patterson and Samuel 
1995; Herbert, Alfken et al. 1997). A-to-I RNA editing activity of ADAR1-i is impaired by 
the product of the vaccinia virus E3L. It weakly inhibits the site-selective editing activity by 
ADAR1 at the GluR-B R/G site and the A site of serotonin 2C receptor. The C-proximal 
dsRBD of E3L was essential for antagonism of ADAR1. The mechanism of ADAR1 
inhibition by E3L is still unknown (Liu, Wolff et al. 2001). 
Beside of endogenously discovered interactors of ADARs, attempts are made to 
influence ADAR activity via creation of synthetic compounds. Already after the discovery of 
ADAR1 from Xenopus leavis attempts to find inhibitors of ADAR activity were made. Not 
surprisingly most of the active molecules (iodoacetic acid, N-ethylmaleimide or p-
hydroxymercuriphenylsulfonic acid) were reagents known to interact with cysteine residues, 
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which in the active site of ADARs functions in coordinating the zinc ion (Hough and Bass 
1994) Inhibition occurred also upon treatment with basic proteins, intercalators and high salt 
conditions but not acidic proteins, ATP, GTP, Mg
2+
, Ca
2+
, EDTA or EGTA. Also high doses 
of RNA, not allowing the formation of homodimers, inhibited the activity (Hough and Bass 
1994). Studies with nucleoside analogues have also been performed. One of the candidates is 
8-azanebularine (8-azaN), which is characterized by a very high propensity to undergo 
covalent hydration of the C6-N1 double bond. After this reaction this analogue would 
perfectly mimic a transition state of adenosine deamination, in that way trapping ADAR in 
unfinished reaction. Inhibition was obtained only at the high concentrations of the analogue 
(Veliz, Easterwood et al. 2003). In order to make a perfect substrate for ADARs for base-
trapping inhibition this analogue has to be incorporated into RNA since ADARs preferentially 
deaminate adenosines in dsRNA. Attempts to create a phosphoramidite containing this 
nucleoside for RNA synthesis were also made (Haudenschild, Maydanovych et al. 2004). 
Also studies with molecules binding next to editing sites were performed. Recently a helix-
threading peptide binding near editing sites of 5-HT2cR has been designed and proven to 
perform a substrate-specific inhibition of these sites (Schirle, Goodman et al. 2010). 
 
1.8 DSS1 
 
DSS1 is a short 70 amino acid long and very acidic protein. This polypeptide contains 
three α-helical folds and two β sheets following first α helix [Fig. 4.40]. Three long aspartic 
acid/glutamic acid-rich stretches contribute to its acidity, 37% acidic residues. Also its content 
of aromatic amino acids is high (Yang, Jeffrey et al. 2002). 
The gene was originally identified as a gene deleted in patients with SHFM (split 
hand/foot malformation) type 1, a developmental disorder in humans (Scherer, Poorkaj et al. 
1994; Crackower, Scherer et al. 1996). Although a tissue-specific expression profile of DSS1 
was detected, in limb bud, craniofacial primordia and skin, deletions in mice in other genes in 
the cluster, DLX5 and DLX6 have lead to the phenotype similar to SHFM, which may 
indicate, that they, and not DSS1, are responsible for this disease (Merlo, Paleari et al. 2002; 
Lo Iacono, Mantero et al. 2008). 
DSS1 is a very abundant protein present in the nucleus and the cytoplasm. DSS1 has 
been shown to be a part of 26S proteasome particle where it binds to the 19S regulatory 
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particle both in mammalian cells and in fission and budding yeast. This binding is possibly 
mediated by lid components Rpn3 and Rpn7, with separate binding sites in DSS1 for both 
proteins (Coux, Tanaka et al. 1996; Sone, Saeki et al. 2004). The function of DSS1 on the 
proteasome was connected in regulating the proteasome interactions and utilizing a specific 
subset of poly-ubiquitinylated p53 protein as a substrate (Funakoshi, Li et al. 2004; Krogan, 
Lam et al. 2004; Gudmundsdottir, Lord et al. 2007; Wei, Williams et al. 2008). Accumulation 
of poly-ubiquitinylated proteins occurs in sem1 mutants, the DSS1 homologue in 
Saccharomyces cerevisiae. These Sem1 deleted cells are temperature-sensitive, ceasing to 
grow at elevated temperatures. In addition, loss of Sem1 triggers or enhances a cell 
differentiation process in diploid S. cerevisiae cells but has no influence on viability of the 
organism (Jantti, Lahdenranta et al. 1999; Marston, Richards et al. 1999; Funakoshi, Li et al. 
2004; Sone, Saeki et al. 2004). 
DSS1 also plays a role in the control of DNA repair and therefore in tumorogenesis. 
Several studies show DSS1 interacting with BRCA2 (breast cancer type 2 susceptibility 
protein) responsible for homologous recombination of double strand breaks in DNA. Amino 
acids in DSS1 responsible for interactions with BRCA2 are highly conserved from yeast to 
mammals. Loss of either BRCA2 or DSS1, both in mammalian and fungal cells, results in 
defects in homologous recombination. DSS1 has been shown to influence affinity of BRCA2 
to ssDNA, therefore affecting its activity. A model based on the crystal structure of DSS1 
bound to BRCA2 proposes DSS1 mimicking oligonucleotides due to its acidic and aromatic 
content and in that way binding to BRCA2, changing conformation of the protein and the 
affinity to ssDNA (Marston, Richards et al. 1999; Yang, Jeffrey et al. 2002; Zhou, Kojic et al. 
2009). Additionally proteasomes have been shown to bind to double-stranded breaks in DNA, 
and specifically BRCA2 binds the proteasome lid components Rpn3 and Rpn7, similar to 
DSS1. However, DSS1 does not regulate BRCA2 affinity for the proteasome (Krogan, Lam et 
al. 2004; Gudmundsdottir, Lord et al. 2007). 
The knock-out animal model for the gene encoding the proteasome subunit DSS1 in 
Caenorhabditis elegans 1/Rpn15/Sem1 has been studied. In C. elegans dss-1 encodes an 
essential protein, which is required for embryogenesis, larval growth, and oogenesis. The 
most similar phenotype to dss-1 knock-out worms have kgb-1 mutants. In kgb-1 mutants an 
increased level  of the GLH-1 RNA helicase appears to result in a defective germ line. In dss-
1 mutants GLH-1 levels were normal suggesting that KGB-1 and DSS-1 are not involved in 
the same regulatory process. It is possible that the oogenesis defects in dss-1 mutants might be 
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caused by the aberrant regulation of degradation of another essential protein required for 
oogenesis, in combination with errors in homologous recombination (Orsborn, Li et al. 2007; 
Pispa, Palmen et al. 2008). 
Recently a polymorphism in human DSS1 was associated to skin squamous cell 
carcinoma. Guanosine at the position 143 is found more frequent as an adenosine substitution 
in this type of tumor. This substitution leads to less effective expression and more cytoplasmic 
localization of the protein (Venza, Catalano et al.). 
Last but not least, budding and fission yeast homologues of DSS1 Sem1 were shown to 
be involved in splicing and in mRNA export pathways. Studies in S. pombe show 
involvement of this protein in crucial interactions with export factor Rae1p FG nucleoporins 
in vivo and in vitro indicating its essential role in mRNA export (Thakurta, Gopal et al. 2005). 
Also studies in S. cerevisiae indicate a similar function of Sem1. Building an interaction map 
using the Epistatic MiniArray Profile (E-MAP) approach helped to link this protein to mRNA 
export and splicing (Wilmes, Bergkessel et al. 2008). Like in case of fission yeast Sem1 was 
shown to be a part of mRNA export pathway in budding yeast, of TREX-2 (nuclear pore 
bound TREX-2 complex). sem1 deletion mutants negatively influence targeting of Thp1, an 
essential subunit of TREX-2, to the complex. Additionally these mutants show an impairment 
in transcription of long GC-rich genes, that leads to higher susceptibility to mutations (Faza, 
Kemmler et al. 2009). 
Specific aims 
52 
 
2 Specific aims 
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Regulation of ADAR activity is a poorly understood topic in A to I editing. Still many 
questions remain unanswered. With this work a search for endogenous molecules that 
modulate ADAR activity was made. 
 
1. Designing and performing a functional editing screen. 
 
The main goal of this work was to design an in vivo yeast editing system, that could be 
employed in a screen for endogenous molecules modulating the activity of ADARs. This 
system would be based on changes in ADAR activity and not only on protein-protein 
interactions broadening in this way the spectrum of potential candidates. The next step in this 
work was, to employ this system in a genome-wide screen. 
 
2. Verifying and confirming results of the screen. 
 
Candidates obtained in the screen would be verified for the false positives and 
afterwards tested in the mammalian system in order to confirm their relevance in an organism, 
that unlike yeast possesses ADAR genes.  
 
3. Investigating mode of action of positive candidates. 
 
If any of the candidates from the screen were also confirmed to have a positive effect in 
the mammalian system, the mode of action of it would be investigated. 
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3 Materials and Methods 
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3.1 In vivo yeast editing system 
 
3.1.1 Basic strain 
 
Yeast strain used in the editing system was haploid Saccharomyces cerevisiae strain 
W303 (MATa, leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15). 
 
3.1.2 Editing substrate vector 
 
A vector expressing HIS3 as a auxotrophy marker gene containing amber stop codon, 
which served as an editing site at the same time was created. All the procedures were carried 
out on pUC18 leu2::HIS3 vector. Firstly a unique XhoI restriction site was introduced via in 
vitro mutagenesis in the 5’ translated region of the HIS3 gene. Thymine, the 101st nucleotide 
of HIS3 was substituted by guanosine. For selection of integrants the KanMX4 gene was 
introduced. KanMX4 was cut out of pFA6-KanMX4 vector using SmaI and SacI restriction 
sites and after blunting introduced into previously blunted NsiI restriction site downstream of 
HIS3 gene. Amber editing substrate was obtained by cloning of annealed and filled 
complementary oligonucleotides containing XhoI restriction sites into the XhoI site of HIS3, 
creating pUC18 HIS3amber construct. Vector for a negative selection carrying URA3 as a 
auxotrophy marker was constructed on the base of vector carrying HIS3. In order to do that 
URA3 was amplified from YCplac33 expression vector and cloned into HIS3 gene using MscI 
and NheI sites removing at the same time 296 nucleotides of the gene [Fig. 3.1]. 
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Fig. 3.1: HIS3-amber and URA3-amber integrative constructs. An architecture of a integrative fragment, 
consisting of editing substrate in the yeast marker gene and accompanied by KanMX4 resistance gene, 
both disrupting LEU2 gene, is shown. Fragment was carried on pUC18 plasmid and was cut with SacI 
and XbaI restriction enzymes prior to genomic integration. 
 
3.1.3 ADAR expressing vectors 
 
Human ADAR1 and rat ADAR2 were cloned into a centromeric tetracycline-inducible 
expression vector for Saccharomyces cerevisiae. Construct pCM251 containing two copies of 
tetO boxes and TRP1 as a yeast marker gene, that have been developed in the group of 
Enrique Herrero (Lleida, Spain), is utilizing a reversible gene expression system, where a 
repressor halting gene expression is released after an induction with tetracycline or 
doxycycline (Arino and Herrero 2003; Yen, Gitsham et al. 2003). 
 
3.1.3.1 Human ADAR1 expression construct 
 
Human ADAR1 has been cut out of pEGFP-C3-hsADAR1 vector with XhoI, blunted 
and subsequently with ClaI and inserted into ClaI and blunted PstI restriction sites of pCM251 
[Fig. 3.2]. 
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Fig. 3.2: Yeast expression vector carrying hsADAR1 gene. A human Flag/His-tagged ADAR1 version was 
cloned into a yeast centromeric vector with 2 TetO box tetracycline inducible system. 
 
3.1.3.2 Rat ADAR2 expression construct 
 
Rat ADAR2 has been amplified from pCDNA3.1-rADAR2 vector with ClaI and EcoRV 
bearing oligos and inserted into ClaI and blunted PstI restriction sites of pCM251 [Fig. 3.3]. 
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Fig. 3.3: Yeast expression vector carrying rADAR2 gene. A rat Flag-tagged ADAR2 version was cloned 
into a yeast centromeric vector with 2 TetO box tetracycline inducible system. 
 
3.1.4 Yeast growth assays 
 
Yeast cultures were grown in 28-30°C conditions. Depending on a growth purpose yeast 
were grown in full medium YPD (1% yeast extract, 2% tryptone, 2% glucose, pH 7.0) or in 
synthetic complete selective medium, SC (0.67% bacto-yeast nitrogen base w/o amino acids 
and with ammonium sulphate, 2% dropout mix (consisting of appropriate amino acids), 2% 
glucose, pH 7.0). Solid media were prepared with an addition of bacto agar (20% in case of 
YPD and 15% in case of SC). SC FOA (5-fluoroorotic acid) solid medium was prepared by 
mixing a solution consisting of: autoclaved water (¼ of end volume), 0.67% bacto-yeast 
nitrogen base w/o amino acids and with ammonium sulphate, 2% dropout mix (always 
supplemented with uracyl), 2% glucose, which was warmed up to 55-60°C and supplemented 
with 1% 5-FOA. After thorough mixing, already autoclaved and still warm (50-60°C) 15% 
agar/water solution (¾ of end volume), was added, mixed and the plates were poured. Very 
acidic pH, needed for permeability of 5-FOA, was never adjusted. Liquid SC FOA medium 
was prepared without agar. Additional possible supplements in the media were: 200µg/ml 
geneticin (G418) and 5µg/ml doxycycline (DOX). 
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Yeast for growth comparison on solid media were grown in 5ml culture overnight and 
in the morning brought to OD660 = 0.01 in deionized autoclaved water. A water based dilution 
series was, consisting of a sample with concentration of OD660 = 0.01 and another four, 
diluted each time in 1:2 ratio, was patched, in form of 3-5µl droplets, onto a Petri dish 
containing selective medium. Growth comparison in liquid media was performed in sterile 96-
well round bottom titer plates. To each well containing 200µl of appropriate medium 10µl of 
water suspension of yeast was added. For the growth curves yeast strains were first grown in 
5ml overnight cultures to be diluted to OD660 = 0.1-0.2 in 20ml of selective medium in the 
morning. Cultures were incubated with vigorous shaking for 24h, each time taking 1ml 
sample for OD measurements. 
 
3.1.5 Yeast competent cells transformation 
 
A 5ml yeast overnight culture was grown in YPD (1% yeast extract, 2% tryptone, 2% 
glucose, pH 7.0) and on the next day 1ml of the culture was transferred to 50ml YPD and 
incubated another 3-4 hours until OD660 reached 0.6. Cells were harvested by centrifugation 
(5min, 2000rpm), washed once and then resuspended in 1ml of 1xTE, 0.1M LiAc. The 
competent cells were used either immediately or in between of a week. For the transformation 
100µl of competent cells were mixed with either 10µg of linearized DNA for genomic 
integration (HIS3amber–KanMX4 or URA3amber-KanMX4 substrates) or 1µg of vector 
DNA (hsADAR1 and rADAR2 expressing vectors), 25µg of sonicated and boiled carrier 
salmon sperm DNA and 700µl of 40% PEG4000 in 1xTE, 0.1M LiAc. For genomic 
integration pUC18 HIS3/URA3amber vectors were restricted with SacI and XbaI restriction 
enzymes and the longer band (~3700bp in case of HIS3) eluted from the gel. The mixture was 
incubated for 30-60 minutes at 37°C and afterwards kept 15 minutes at 42°C. The 
transformed cells were recovered after centrifugation in water and plated on appropriate 
selective medium (SC –his G418 (200µg/ml) and SC -ura G418 for editing substrate 
integration and SC -his-trp G418 and SC -ura-trp G418 for ADAR expressing vectors 
transformation). 
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3.1.6 Yeast genomic DNA extraction 
 
A 5ml overnight culture in appropriate medium was spun down (5min, 1000rpm), pellet 
resuspended in 200µl lysis buffer (2% Triton X-100, 1% SDS, 100mM NaCl, 10mM Tris-HCl 
pH 8.0, 1mM EDTA pH 8.0) and transferred to an Eppendorf tube. 200µl of 
phenol:chloroform:isoamyl alcohol (25:24:1) and 200µl of acid etched glass beads has been 
added and vortexed at the maximum speed for 10min and after adding another 200µl TE still 
vortexed for another 5min. Aqueous phase was transferred to 1ml 96% ethanol, incubated 10-
20min at -20°C and spun at full speed for 5min. RNA contamination was digested with 5µl of 
10mg/ml RNAse A solution in 200µl TE at 37°C. Digested sample was purified again with 
equal amount of chloroform:isoamyl alcohol (24:1) and after centrifugation aqueous phase 
was precipitated with 20µl of 5M KAc and 800µl of 96% ethanol for 30min to overnight at -
20°C. After precipitation DNA was washed with 70% ethanol and resuspended in 50µl of 
deionized water. 
 
3.1.7 Yeast RNA extraction 
 
A 5ml overnight culture was diluted to OD660=0.1-0.2 and incubated in 5ml selective 
medium (with DOX induction 5µg/ml when needed) for another 6 hours. The cultures were 
spun down at 1000rpm and washed with DEPC treated deionized water once. Yeast pellet was 
resuspended in 500µl of the AE lysis buffer (50mM NaOAc pH 5.5, 10mM EDTA pH 8.0) 
and 100µl of 10% SDS was added. The suspension was added to hot (65°C) RNA phenol (pH 
4.0) and after mixing vigorously rapidly frozen in liquid nitrogen. The samples were then 
thawed on 65°C, vortexed for 30s and incubated with shaking for 4min at this temperature. 
The whole freezing and thawing procedure was still repeated two times. Samples were 
centrifuged for 5min at the full speed, extracted with 700µl phenol:chloroform:isoamyl 
alcohol (25:24:1) and then with chloroform:isoamyl alcohol (24:1) once. The aqueous phase 
was precipitated with 2.5x volume 96% ethanol and 0.1x volume 3M NaOAc pH 5.0 for 
30min at -80°C or overnight at -20°C. After precipitation DNA was washed with 70% ethanol 
and resuspended in 50µl of DEPC water. In that way obtained RNA was DNaseI digested 
twice, first with 0.5µl of 50u/µl DNaseI for 30min-1h at 37°C in 100µl followed with PCI/CI 
extraction and 96% ethanol/3M NaOAc precipitation and second with 10µl of 1u/µl DNaseI 
for 30min at 37°C in 100µl followed by heat inactivation at 65°C for 10min with addition of 
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25mM EDTA and 96% ethanol/3M NaOAc precipitation. After washing isolated RNA was 
resuspended in 50µl DEPC treated water. 
 
3.1.8 Yeast protein extracts 
 
A 5ml culture in an appropriate medium was grown overnight and in the morning 
diluted to OD660 = 0.1-0.2 and incubated in 5ml selective medium (with DOX induction 
5µg/ml when needed) for another 6 hours. Cultures were centrifuged for a minute at full speed 
and then the pellet resuspended in YEX lysis buffer (1.85M NaOH, 7.5% β-mercaptoethanol) 
and incubated 10min on ice, 150µl of cold 50% trichloroacetic acid was added and incubated 
another 10min on ice. The extracts were centrifuged 5min at full speed and resuspended in 2x 
SDS loading buffer (220mM Tris-HCl pH 6.8, 1.8% SDS, 29% glycerol, 0.03% 
bromophenol-blue, 0.03% β-mercaptoethanol). The colour suppose to be blue, if it turned 
yellow 20-50µl 1M Tris-HCl pH 8.8 were added until the colour turned blue. The extracts 
were boiled for 5min and centrifuged at full speed for 5min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
62 
 
3.2 Mating assay 
 
3.2.1 Mating assay cDNA library 
 
For mating assay with editing yeast strain a pretransformed human fetal brain 
Matchmaker cDNA library in a Saccharomyces cerevisiae strain Y187 (MATα, ura3-52, 
his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, gal80Δ, met-URA3::GAL1UAS-GAL1TATA-
LacZ MEL1) has been used . The library was developed by BD Biosciences Clontech (cat. no. 
638831). cDNA in this library have been synthesized on a mRNA template obtained from 
whole brains of spontaneously aborted male/female fetuses using an XhoI-(dT)15 primer and 
after ligation to EcoRI adaptor cloned via this restriction sites to pACT2 AD mammalian 
expression vector. Library contained 3.5x10
6
 independent clones. 
 
3.2.2 Mating assay procedure 
 
A 50ml culture of the editing strain (AHA2) was set up in SC-trp medium with addition 
of G418 (200µg/ml) for overnight incubation. Next morning the culture suspension of more 
than 1x10
7
 has been joined with 1x10
8
 of frozen stock of cDNA library containing strain 
Y187 in 50ml of 2x YPDA (2% yeast extract, 4% tryptone, 4% glucose, 0.01% adenine, pH 
7.0) and incubated at 30°C for 20-24 hours in a 2l flask with gentle swirling (30-50rpm). The 
culture was spun down, resuspended in water, number of cells counted and ~1x10
6
 cells were 
spread on a certain number of 100mm Petri dishes, containing SC -his-leu-trp medium with 
addition of 40mM 3-amino-1,2,4-triazole decreasing His3 expression, to cover desired 
number of cDNA library clones. After few days the colonies growing the fastest were picked 
up and transferred onto plates with appropriate selective medium and also frozen in YPD, 
15% glycerol and kept on -80°C. 
A negative control diploid strain was also obtained in the same procedure. Y187 yeast 
strain, pretransformed with pTD1-1 vector, was mated with the editing strain. pTD1-1 
encodes an AD/SV40 large T antigen fusion protein and uses LEU2 as a yeast marker 
auxotrophy gene.  
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3.2.3 Efficiency of mating assay 
 
Viability of strains taking part in the mating, of the diploid strain effecting from the 
process and mating efficiency were calculated according to Matchmaker cDNA library 
manual. In case of performed screening calculated viability of mated strains was as followed: 
AHA2 - 1x10
8
 and Y187 - 5.7x10
6
 and diploids strain - 7.4x10
6
, the mating efficiency was 
calculated to be of 129%. Using viability of limiting strain, in this case Y187, and amount of 
the mating culture used for plating the number of cDNA library clones covered has been 
calculated, which was 3.33x10
6
. The amount of the clones screened was slightly lower than 
the number of the independent clones of the library, which was 3.5x10
6
. The amount of 
colonies that have appeared on dishes with SC –his-leu-trp 40mM 3-AT medium was roughly 
2x10
3
. As a first step of selection only the biggest colonies were picked up and streaked out 
for further growth. 
 
3.2.4 Removal of the expression vector from yeast strains 
 
A single colony of desired diploid yeast strain, containing pCM251-rADAR2 and 
cDNA library vectors, was grown overnight in 2-5ml medium selecting only for auxotrophy 
marker gene found on cDNA library vector (LEU2) and KanMX4 being SC –leu G418. After 
overnight incubation at 30°C the culture was diluted 1:1000 to the same medium and again 
incubated overnight. Passaging was repeated still 2 times and after the third passage the 
culture was streaked out on solid medium again with tryptophan. Grown single colonies were 
patched on either SC –leu or SC –trp plates for phenotype determination and only the colonies 
growing on SC –leu but not SC –trp were picked up. 
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3.3 Confirmation of mating assay results in tissue culture 
 
3.3.1 Tissue culture expression vector 
 
The vector was based on the pcDNA3.1(-) (Invitrogen), which was restricted with XhoI 
and EcoRI enzymes, where a 6 x Myc-tag fragment cut out with the same enzymes from KS 
7myc no Ochre vector was placed. The vector obtained in that way was used as a template to 
clone in NLS sequence from NLS GFP vector via PCR using MfeI and EcoRI restriction sites 
into cleaved with EcoRI pcDNA3.1(-)-6Myc vector. In order to clone various candidates in 
three possible frames three different versions of the NLS bearing vectors were prepared; with 
EcoRI site downstream of NLS being in frame, with one nucleotide in front of it and with two 
[Fig. 3.4]. 
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Fig. 3.4: Vector for expression of Myc-tagged screening candidates in tissue culture. pCDNA3.1 (-) 
vector was equipped with 6x Myc-tag and a NLS sequence and prepared in three different, frame-
dependent versions for cloning at EcoRI site. 
 
3.3.2 Cloning of yeast screen candidates into tissue culture expression vector 
 
Yeast screen candidates were cloned into one of the pcDNA3.1(-)-6Myc-NLS vectors 
using already preexisting EcoRI site from the yeast expression vector. Since this restriction 
site was in second frame according to yeast expression frame to correct it in mammalian 
expression vector the frame had to be shifted by one nucleotide more than it would come out 
from the frame of the gene in the yeast expression vector. Genes in the first frame were 
cloned to a vector with one additional nucleotide, ones in the second frame into vector with 
EcoRI site in frame and ones in the third frame into a vector with two additional nucleotides. 
Cloning was performed according to the frameshift via PCR using 5’ primer annealing further 
upstream used previously for amplifying the library hits for sequencing or specific primer 
containing EcoRI restriction site and various 3’ primers depending on the presence of the 
restriction sites in the amplified sequence (KpnI, HindIII, BamHI, BglI). Additionally a bare 
sequence of DSS1 gene or truncated versions of the protein sequence were cloned into 
pcDNA3.1(-)-6Myc, pcDNA3.1(-)-6Myc-NLS and pCaggs vector, bearing Myc-tag sequence 
on the 3’ end, via PCR using EcoRI and BamHI and EcoRI and XhoI restriction sites 
respectively. 
 
3.3.3 Tissue culture  
 
Tissue culture cell lines; human embryonal kidney cells (Hek 293), HeLa cervical 
cancer cells and Hek 293 stably transformed with Flag-tagged rADAR2 were cultivated in 
cell culture dishes at 37°C, 5% CO2 and constant humidity. The medium used was DMEM 
(Dulbecco’s modified Eagle’s Medium), high glucose (4,5g/l) with addition of heat 
inactivated fetal bovine serum (10%), 2mM L-glutamine and 1x penicillin/streptomycin  
solution (100x stock = 10000 Units/ml penicillin, 10mg/ml streptomycin). rADAR2 stable 
cell lines were grown in a presence of 300µg/ml G418 (geneticin). Adhesive cell culture was 
passaged by exposing the cells to the digestion of 1x trypsin EDTA in PBS solution (10x 
stock = 5mg/ml trypsin, 2,2mg/ml EDTA) for 5-10 minutes at room temperature and 
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afterwards inactivated with serum containing medium. For longer maintenance of the cell 
lines the cells were kept at -80°C in 10% DMSO (dimethyl sulfoxide) and 90% fetal bovine 
serum. All media and reagents used for tissue culture were produced by PAA, Austria. 
 
3.3.4 Transfection 
 
Tissue culture cell lines were transfected using Nanofectin reagent (PAA, Austria) 
according to the manufacturer’s instructions. After 32-72 hours of incubation the cells were 
processed to obtain RNA, protein extracts or were stained to visualize protein expression. 
Cotransfections of RNAG and vectors expressing screen candidates were performed in 1:4 
ratio with the latter in an optimal amount suggested by the manufacturer. 
 
3.3.5 Creation of cell line stably expressing rADAR2  
 
Stable cell lines expressing rADAR2 were prepared by Aamira Tariq in our laboratory 
on the base of Hek 293 cell line, transformed transiently with pCDNA3.1-rADAR2 and 
selected for positive integration using 400µg/ml G418. 
 
3.3.6 Tissue culture RNA isolation 
 
The layer of cells growing on a dish was washed with 1xPBS and RNA was isolated 
directly from the dish using guanidinium thiocyanate-phenol-chloroform extraction with 
TRIzol or TriFast reagents (Invitrogen or Peqlab respectively) according to manufacturer’s 
protocols and after 96% ethanol/3M NaOAc precipitation and 70% ethanol washing step were 
kept in deionized water treated with DEPC at -20°C. Before RT-PCR, RNA was treated, 
depending on a purpose, once or twice with DNaseI, 10µl of 1u/µl DNaseI for 30min at 37°C 
in 100µl followed by heat inactivation at 65°C for 10min with addition of 25mM EDTA and 
96% ethanol/3M NaOAc precipitation. In case of RNAs expressed from plasmids (RNAG) 
additional treatment with DpnI, an enzyme cutting only Dam methyleted DNA or with 
frequent cleaving restriction enzyme like AluI was applied. 
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3.3.7 Tissue culture protein extracts 
 
Tissue culture cells were washed with 1xPBS, detached from the surface with a cell 
scraper, transferred to an Eppendorf tube and collected via short centrifugation (10s at full 
speed). Cells resuspended in an appropriate amount (depending on a size of the dish) NET-2 
buffer (150mM NaCl, 80mM Tris pH 7.4, 0.05% NP-40) were sonicated 3x 15s with 30% 
output and 50% pulse keeping in between on ice for another 15s. The cell lysate was spun 
down twice at 4°C for 10 minutes at full speed to get rid of insoluble proteins transferring the 
supernatant to a new tube each time. The remaining lysate was mixed with 2× SDS sample 
buffer (220mM Tris-HCl pH 6.8, 1.8% SDS, 29% glycerol, 0.03% bromophenol-blue, 0.03% 
β-mercaptoethanol), boiled for 5 minutes, centrifuged for 5 minutes and kept at -20°C until 
use. 
 
3.3.8 Immunoprecipitation assay 
 
The cell extracts for immunoprecipitation were prepared the same way as described 
above but only a small aliquot of it was mixed with 2xSDS sample buffer as an input control. 
Concentration of the extract was measured using the Bradford reagent (Biorad) and the equal 
amounts of them has been added to already coupled with proper antibody Protein A 
Sepharose beads (GE Healthcare). 3-5mg of the beads were used per sample, swollen in NET-
2 buffer and washed twice in it before adding 500µl of the antibody solution. The beads were 
incubated on a rotating wheel for 2h at the room temperature or over night at 4°C and washed 
three times in 500µl NET-2 buffer. Immunoprecipitation lasted 1-2h incubated on a rotating 
wheel at the room temperature. Afterwards the unbound extract was washed off again with 3 
washings with NET-2 buffer. After last washing the excess of the buffer was removed and the 
beads were resuspended in 30-40µl of 2x SDS sample buffer, boiled for 5 minutes, 
centrifuged for 5 minutes and kept at -20°C until use. 
 
3.3.9 In situ staining 
 
Transfected cells grown on acid-etched coverslips after 32 to 48 hours were washed 
once with 1×PBS and fixed for 5 minutes with a fixing solution (2% paraformaldehyde, 
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1×PBS, 0.05% Triton X-100). The next washing step was followed by a one minute 
methanol-permeabilisation-step and another washing step. In order to visualize expressed 
proteins an immunocytology was performed. The fixed cells were blocked with 10% horse 
serum solution in 1xPBST (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.76mM KH2PO4, 
pH 7.4, 0.2% Tween-20). The cells were kept in primary antibody for 2 hours at room 
temperature or over night at 4°C in a moist chamber, washed 3 times with 2.5% horse serum 
solution in 1xPBST, kept in secondary antibody for 1 hour at room temperature in a moist 
chamber and after that still washed 3 times with 2.5% horse serum 1xPBST solution. For 
visualization of chromatin, preparations were mounted with Antifade (1g p-
phenylenediamine/100ml phosphate buffer (150mM NaCl, 10mM KH2PO4, 10mM 
Na2HPO4), pH to 8.0 with carbonate buffer (500mM NaHCO3, 500mM Na2CO3); mix 1 part 
with 8 parts of glycerol) containing DAPI.  
 
3.3.10 Microscopical analysis 
 
Microscopic images were captured on a Zeiss fluorescence microscope equipped with 
an ORCA cooled charged-coupled device camera (Hamamatsu Middlesex, CA). Images were 
imported into Photoshop 4 (Adobe Systems, Mountain View, CA) with the help of a QED 
plug-in module (QED-Imaging, Pittsburgh, PA). 
 
3.3.11 FACS analysis 
 
The flow cytometry data was collected on a FACScalibur (Becton & Dickinson) using 
the CellQuest 3.3 software at the BioOptics department of the Institute of Molecular 
Pathology, Vienna, Austria. The data was further analysed with the FlowJo 6.3.1 software. 
 
3.3.12 Cloning of FACS reporter system 
 
In order to investigate influence of ADAR2 activators in the tissue culture an A to I 
editing substrate was cloned between red fluorescent protein (RFP) and green fluorescent 
protein (GFP), used as a constitutively expressed control and as an editing efficiency marker 
respectively, in RNLG. (Schoft, Schopoff et al. 2007) Modified GluR-B R/G sequence, 
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flanked with XhoI sites and with addition of two nucleotides to keep GFP in frame with it, 
was amplified via PCR and cloned into polylinker of RNLG using HindIII and BamHI 
restriction sites. Additionally to RNAG vector a construct with ’pre-edited’ version of the 
editing substrate containing tryptophan (W) codon as a positive control named RNWG has 
been prepared [Fig. 3.5]. 
 
 
 
Fig. 3.5: FACS reporter system construct RNAG. A fusion protein sequence consisting of RFP, NLS, 
linker, Amber stem-loop and GFP was expressed from pDsRedExpress-C1 vector (Clontech) carrying 
kanamycine resistance gene for bacterial propagation. 
 
3.3.13 FACS data analysis 
 
Each time a readouts of 30000 cells were taken. The red and green fluorescence 
readouts of each cell were in effect plotted with help of FlowJo 6.3.1 software of on a graph 
with logarithmic scale with red fluorescence on y axis and green fluorescence on x axis. For 
statistical purposes 6 different gates were taken with very broad window for the green 
fluorescence and very narrow for the red one to observe changes of the green fluorescence 
compared to fairly stable red fluorescence. The gates were chosen above a region of 
untransfected cells background and below a region where cell density started to drop down. 
The mean green florescence values from each gate calculated using Excel software 
(Microsoft) were divided by mean red fluorescence values to become normalized relative 
fluorescence values, which were plotted again on the graph on x axis against the chosen gates 
on y axis. 
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3.4 Other techniques used 
 
3.4.1 Polyacrylamide gel electrophoresis (SDS PAGE) 
 
Protein separation by molecular weight was performed in a polyacrylamide gel matrix. 
A SDS gel is composed of a resolving gel (x% 30:1 acrylamide/bis-acrylamide according to 
the size of the proteins to be resolved, 375mM Tris-HCl pH 8.8, 0.1% SDS) and a stacking 
gel (concentrates negatively charged proteins to a thin boundary; 3.6% acrylamide (30:1 
acrylamide/bis-acrylamide), 110mM Tris-HCl pH 6.8, 0.1% SDS, 13% glycerol). The 
proteins were mixed with 2× SDS sample buffer (220mM Tris-HCl pH 6.8, 1.8% SDS, 29% 
glycerol, 0.03% bromophenol-blue, 0.03% β-mercaptoethanol), boiled for 5 minutes, 
centrifuged for 5 minutes and loaded onto the gel. Electrophoresis was carried out in 1× SDS 
running buffer (25mM Tris-HCl, 190mM glycine, 0.1% SDS). 20mA electric current was 
applied per gel. 
 
3.4.2 Western Blotting 
 
After electrophoresis, the proteins were transferred to a polyvinylidene fluoride 
membrane (GE Water & Process Technologies) via tank-blotting. For that, the membrane 
activated in methanol and equilibrated in transfer buffer (20mM Tris-HCl, 150mM glycine) 
was placed on the gel and all air bubbles were removed. The gel and membrane were placed 
between two Whatman papers and two sponges, and that sandwich was then put into the tank, 
which was filled up with transfer buffer. The transfer was carried out at room temperature 
with icepacks in the apparatus at 360-450mA for 80 minutes. Afterwards the membrane was 
blocked with 5% dry skim milk in TBST (25mM Tris, pH 7.4, 3.0mM KCl, 140mM NaCl and 
0.05% Tween 20) for 20 minutes at room temperature. The primary antibody was diluted in 
0.5% milk in TBST and applied to the membrane. The membrane was shaken in the antibody 
solution for one to two hours at room temperature or overnight at 4°C. It was then washed 
three times for 10 minutes with 0.5% milk in TBST. The secondary antibody was diluted in 
0.5% milk and the blot was again incubated for one hour. This was followed by three washing 
steps (10 minutes each, 0.5% milk in TBST). The proteins on the blot were either detected by 
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chemiluminescence or NBT/BCIP chromogen precipitation. For the chemiluminescence, the 
secondary antibody had to be coupled to horseraddish peroxidase. For the detection the 
PIERCE supersignal solution was used according to the manufacturers instruction. For the 
chromogen detection, the secondary antibody had to be coupled to alkaline phosphatase. In 
the presence of an alkaline phosphatase enzyme, the chromogen NBT/BCIP produces a purple 
precipitate. The detection was carried out as recommended by the manufacturer.  
 
3.4.3 Reverse transcription 
 
The cDNA was synthesized with RevertAid M-MuLV Reverse Transcriptase 
(Fermentas) according to the manufacturer’s instructions using sequence specific oligos. 1/4 
of the heat inactivated RT-reactions were used as templates for PCR reactions.  
 
3.4.4 Cycle sequencing 
 
Sequencing was performed with use of BigDye® Terminator v3.1 cycle sequencing kit 
(Applied Biosystems) according to manufacturer’s instructions and afterwards by the 
Department of Systematic and Evolutionary Botany at the Faculty of Life Sciences, 
University of Vienna. 
 
3.4.5 Poisoned primer reaction 
 
To certain amount of RNA (0.5-1µg in case of in vitro transcribed and 5-100µg in case 
of total RNA) 4pmol of radioactively labelled primer (P
32
) was added and resuspended in 4µl 
of the hybridisation buffer (225mM Hepes pH 7.0, 450mM KCl). After 1 minute of boiling 
the mixture was slowly cooled down. Afterwards 2.2µl of the extension mix (0.6µl 10x 
extension mix (1.3 Tris-HCl pH 8.5, 100mM DTT, 100mM MgCl2), 0.3µl poisoned mix 
(1mM dATP, dCTP, dGTP, 4mM dTTP), 0.3µl AMV reverse transcriptase (4u/µl New 
England Biolabs), 1µl DEPC treated water) was added and the mixture was incubated for an 
hour. The reaction was stopped by addition of 30µl of 96% ethanol, 1µl of 3M NaOAc pH 
5.0, 1µl 0.5M EDTA and following precipitation for 30min at -80°C or overnight at -20°C. 
After precipitation the samples were washed with 70% ethanol, resuspended in 10µl of DEPC 
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treated deionized water and separated on 10-12% native acrylamide gel (29:1 acrylamide/bis-
acrylamide, 8M urea, 1x TBE (0.89M Tris-HCl, 0.89M boric acid, 20mM EDTA set to pH 
8.3)). 
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3.5 Primers 
 
The following primers were used in this investigation: 
 
Name Sequence 5‘ – 3‘ Purpose 
leu2-1 AGGATATACCATTCTAATGT 5’ primer for amplification of disrupted sequence 
of LEU2 gene 
leu2-2 AGCAGACAAGATAGTGGCGA 3’ primer for amplification of disrupted sequence 
of LEU2 gene 
MJ1136 GGTGGAGTTCAAGTCCATCTACAT
GG 
5’ primer for RT-PCR of RNAG (binds to 3`end of 
RFP) 
MJ1137 GTGCAGATGAACTTCAGGGTCAGC 3’ primer for RT-PCR of RNAG (binds to 5` end of 
GFP) 
MJ1421 CTATTCGATGATGAAGATCCACCAA
ACC 
5’ primer for amplification of the pACT2 (cDNA 
library) content 
MJ1422 GTGAACTTGCGGGGTTTTTCA 
TCTACGA 
3’ primer for amplification of the pACT2 (cDNA 
library) content 
MJ1715 CACTCGAGCTTCCCAGAAAAAGAG
GCAG 
Forward primer used to introduce a XhoI 
restriction side in a HIS3 
MJ1716 AGCTCGAGTGCTCTATCGCTAGGG
GAC 
Reverse primer used to introduce a XhoI 
restriction site in a HIS3 
MJ1717 GGTGAGCGCTAGGAGTCAC Forward primer containing EcoR47III restriction 
site used to cut pUC18 leu2:HIS3 plasmid 
upstream of HIS3 
MJ1718 AATGATGCATTACCTTGTCATC Reverse primer containing NsiI restriction site 
used to cut pUC18 leu2:HIS3 plasmid 
downstream of HIS3 
MJ1745 TCGATTTAGGTGGGGTATATGTGC
TCAATGTATAGCCTACCCAGATCA 
Forward primer for creation of short version of 
GluR-B amber stem-loop substrate 
MJ1746 TCGATGATCTGGGTAGGCTATACA
TTGAGCACATATACCCCACCTAAA 
Reverse primer for creation of short version of 
GluR-B amber stem-loop substrate 
MJ1747 TCGATTTGGGTGGGGTATATGTGC
TCAATGTATAGCCTACCCAGATCA 
Forward primer for creation of short version of 
GluR-B W stem-loop substrate 
MJ1748 TCGATGATCTGGGTAGGCTATACA
TTGAGCACATATACCCCACCCAAA 
Reverse primer for creation of short version of 
GluR-B W stem-loop substrate 
MJ1787 ATGTGTATATATGTATACCTATG Forward sequencing primer of KanMX4 insert put 
into 3’ flanking region of HIS3 gene in pUC18-
leu2:HIS3 plasmid 
MJ1788 GCTTCATCGGAGATGATTCG Reverse primer used to sequence KanMX4 insert 
put into 3ʼ flanking region of HIS3 gene in pUC18-
leu2:HIS3 plasmid 
MJ1832 GCGGAATACCCTCGCCAG Reverse sequencing primer placed after start 
codon of rADAR2 
MJ1833 GTCGCTGGATGCGGGTAC Forward sequencing primer placed before the end 
of rADAR2  
MJ1845 GCTCATCGATATGGACTACAAAGA
CGATGAC 
5ʼ primer for amplification of rADAR2 gene out of 
pCDNA3.1-rADAR2 containing ClaI 
MJ1846 GCTCGATATCCTATAGAATAGGGC
CCTCTAG 
3ʼ primer for amplification of rADAR2 gene out of 
pCDNA3.1-rADAR2, contains EcoRV 
MJ2073 GATCTCGAGTTAGGTGGGTGGAAT
AGTATAAC 
Forward primer to amplify GluR-B R/G stem-loop 
with XhoI sticky ends to create amber stem-loop 
(additional preliminary stop codon was created) 
MJ2074 GATCTCGAGTTGGGTGGGTGGAAT
AGTATAAC 
Forward primer to amplify GluR-B R/G stem-loop 
with XhoI sticky ends to create W stem-loop loop 
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(additional preliminary stop codon was created) 
MJ2075 TAACTCGAGAGCTGGGTAGGTGGG
ATACTATAA 
Reverse primer to amplify GluR-B R/G stem-loop 
with XhoI sticky ends to create amber and W 
stem-loops loop (additional preliminary stop 
codon was created) 
MJ2080 GTAATTCTGCTAGCCTCTG Reverse primer downstream of amber/W stem-
loop containing NheI site 
MJ2102 TTCTACGTAGGCTCCAATG Primer for internal sequencing of rADAR2 
MJ2103 TTGCTGATACCGCTGAGC Primer for internal sequencing of rADAR2 
MJ2139 GTAGAACAATATGCTCAATGTTGTT
CTAGTATCCCAC 
Forward primer to get rid of preliminary stop 
codon from stem-loop 
MJ2140 CTAGAACAACATTGAGCATATTGTT
CTACTATTCCAC 
Reverse primer to get rid of preliminary stop 
codon from the stem-loop 
MJ2256 ATCATGGCCAAAGCTACATATAAG
GAACGTG 
Forward primer to amplify URA3 without start 
codon and clone it in stem-loop-HIS3 constructs, 
contains BalI (MscI) site. 
MJ2257 ATACGCTAGCTTAGTTTTGCTGGC
CGCAT 
Reverse primer to amplify URA3 with stop codon 
and clone it in stem-loop-HIS3 constructs, 
contains NheI restriction site. 
MJ2263 ATGACAGAGCAGAAAGCCCT Forward primer for RT-PCR of HIS3 
MJ2264 CTACATAAGAACACCTTTGGT Reverse primer for RT-PCR of HIS3 
MJ2274 CATACTCGAGCATCAGGGGAAACC
AGGGATTTCCATAGGATATACGC 
5ʼ primer for formation of hepatitis delta type 1 
amber editing substrate for in vivo yeast editing 
system 
MJ2275 CATACTCGAGCATCAGGGGAAACC
AGGGATTTCCATGGGATATACGC 
5ʼ primer for formation of hepatitis delta type 1 
control ‘pre-edited’ version of editing substrate for 
in vivo yeast editing system 
MJ2276 CATACTCGAGAGCACCGGGGACCA
GTGGAGCCATGGGATGCGTATATC 
3ʼ primer for formation of hepatitis delta type 1 
editing substrate for in vivo yeast editing system 
MJ2384 AGCACTCGAGAAAGTGGCATATGC
GACGGCCATGGACTGGTTC 
5’ primer for formation of Gabra-3 amber editing 
substrate for in vivo yeast editing system 
MJ2385 GAAGCTCGAGAAAGGCATAACAGA
CGGCTATGAACCAGTCCAT 
3’ primer for formation of Gabra-3 amber editing 
substrate for in vivo yeast editing system 
MJ2386 GAAGCTCGAGAAAGGCATAACAGA
CGGCCATGAACCAGTCCAT 
3’ primer for formation of Gabra-3 control ‘pre-
edited’ editing substrate for in vivo yeast editing 
system 
MJ2420 GCAACGTGCTGGTTATTGTG pCaggs forward sequencing primer 
MJ2431 CGCAAATGGGCGGTAGGCGTG Forward primer for sequencing of pcDNA3.1 
vectors 
MJ2577 TCCCAATTGGACCATGGGGTGGCC
CAC 
5ʼ primer containing MfeI restriction site for NLS 
cloning from NLS GFP in pGEX2T into 
pcDNA3.1(-)-6Myc expression vector 
MJ2578 CATGAATTCGTCTTCTACCTTTCTC
TTCTT 
5ʼ primer containing EcoRI restriction site for NLS 
cloning from NLS GFP in pGEX2T into 
pcDNA3.1(-)-6Myc expression vector 
MJ2579 CATGAATTCCGTCTTCTACCTTTCT
CTTCTT 
5ʼ primer containing EcoRI restriction site for NLS 
cloning from NLS GFP in pGEX2T into 
pcDNA3.1(-)-6Myc expression vector with 
addition of one nucleotide upstream of restriction 
site 
MJ2580 CATGAATTCGCGTCTTCTACCTTTC
TCTTCTT 
5ʼ primer containing EcoRI restriction site for NLS 
cloning from NLS GFP in pGEX2T into 
pcDNA3.1(-)-6Myc expression vector with 
addition of two nucleotides upstream of restriction 
site 
MJ2581 CCGGTACCCAGTATCTACGATTCA
TAGAT 
3ʼ primer for cDNA library amplification from 
pACT2 containing KpnI 
MJ2582 CCAAGCTTCAGTATCTACGATTCAT 3ʼ primer for cDNA library amplification from 
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AGAT pACT2 containing HindIII 
MJ2584 GCGAAGCTTGGCTCGAGTTAGGTG
GGTGG 
5ʼ primer for GluR-B R/G stem-loop with amber 
stop codon cloning to RNLG vector containing 
HindIII 
MJ2585 GCGAAGCTTGGCTCGAGTTGGGTG
GGTGG 
5ʼ primer for GluR-B R/G stem-loop with Trp 
codon cloning to RNLG vector containing HindIII 
MJ2586 AGGGATCCCTCGAGAGCTGGGTA
GGT 
3’ primer for cloning GluR-B R/G stem-loop with 
BamHI 
MJ2648 CCAAGCTTCAGTATCTACGATTCAT
AGAT 
3ʼ primer for cDNA library amplification from 
pACT2 containing AflII (BspTI) 
MJ2649 TCCCAATTGGCGGCCGCGTCGAC 5ʼ primer for cDNA library amplification from 
pACT2 containing MfeI instead of EcoRI 
MJ2679 TCGAATTCATGATTATCTACCGGGA
CCT 
A primer containing EcoRI site to amplify 
candidate no. 60 omitting stop codon in 5ʼUTR 
MJ2726 TCTACCTAATGGATGGAAATGTCA
GTAAC 
Forward RT-PCR CyFip2 primer 
MJ2727 ATCCCGGATCTGAACCATCTG Reverse RT-PCR CyFip2 primer 
MJ2729 ATGAATTCATGGTGGAGGCTTTCT
GTG 
5ʼ primer to amplify candidate no. 02 without stop 
codon in 5ʼUTR 
MJ2730 ATGAATTCATGGTGGATTACTATGA
AGTT 
5ʼ primer to amplify candidate no. 48 without stop 
codon in 5ʼUTR 
MJ2734 CCGGATCCCAGTATCTACGATTCA
TAGAT 
3ʼ primer for cDNA library amplification from 
pACT2 containing BamHI 
MJ2774 ATGAATTCATGTCAGAGAAAAAGCA
GC 
5ʼ primer with EcoRI restriction site to clone DSS1 
into 3’ 3xMyc containing pCaggs 
MJ2775 ATCTCGAGTGAAGTCTCCATCTTAT
AAC 
3ʼ primer with XhoI restriction site to clone DSS1 
into 3’ 3xMyc containing pCaggs 
MJ2783 TACTCGAGATCTTCATCTTCATCTA
AGC 
A reverse primer containing XhoI restriction site to 
clone 1
st
 35 amino acids of DSS1 into 3’ 3xMyc 
containing pCaggs 
MJ2784 TAGAATTCATGGCACATGTCTGGG
AGGAT 
A forward primer containing EcoRI restriction site 
to clone 2
nd
 35 amino acids of DSS1 into 3’ 
3xMyc containing pCaggs (with start codon) 
MJ2785 TAGGATCCCTAATCTTCATCTTCAT
CTAAGC 
A reverse primer containing BamHI restriction site 
to clone 1
st
 35 amino acids of DSS1 into 
pCDNA3.1-6Myc-NLS0 vector (with stop codon) 
MJ2786 TAGGATCCCTATGAAGTCTCCATCT
TATAAC 
A reverse primer containing BamHI restriction site 
to clone 2nd 35 amino acids of DSS1 into 
pCDNA3.1-6Myc-NLS0 vector (with stop codon) 
MJ2811 ATGAATTCAATGTCAGAGAAAAAGC
AGC 
A forward primer containing EcoRI restriction site 
to clone DSS1 into pCDNA3.1-6Myc vector 
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3.6 Antibodies 
 
The following antibodies were used in this study: 
 
Name Target Source Dilution Company 
309 hsADAR1 Rabbit 1:500 (WB) homemade 
9E10 Myc-tag Mouse 1:3 (WB), 1:1 (IP, Cyt) homemade 
Anti-FLAG Flag-tag Rabbit 1:1000 (WB), 1:300 (Cyt) Sigma 
Anti-Rabbit rabbit (secondary antibody, 
coupled to horseradish 
peroxidase) 
Goat 1:10000 (WB) Axell 
Anti-Rabbit Rabbit (secondary antibody, 
coupled to alkaline 
phosphatase) 
Goat 1:1000 (WB) Pierce 
Anti-Mouse Mouse (secondary antibody, 
coupled to alkaline 
phosphatase) 
Goat 1:1000 (WB) Sigma 
Alexa Fluor 
568 Anti-
Mouse 
Mouse (secondary antibody) Goat 1:400 (Cyt) Invitrogen 
Alexa Fluor 
488 Anti-
Rabbit 
Rabbit (secondary antibody) Goat 1:400 (Cyt) Invitrogen 
 
(WB = Western Blotting, Cyt = in situ staining) 
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4.1 Basic yeast strain 
 
In order to screen for enhancers and inhibitors of ADAR activity a yeast model was 
designed. Two different auxotrophy marker genes were employed: HIS3 was used for positive 
selection, while URA3 was used for negative one. A canonical editing site, which is at the 
same time a stop codon, was introduced in the sequence of these genes. Expression of the 
gene was only possible after editing of the stop codon by ADARs. The substrate-reporters 
fusions were introduced into the genome of Saccharomyces cerevisiae strain W303. At the 
same time ADAR expressing vector constructs were introduced. With this system one can 
screen for activators of editing, as this results in an increase of His3 expression and in turn of 
yeast growth. In addition, one can screen for inhibitors of editing, as this causes an increase in 
Ura3 expression and in turn to a decreased growth in the presence of 5-fluoroorotic acid (5-
FOA) being converted by this protein into toxic 5-fluoroacil. 
 
4.1.1 Creation of basic strains 
 
The strain and needed controls were created by integrating a marker gene with the 
editing substrate into the genome of the auxotroph Saccharomyces cerevisiae strain W303 in 
order to obtain a stable, one copy expression. The introduced fragment consisted of HIS3 or 
URA3 genes containing an insert derived from the glutamate receptor subunit B R/G site and 
kanamycin resistance cassette (KanMX4 gene) all integrated into the leu2 locus in the 
genome. For creation of the editing stem-loop, not the original coding frame of GluR-B was 
used but it was shifted by one nucleotide upstream. A nucleotide change of an adenosine in 
front of the one being edited into thymine changed AAG codon encoding lysine into TAG 
codon encoding amber stop codon. This codon was used as a switch between unedited state, 
which meant a preliminary stop in translation and edited state (TTG – tryptophan) when the 
translation proceeded. Compensatory mutation was introduced also on the 3’ part of the stem-
loop sequence. Additionally a ’pre-edited’ version of the editing substrate containing 
tryptophan (W) codon as a positive control has been prepared [Fig. 4.1]. 
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Fig. 4.1: RNA folding predictions of glutamate receptor subunit B R/G editing site, editing substrate used 
in yeast system based on GluR-B R/G site with amber stop codon as an editing site and a ‘pre-edited’ 
version of this substrate with edited adenosine in a circle. Editing substrates are shown in their XhoI 
restriction site context. 
 
Accordingly, two strains were obtained for each selection and both contained marker 
genes with an amber stop codon as an editing site (from now on AH and AU for HIS3 and 
URA3 respectively). In addition, the strains with a ‘pre-edited’ variant of the editing substrate 
were constructed, with a tryptophan (W) codon instead of the amber stop codon (from now on 
WH and WU respectively). Integrants were selected on YPD G418 medium and verified by 
PCR [Fig. 4.2 and Fig. 4.3]. 
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Fig. 4.2: Amplification products of editing substrate for determination of homologous integration. Proper 
integration gives rise to 3209bp fragment amplified using leu2-1 and leu2-1 primers and 812bp fragment 
using MJ2140 as a reverse primer instead. In case of non-homologous integration also a wild type LEU2 
gene would be amplified with a product of 940bp in size. 
 
 
 
Basic strains were transformed with the tetracycline inducible centromeric vector 
pCM251, which carries either hsADAR1 fused to a Flag- and His-tags or rADAR2 with Flag-
tag. As a control, a strain transformed with an empty pCM251 vector was created. Since the 
selection marker on the centromeric vectors was TRP1 gene the positive transformants were 
selected on a SC –trp G418 medium. Strains containing an empty centromeric vector were 
termed AHE, WHE, strains expressing hsADAR1 were termed AHA1, WHA1 and strains 
expressing rADAR2 were termed AHA2, WHA2. 
Fig. 4.3: Determination of homologously 
integrated HIS3amber-KanMX4 editing 
substrate into leu2 locus. The first panel 
shows Gene Ruler DNA Ladder Mix marker 
(Fermentas) and bands amplified from 
pUC18 HIS3amber-KanMX4 vector as 
positive controls with leu2-1 and leu2-2 
primers in the second lane and leu2-1 and 
MJ2140 in the third. The next panel shows 
an evidence of the homologous integration 
with yeast total DNA amplification products 
of 3209bp in case of the leu2 with properly 
integrated editing substrate in the first lane 
and 812bp in case of 5’ leu2-editing 
substrate in the second lane.  
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Expression of ADARs and the editing substrate was tested by RT-PCR. This assay also 
showed a leaky expression of ADAR in the absence of DOX [Fig. 4.4]. 
 
 
 
Fig. 4.4: Confirmation of  mRNA transcribed from HIS3-editing substrate, hsADAR1 and  rADAR2 genes. 
The indicated strains were grown on appropriate media in the presence or absence of DOX. RT-PCR was 
performed with MJ2139 and MJ2080 for HIS3, MJ317 and MJ532 for hsADAR1 and MJ2102 and 
MJ2103 for rADAR2. On the first panel expression of HIS3-editing substrate is shown in all examined 
strains. Second shows expression of hsADAR1 mRNA only in AHA1 strain and increase in amplification 
product in case of DOX induction. The same effect can be seen in case of rADAR2 mRNA in AHA2 strain. 
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Expression of ADARs in the obtained strains was also shown via Western Blotting 
using antibodies against hsADAR1 or against Flag-tag epitope in case of rADAR2. 
Surprisingly expression was only detected upon addition of DOX [Fig. 4.5]. 
 
   
 
Fig. 4.5: Picture of blots stained with anti-hsADAR1 primary antibody (309), with anti-Flag primary 
antibody and with horse radish peroxidase conjugated secondary antibodies. AH, AHA1, WHA1 and 
AHA2 yeast strains were grown on selective media without and with addition of doxycycline induction. 
Protein extracts isolated from the cultures were separated via SDS-PAGE. In both cases, hsADAR1 and 
rADAR2, the protein expression is only detectible in ADAR expressing strains and only upon DOX 
induction of the yeast culture. 
 
Although both of the proteins, hsADAR1 and rADAR2 seemed to be properly 
expressed, only rADAR2 in yeast had the predicted effect on the growth of the developed 
strains on the selective media. Additionally, leaky expression previously visible in RT-PCR 
experiment leads to growth on selective media even in the absence of DOX induction [Fig. 
4.6]. 
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Fig. 4.6: Growth comparison of indicated strains on different selective media for phenotypical 
comparison of the strains expressing hsADAR1 and rADAR2. Strain expressing hsADAR1 in contrast to 
one expressing rADAR2 did not grow on medium lacking histidine and even induction via DOX didn’t 
induce growth. 
 
To understand, why yeast expressed ADAR1 did not lead to editing of the reporter, 
several assays were performed. First, hsADAR1 was expressed in HeLa cells from its original 
vector and pulled down via immunoprecipitation with an anti-hsADAR1 antibody. The 
immunoprecipitated material was able to edit a hsADAR1 editing substrate (FlnA) in vitro 
[data not shown]. Second, HeLa cells expressing hsADAR1 from the same vector were used 
later in FACS experiments together with a fluorescence editing reporter (GluR-B R/G amber 
stem-loop). A major effect on editing was observed [Fig. 4.30]. 
Even though the hsADAR1 is properly expressed in yeast, it seems to be inactive, as the 
designed substrate is not edited [Fig.4.7]. Importantly, the same ADAR1 construct is active 
when expressed in mammalian cells, indicating, that the protein is not properly folded or lacks 
some important cofactors in yeast. 
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4.1.2 Yeast strain for enhancer screening 
 
An appropriate strain was developed for positive selection, to allow isolation of 
enhancers of editing. Enhancement in ADAR activity resulted in increased growth. To 
achieve this a HIS3-editing substrate was integrated into Saccharomyces cerevisiae W303 as a 
marker gene [Fig. 3.1 and Fig. 4.1]. rADAR2 gene was expressed from tetracycline inducible 
centromeric yeast expression vector [Fig. 3.3]. Induction by doxycycline and expression of 
His3 was tested on liquid and solid selective media [Fig. 4.8 and Fig. 4.9]. All strains showed 
the expected phenotype reflecting the auxotorphy markers used for introduction of transgenes. 
Interestingly, leakiness of the tetracycline inducible promoter can be observed when the 
AHA2 strain is growing on media lacking histidine. Even in the absence of doxycycline 
growth can be observed. DOX induction significantly increases the growth on the selective 
medium. The leakiness is even more apparent on solid media. Here the uninduced AHA2 
strain is growing almost as good as WHA2 on medium lacking histidine. DOX induction 
improves the growth only marginally. 
 
Fig. 4.7: Editing level comparison 
of the editing substrate expressed 
in the developed yeast strains 
expressing hsADAR1 gene. (edited 
adenosine marked with an 
asterisk) Both AHA1 and AUA1 
strains were grown on the 
selective liquid media without or 
with an addition of DOX 
induction. cDNA obtained via 
reverse transcription was 
amplified using MJ2263 and 
MJ2080 primers and sequenced 
with MJ2263 primer. There is no 
visible effect on editing in case of 
expression of hsADAR1. (for 
rADAR2 editing levels Fig. 4.10 
and Fig. 4.16) 
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Fig. 4.9: Growth comparison of the developed strains on different selective solid media for phenotypical 
comparison. AH, WH, AHA2 and WHA2 strains were grown on different solid selective media in a 
dilution series. 
 
Direct proof of editing of the substrate by rADAR2 in yeast was provided by bulk 
sequencing of RT-PCR products obtained from the HIS3-editing substrate mRNA. A high 
level of editing was visible even without DOX induction due to the leakiness of the system. 
Induction by DOX led to 100% editing [Fig. 4.10]. 
Fig. 4.8: Growth comparison of the 
developed strains on different 
selective liquid media for 
phenotypical comparison. AH, WH, 
AHE, WHE, AHA2 and WHA2 
strains were grown on different 
liquid selective media in 96-well 
microtiter plate. 
 
Results 
86 
 
 
 
The yeast strain AHA2 together with control strains has been used for screening for 
enhancers of rADAR2’s editing activity. Since the leakiness of the system reduces the 
stringency of the screen, a 3-amino-1,2,4-triazole (3-AT) selection was applied. This 
compound is a competitive inhibitor of the HIS3 gene product, imidazoleglycerol-phosphate 
dehydratase, and should reduce the background expression of HIS3. Thus, only the clones that 
have elevated expression of HIS3 were expected to survive. Different concentrations of 3-AT 
were tested. Concentrations higher than 20mM 3-AT reduced background growth to 
undetectable levels [Fig. 4.11]. In the screen a concentration of 40mM 3-AT was used. 
 
Fig. 4.10: Comparison of the editing level of the substrate 
expressed in the developed yeast strain expressing rADAR2 gene 
(edited adenosine marked with an asterisk). AHA2 strain was 
grown on the selective liquid media without or with an addition of 
DOX. cDNA obtained via reverse transcription was amplified using 
MJ2263 and MJ2080 primers and sequenced with MJ2263 primer. 
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4.1.3 Yeast strain for inhibitor screening 
 
To allow for a negative selection on editing activity a strain containing an editable stop 
codon upstream of URA3 was created [Fig. 3.1]. Additionally, the rADAR2 gene was 
introduced on a tetracycline inducible centromeric expression vector [Fig. 3.3]. The drug 5-
fluoroorotic acid (5-FOA) was added to the media. Ura3 converts FOA to 5-fluoro-uracil 
which is toxic to cells. Thus, editing leads to expression of Ura3 which in turn is toxic. Only 
cells that are inhibited in their editing activity are therefore able to grow on this medium. 
Transformation of this starting strain with an expression library, therefore allows to screen for 
factors that inhibit ADAR activity. The proper phenotype of strains and also induction of 
ADAR by doxycycline was tested on liquid and solid selective media [Fig. 4.12 and Fig. 
4.13]. All strains show the expected phenotypes corresponding to the auxotrophic markers 
introduced. Again, leakiness of the tetracycline inducible promoter was observed. DOX 
induction significantly increases the growth on the selective medium. In comparison to His3 
expressing strain [Fig. 4.8 and Fig. 4.9] the leakiness is not that extent and the DOX induction 
is more visible. 
 
Fig. 4.11: A growth 
comparison of AHA2 yeast 
strain grown in the SC-his-trp 
medium containing an 
increasing concentration of 3-
AT. 10
5
 cells of AHA2 yeast 
strains were incubated on 10cm 
dishes for 3 days. On the 
picture growth on medium with 
different concentrations of 3-
AT is shown (0, 5, 10 and 
15mM). From 20mM on no 
growth could be observed. 
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Fig. 4.13: Growth comparison of the developed strains on different solid selective media for phenotypical 
comparison. AU, WU, AUA2 and WUA2 strains were grown on different solid selective media in a 
dilution series. 
 
In order to utilize 5-FOA in screens its influence on growth was tested. DOX increases 
the growth in medium without Ura, while it decreases the growth on medium with 5-FOA as 
seen on liquid media [Fig. 4.14]. On solid media 5-FOA prohibits the growth of strains 
expressing Ura3, but due to leakiness of the system and the smaller difference between 
uninduced and induced strain, also the uninduced AUA2 strain fails to grow on 5-FOA 
containing media [Fig. 4.15]. 
 
Fig. 4.12: Growth comparison of the 
developed strains on different liquid 
selective media for phenotypical 
comparison. AU, WU, AUE, WUE, 
AUA2 and WUA2 strains were grown 
on different liquid selective media in 
96-well microtiter plate. 
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Fig. 4.15: Study of 5-FOA effect on URA3 expressing strains on solid media. AU, AUA2 and WUA2 
strains were grown on different solid selective media in a dilution series. 
 
Direct proof of editing of the substrate by rADAR2 could be provided by bulk 
sequencing of RT-PCR products obtained from the URA3-editing substrate mRNA, which had 
been isolated from the yeast strain AUA2 (expressing rADAR2). There is a moderate level of 
editing visible in the absence of DOX due to the leakiness of the system but the extent of 
editing increased after induction with DOX [Fig. 4.16]. Editing levels of AUA2 strain are 
comparably lower than the ones of AHA2 which would explain the differences in growth 
between them. 
 
Fig. 4.14: Study of 5-FOA effect on URA3 expressing strains 
on liquid media. AUE, AUA2 and WUA2 strains were grown in 
different liquid selective media in 96-well microtiter plate. 
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The yeast strain AUA2 together with control strains has not been used for screening for 
inhibitors of rADAR2’s editing activity in this study. 
 
4.1.4 Additional substrates tested 
 
Besides the editing substrate derived from GluR-B Q/R site additional substrates 
were tested. For example, a shortened version of the GluR-B-derived substrate was tested 
in an attempt to interfere as little as possible with the mRNA structure and with folding and 
function of protein translated from this mRNA. However, this shortened version has not 
been a good substrate for rADAR2. Other substrates that were tested for editing in yeast 
were derived from the hepatitis delta virus type 1 amber/W site present in the antigenome 
of the virus or from the Gabra-3 I/M editing site. Also, these substrates were known to be 
edited by both ADAR enzymes (Sato, Wong et al. 2001; Ohlson, Pedersen et al. 2007). 
The hepatitis delta virus substrate was adapted from the minimal U23/D5 substrate (Sato, 
Wong et al. 2001) [Fig. 4.17]. 
 
Fig. 4.16: Comparing the editing level of the substrate expressed 
in the developed yeast strain expressing rADAR2 gene (edited 
adenosine marked with an asterisk). The AUA2 strain was grown 
on the selective liquid media without or with an addition of DOX. 
cDNA obtained via reverse transcription was amplified using 
MJ2263 and MJ2080 primers and sequenced with MJ2263 primer. 
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Fig. 4.17: RNA folding predictions of editing substrates tested in yeast system based on GluR-B R/G, 
hepatitis delta virus type 1 amber/W and Gabra-3 I/M editing sites with edited adenosine in a circle. 
Editing substrates are shown in their XhoI restriction site context. 
 
The strains were tested on liquid or solid selective media [Fig. 4.18 and Fig. 4.19]. 
None of the strains containing editable version of the substrate and expressing either 
hsADAR1 or rADAR2 seemed to be editing the substrate, which resulted in lack of 
expression of HIS3 and no growth on histidine-lacking medium. Also, the addition of DOX 
didn’t improve the growth. A possible change in editing was not investigated further than 
phenotype comparison. 
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Fig. 4.18: Growth comparison of yeast strains bearing hepatitis delta virus type 1 based substrate on 
solid media. AHEhep, AHA1hep, AHA2hep and WHA2hep strains were grown on different solid selective 
media in a dilution series. 
 
 
 
Fig. 4.19: Growth comparison of yeast strains bearing Gabra-3-
derived substrate on liquid media. AHEgab, AHA1gab, AHA2gab, 
WHA1gab and WHA2gab strains were grown in different liquid 
selective media in 96-well microtiter plate. 
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4.2 Results of mating assay 
 
To screen for activators of editing the test strain AHA2 described above was mated with strain 
Y187, expressing a human fetal brain cDNA library from a LEU2 vector. 7.4x10
6 
mated 
colonies were screened on 40mM 3-AT medium. Approximately 2x10
3
 colonies appeared on 
the selective plates. The fastest colonies (a total of 61) were picked for further analysis. 
 
4.2.1 Confirmation of yeast strains obtained in the screen 
 
To exclude false positive colonies and to confirm that expression of rADAR2 was essential 
for growth on medium lacking histidine the rADAR2 bearing vector was selectively lost from 
the strains by growth under non-selective conditions. As expected diploids that had lost the 
rADAR2 plasmid failed to grow on his
-
 plates [Fig. 4.20]. 
 
 
 
Fig. 4.20: Phenotype comparison of the strains obtained in the screen expressing or not expressing 
rADAR2. In this case a selection of 7 diploid strains with an additional diploid control was grown on 
different solid selective media for 2 days. 
 
4.2.2 Hits obtained in the screen 
 
no protein function frame 
gene 
length 
(bp) 
Coding 
repetitive 
elements 
1 
chromosome 5 
contig 
    
SINEs 
(ALU, MIR) 
2 FABP7 
transport of a hydrophobic 
ligand 
2 997 Coding none 
3 chromosome 7     none 
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contig 
4 
chromosome 15 
contig 
    
SINEs 
(ALU, MIR) 
5 short stretch      
6 RPS17L4 
small subunit ribosomal 
protein 
2 502 Coding none 
7 
chromosome 12 
contig 
    LINEs 
8 PDPR pyruvate dehydrogenase  7999 3'UTR 
SINEs 
(ALU) 
9 CAMKV kinase like protein  3028 3'UTR none 
10 STK38 serine/threonine kinase 3 3569 Coding none 
11 SSRP1 
transcriptional elongation 
factor 
2 2818 Coding none 
12 
chromosome 15 
contig 
     
13 
 
 
oncogene, transcription 
factor 
2 1511 Coding none 
14 
CytC oxidase sub 
II 
oxidase 2 684 Coding none 
15 short stretch     none 
16 
chromosome 16 
contig 
    
SINEs 
(ALU, MIR) 
17 HN1 
androgen regulated 
protein 
3 1584 Coding none 
18 no significant hits      
19 COF1 actin-modulating protein 2 1234 Coding none 
20 
CytC oxidase sub 
III 
oxidase 2 781 Coding none 
21 KAT5/HTATIP histone acetyltransferase 3 2313 Coding none 
22 DYRK2 tyrosine kinase  6159 3'UTR none 
23 WIPF2 
organisation of the actin 
cytoskeleton 
 5525 3'UTR 
SINEs 
(ALUs) 
24 
chromosome 5 
contig 
    LTR 
25 no amplification      
26 
chromosome 15 
contig 
    
SINEs 
(ALU) 
27 MARCKSL1/MRP calmodulin transduction 3 1545 Coding none 
28 RPS3 
small subunit ribosomal 
protein 
3 840 Coding none 
29 
chromosome 8 
contig 
    
SINEs 
(ALU) 
30 
chromosome 5 
contig 
    none 
31 PSMB4 proteasome protein 3 925 Coding none 
32 SOX1 
embryonic transcription 
factor 
 4108 3'UTR none 
33 IGFBP4/IPB4 
growth factor binding 
protein 
 2235 3'UTR none 
34 
chromosome 1 
contig 
    none 
35   glutathione peroxidase 2 594 Coding none 
36 
 
 
oncogene, proteasome 
protein 
3 494 Coding none 
37 no amplification      
38 chromosome 17     SINE 
NPDC1 
GPX4 
DSS1/SHFM1 
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contig (ALU) 
39 
chromosome X 
contig 
    
SINE 
(ALU) 
40 HNRNPA2B1 hnRNP 2 1714 Coding none 
41 
chromosome 13 
contig 
    
SINE (MIR) 
LINE 
42 ZBTB4 transcription regulation  5852 3'UTR none 
43 short stretch      
44 
chromosome 17 
contig 
    
SINE 
(ALU) 
45 
chromosome 1 
contig 
    LINE 
46 no hits      
47 
chromosome X 
contig 
    none 
48 DNAJB6 chaperone 3 2484 Coding none 
49 STMN2 
membrane/cytoskeleton 
interaction 
2 1814 Coding  
50 no significant hits      
51 NBPFs 
neuroblastoma breakpoint 
family proteins 
 4337 3'UTR none 
52 Q5TGE2 
ubiquitin conjugated 
enzyme 
 1880 3'UTR 
LINE, SINE 
(ALU) 
53 
chromosome 10 
contig 
    none 
54 short stretch      
55 CytB oxidase 1 1135 Coding  
56 
chromosome 20 
contig 
    
LINE, SINE 
(ALU) 
57 EEF1A1 
translation elongation 
factor 
 3510 3'UTR none 
58 no amplification      
59 
chromosome 22 
contig 
    none 
60 TCTP tumour protein 1 1127 Coding  
61 no significant hits     
SINE 
(ALU) 
 
 
 
 
 
 
 
 
 
 
 
- transcription factors 
- mitochondrial proteins 
- oncogenes 
- kinases 
- cytoskeleton associated proteins 
- proteasome associated proteins 
- ribosomal proteins 
- RNA binding proteins 
- chaperones 
- translation factors 
Fig. 4.21: A table listing sequencing 
results and a short description of genes 
from all 61 yeast strains obtained in the 
screen. The names of the proteins, their 
function, the frame, in which the cDNA 
sequence was cloned in yeast expression 
vector, and the length of the whole gene 
are listed. Also, the information if the 
query sequence aligns to the coding 
regions and the presence of the 
repetitive elements in the sequence is 
provided. 
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Out of 61 hits the plasmid DNA of 58 diploid strains from the screen were sequenced 
successfully. Of these 58 hits 4 sequences were too short to yield clear results and another 4 
sequences did not align with the human genome. The remaining 50 hits were divided into two 
major groups: i) 30 candidates aligned to annotated protein coding sequences and ii) 20 
candidates aligned to non-annotated, unresolved DNA contigs. The biggest subgroups among 
the candidates aligning to the coding sequences are as follows: transcription factors – 5 hits, 
mitochondrial proteins – 5, oncogenes – 4, kinases – 3, cytoskeleton associated proteins – 3 
and proteasome associated proteins - 3. Only three proteins were RNA binding proteins, out 
of which two are ribosomal proteins.  
 
4.2.3 Non-coding result of the screen 
 
Further investigation revealed that 10 out of 30 hits that aligned to mRNAs were located 
in the respective 3’UTRs. Moreover, 18 out of 20 candidates were not in frame with the 
upstream Gal4 activation domain of the expression plasmid. Additionally, the remaining 2 
candidates were either a mitochondrial protein sequence with a different genetic code, which 
cannot be translated in the cytoplasm or a stop codon containing 5’UTR fragment raising the 
possibility of the proteins also not being properly expressed from these sequences.  
4.2.4 Assays for selection of the best candidates 
 
To further select the best out of 61 candidate strains we wanted to compare the strains 
via growth on selective media. However, this turned out to be inconclusive as too small 
differences occurred between the strains to choose the ones that grow the fastest [Fig. 4.22]. 
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Different candidate strains were also tested on selective liquid media. In order to do that 
a diploid strain lacking ADAR2 was created for comparison. On medium containing histidine 
all strains grow with comparable velocity. As expected, diploid strains expressing both 
rADAR2 and hits showed different growth on medium without histidine. Strains containing 
hit #10 and #36 grew faster than the control strain and strain #36 grows faster than strain #10. 
The last graph shows growth on medium lacking histidine of the rADAR2 expressing strains 
normalized to empty strains [Fig. 4.23]. 
 
Fig. 4.22: Growth comparison between few diploid 
strains obtained in the screen on selective media. 
Diploid control strain and chosen candidate strains 
were grown on different solid selective media in a 
dilution series. Candidate strains show faster growth on 
SC –his-leu-trp medium than the control strain but not 
much difference between themselves. 
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Fig. 4.23: Picture of the growth curves of the three strains: diploid control strain (C) and two candidate 
strains; 10 and 36. The diploid strains expressing rADAR2 (A) and with an empty vector (E) were grown 
for over 24h in selective media selecting only for trp1and leu2 and in media selecting for his3, trp1 and 
leu2. 
 
Although growth curves in liquid media showed clear differences a more direct way to 
determine editing levels was sought. The first choice would have been a poisoned primer 
reaction (Keegan, Rosenthal et al. 2007). Several primers situated downstream of the editing 
site were tested. While clear stops were observed on in vitro transcribed RNA no products 
were obtained on total RNA. This might be due to low abundance of the HIS3 transcript 
and/or low purity of the RNA [Fig. 4.24]. 
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To assess the differences in editing levels between different candidates editing levels 
were directly compared by sequencing of the substrate site. A diploid strain carrying an empty 
cDNA library vector and expressing rADAR2 served as a negative control. Heights of 
adenosine and guanosine peaks in the electrophorograms at the editing site were measured. 
The height of the guanosine peak was divided by the combined heights of guanosine and 
adenosine peaks. The method was tested in biological replicas. This indicated quite some 
variability amongst replicas [Fig. 4.25]. However, replicas showed the same trend with little 
standard deviation [Fig. 4.26]. 
 
 
Fig. 4.24: Picture of primer extension reaction of the editing 
substrate separated on 10% polyacrylamide gel. On RNA a 
reaction with AMV Reverse Transcriptase and a radiolabeled 
primer was performed. Shown are: radiolabeled primer only, in 
vitro transcribed RNA from pUC18 HIS3amber and pUC18 HIS3w 
vectors and total RNA from liquid cultures of AHE, AHA2 and 
WHA2 strains. One can amplify shorter and longer fragments from 
in vitro transcribed RNA but not from the total RNA. 
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Fig. 4.25: Sequence comparison between RT-PCR amplification products of his3-editing substrate of 
different candidates (edited adenosine marked with an asterisk). The strains were grown in selective 
liquid media containing DOX (5µg/ml). cDNA obtained via reverse transcription was amplified using 
MJ2263 and MJ2080 primers and sequenced with MJ2263 primer. The electrophorograms are showing 
slight differences in editing between different repeats for each candidate and also that all chosen 
candidates show higher editing levels than in case of the control strain carrying empty cDNA library 
vector. 
 
 
 
The same RT-PCR procedure was applied to all isolated candidates. However, 11 could 
not be amplified and were thus not considered in this assay. Of the remaining clones, 32 
candidates showed higher editing levels than the control strain while 17 candidates even 
suggested a decrease in editing [Fig. 4.27 A]. Four candidates showed editing levels higher 
than 80-90% which corresponds to a 50% increase in editing compared to the control strain. 
About half of the candidates showed an increase of more than 14% in editing [Fig. 4.27A].  
Verification by sequencing was repeated in a second run this time including all 
candidates except candidate #22, which could not be amplified. In this round the results of 
editing are slightly different from the first round. Only 2 candidates showed lower editing 
levels than the control in this run. All but 2 candidates exceeding 14% threshold in the first 
run exceeded the it also this time [Fig. 4.27B]. While repeats of the sequencing showed some 
variation, most of candidates displaying high editing did so in both rounds of the experiment.  
% 
Fig. 4.26: Difference in editing 
levels between triplicates of few 
chosen screen candidates. The 
mean value with the standard 
deviation is shown. The graph 
shows a control strain showing 
editing activity at ~40% and 
few chosen candidates with 
editing levels exceeding it. 
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Fig. 4.27: Difference in editing levels between all screen candidates. Values are normalized to the control 
showing % of editing above or below editing level of the control, which was 43% and 36% in the first and 
the second run respectively. Both graphs show also 14% threshold and candidates exceeding it in the first 
run indicated with asterisks. 
A B 
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4.3 Confirmation in tissue culture 
 
Candidate clones leading to highest editing levels had to be verified in a mammalian 
system. Therefore, 15 best hits were cloned into a tissue culture expression vector and 
transfected in a HeLa cell line for indirect and direct assessment of their ability to enhance 
editing. 
 
4.3.1  Hits expressed in mammalian system 
 
HeLa cells express ADAR1 and ADAR2 at moderate levels leading to detectable 
editing of endogenous substrates (Rueter, Burns et al. 1995; Yang, Sklar et al. 1995). The 15 
hits were cloned and expressed from a vector containing a Myc-tag and a NLS directing the 
proteins to the nucleus [Fig. 4.28]. Candidates that were initially out of frame in the yeast 
expression vector were cloned in two versions: in the original out of frame version, and the 
corrected one allowing translation of the proper polypeptide. Non-coding candidates were 
cloned only in the original frame.  
 
# protein editing level – control [%] sequence 
1 chromosome 5 contig 18  
2 FABP7 18 coding 
10 STK38 14.5 coding 
11 SSRP1 17 coding 
21 KAT5/HTATIP 16.5 coding 
22 DYRK2 50 3’UTR 
23 WIPF2 19 3’UTR 
32 SOX1 15 3’UTR 
35 GPX4 16.5 coding 
36 DSS1/SHFM1 35 coding 
42 ZBTB4 27 3’UTR 
44 chromosome 17 contig 14.5  
48 DNAJB6 38.5 coding 
52 Q5TGE2 30.5 3’UTR 
60 TCTP 47 coding 
 
Fig. 4.28: A table listing the candidates chosen for confirmation in the tissue culture. The editing levels 
from the first run normalized to the editing level of control strain, which was 43%, are listed. Also coding 
character of the candidates is indicated. 
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Successfull expression was tested by Western Blotting. Sequences cloned out of frame  
only expressed polypeptides slightly larger than the Myc- and NLS sequence [Fig. 4.29]. 
Moreover, cytological staining of HeLa cells expressing the Myc-tagged candidates proved 
their predominant nuclear localisation. Transfection efficiency was ranging from 20 to 50% 
and varied slightly throughout the experiments [Fig. 4.29]. 
 
 
 
Fig. 4.29: Western Blotting and cytological staining of two candidates. As an example expression of 
candidates #36 and #60 are shown. Candidates were cloned out of frame and in frame and these two 
variants along with the empty vector control were transfected into HeLa cell line. Western Blotting and 
detection with an anti-Myc antibody showed proper expression of the polypeptides. Shown with staining 
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in the red channel the polypeptides are visible in the nucleus due to the presence of NLS. Scale bar: 
10µm. 
 
4.3.2 A FACS reporter system for quantification of editing levels 
 
For quantitative assessment of editing in tissue culture cells a GluR-B amber editing site 
was introduced in a vector expressing RFP and GFP separated by a short linker (Schoft, 
Schopoff et al. 2007). The editing site was a part of a stop codon. Introduction downstream of 
RFP allows constitutive expression of RFP and editing-dependent expression of GFP. The 
fluorescence has been measured by flow cytometry and in particular by fluorescence-activated 
cell sorting flow cytometer (FACS). The cells were transfected with both the editing substrate 
(RNAG) and the candidates. 
For graphic depiction, the red fluorescence was plotted on a logarithmic scaled x axis, 
while the green fluorescence was plotted on the y axis. If both proteins are expressed in equal 
amounts the readout of each single cell would lie on the diagonal of the graph. This is the case 
in a ‘pre-edited’ version of RNAG vector (RNWG). HeLa cells with moderate ADAR1 and 
ADAR2 expression readouts are placed more towards the x axis. Increased editing would shift 
the readouts towards the diagonal of the graph. Maximal editing is achieved upon 
cotransfection of hsADAR1 or rADAR2, shifting most cells to the diagonal [Fig. 4.30]. The 
same changes could also be visualized upon microscopic inspection [Fig. 4.31]. 
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Fig. 4.30: FACS graphs of editing substrate and various controls. The  untransfected control, RFP and 
GFP only expressing vectors, RNLG, the vector the system was based on, RNAG, the editing substrate 
containing vector, RNWG, the ‘pre-edited’ version of RNAG and cotransfections of RNAG with hsADAR1 
and rADAR2 expressing vectors from strong promoters as controls are shown to  confirm functionality of 
the system. 
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Fig. 4.31: Microscopic pictures showing HeLa cells transfected with vectors constructed for FACS 
analysis expressing RFP and GFP. After transfection of HeLa cells with appropriate constructs the cells 
were incubated 36-48 hours before fixing. Expression of RFP and GFP in case of RNLG and RNWG are 
at comparable levels but in case of RNAG, where expression of GFP depends on editing by ADARs, it is 
at the level visibly lower than RFP. To help in visualization of GFP expression in that case a photo of 
GFP expression made under longer exposure was added. Scale bar: 10µm. 
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4.3.3 Testing screen candidates in FACS reporter system 
 
Chosen candidates were tested three times via FACS to allow statistical evaluation. 
Since cotransfection of RNAG with the candidate vectors reduced transfection efficiency an 
empty ‘candidate’ vector was used as control. Transfection efficiencies were in the range of 
20-50%. Of all tested hits the in frame variant of hit #36 showed the most obvious difference 
in the FACS assay [Fig. 4.32]. 
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Fig. 4.32: Influence of different candidates on editing of the RNAG substrate shown via FACS assay 
immunostainings showing efficiency of transfection. After transfection cells were incubated 36-48 hours 
for immunostaining and 72h for FACS analysis. Cells transfected with hits are stained with anti-Myc and 
Alexa Fluor 568 antibodies. RNAG only, empty vector control and hits #1, #22 and #2, which had no 
visible effect on editing, and hit #36, which has a visible effect on editing, are shown. Scale bar: 10µm . 
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To evaluate the FACS results a statistical approach was applied. The area of each graph 
above the readouts from untransfected cells and excluding cells at the very top of the graph 
was divided into six equal gates [Fig. 4.33]. This way narrow pools in red fluorescence were 
compared to wide changes in green fluorescence intensity. For each cell in a gate green 
fluorescence values were divided by the red fluorescence values. The mean values of this 
calculation together with the standard deviation were plotted for each gate on the x axis of a 
two dimensional graph. This more sensitive method allowed to identify #2 and #22 as two  
additional candidates, showing only a slight increase when compared to #36 [Fig. 4.33]. 
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Fig. 4.33: Mean values of red versus green fluorescence of all candidates in six different gates. In each 
case the values of candidates are compared to the ones the control. In case of coding hits readouts 
between out of frame and in frame versions of them were compared. Additionally, one graph from FACS 
analysis with chosen gates is shown. 
 
For this study candidate #36, showing the strongest effect, was further investigated.  
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4.4 DSS1, an enhancer of RNA editing 
Candidate #36 contains a full length mRNA encoding DSS1. To confirm the indirect 
results obtained using the FACS reporter system also direct influence of this protein on 
editing substrates was investigated. Editing levels of both; RNAG and endogenous CyFip2 
editing substrates after DSS1 overexpression were studied. Additionally attempts to elucidate 
the mode of action of this enhancer were made. 
 
4.4.1 Editing of RNAG in HeLa 
 
To verify an increase of editing induced by DSS1, editing levels of the amber site in 
RNAG was investigated. RNA isolated from transfected HeLa cells was reverse transcribed 
and afterwards the editing site was amplified and sequenced. Sequencing results showed an 
increase in editing upon coexpression of DSS1 [Fig. 4.34]. 
 
 
 
Fig. 4.34: Sequence comparison of the RNAG transcript edited in HeLa cells with or without the 
expression of candidate DSS1 (edited adenosine marked with an asterisk) The cDNA obtained via reverse 
transcription was amplified using MJ1136 and MJ1137 primers and sequenced with MJ1136 primer. The 
electrophorograms show two separate repeats of editing of RNAG in HeLa cells via endogenous ADARs. 
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4.4.2 Editing of CyFip2 in the cell lines stably expressing rADAR2 
 
Since transiently transfected substrates and enhancers of editing rely on the 
cotransfection of both plasmids into the same cell the effect of DSS1 on endogenous editing 
substrates should be determined. HeLa and U2OS cell lines routinely used in our lab showed 
no detectable editing of any previously reported ADAR2 transcripts. Thus, to confirm the 
influence of DSS1 on ADAR2 activity several Hek 293 cell lines stably expressing rADAR2 
were generated in the lab (courtesy of Aamira Tariq). A number of cell lines with different 
levels of rADAR2 expression were tested on CyFip2, a known ADAR2 substrate. Of these, 
clone 6 and 11 show low editing levels while clones #5 and #10 show high levels reaching up 
to 70% of CyFIP2 editing [Fig 4.35 and Fig. 4.36]. 
 
 
 
Fig. 4.35: Comparison of editing levels of CyFip2 K/E editing site in Hek 293 cell line and few 
examplatory rADAR2 expressing strains based on Hek 293 (edited adenosine marked with an asterisk). 
 
The best choice for studying the influence of DSS1 on editing would be a cell line with 
low or moderate editing levels, for example cell lines 6 and 11. Immunostainings and FACS 
analysis indicated that low editing levels of some cell lines are caused by a variable number of 
cells lacking ADAR2 expression [Fig. 4.36]. To exclude inhomogeneous cell populations we 
decided to use the stable Hek line #10 which shows the highest editing level of CyFip2 and 
consists of a homogeneous ADAR2 expressing population [Fig. 4.36].  
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Fig. 4.36: FACS graphs of RNAG editing in Hek 293 and stably expressing rADAR2 cell lines and the 
immunostaining of these cell lines. After transfection the cells were incubated 36-48 hours for 
immunostaining and 72 for FACS analysis. The cells were stained for the presence of rADAR2 with anti-
Flag and Alexa Fluor 488 antibodies. On FACS graphs are two different populations of cells visible; one 
resembling Hek 293 and one fully edited. The first population of cells is visible in clones 6 and 11 and 
slightly in 5, but completely disappears in clone 10 in favour of the fully edited. The FACS data  
correlates nicely with the percent of cells expressing rADAR2 visible in the immunostaining. Scale bar: 
10µm . 
 
Using cell line Hek #10 the influence of DSS1 on CyFip2 editing was tested. 
Transfection of the cell line with DSS1 expressing vector was performed [Fig. 4.37]. 
 
 
 
Fig. 4.37: Transfection efficiency of DSS1 expressing vector in the Hek A2 10 stable cell line. After 
transfection the cells were incubated 36-48 hours and stained for the presence of rADAR2 with anti-Flag 
and Alexa Fluor 488 antibodies and for the presence of hits with anti-Myc and Alexa Fluor 568 
antibodies. Transfection of DSS1 in frame expressing vector is shown in comparison to untransfected 
control. Scale bar: 10µm. 
 
Sequencing of RT-PCR products of CyFip2 demonstrated a statistically significant 
increase in editing upon cotransfection of in frame DSS1, while all controls displayed the 
same editing levels. Coexpression of DSS1 resulted in an increase in editing by ~7%. 
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Cotransfecting a vector, which contained only the DSS1 ORF, lacking its untranslated regions 
and flanking vector sequences had an even stronger effect of up to 8 % on editing [Fig. 4.38]. 
 
 
 
Fig. 4.38: CyFip2 editing site sequence comparison after transfection a cell line stably expressing 
rADAR2 with different versions of DSS1 expressing vectors (edited adenosine marked with an asterisk). 
The cDNA obtained via reverse transcription was amplified using MJ1136 and MJ1137 primers and 
sequenced with MJ1136 primer. The electrophorograms show two experiments: first a comparison of out 
of frame and in frame DSS1 variant is shown and second the vector expressing only the translated part of 
DSS1 gene is shown in two repeats. 
 
4.4.3 Interactions of DSS1 
 
To elucidate the mode of action by which DSS1 affects activity of rADAR2, we tested 
whether there is a direct interaction between the two proteins. Hek A2 10 stable cell lines 
transiently expressing Myc-tagged DSS1 were used for immunoprecipitating Myc-DSS1. 
However, no coprecipiation of rADAR2 could be detected in these experiments [Fig. 4.39]. 
UV crosslinking, use of mild buffers or shortened incubation times failed to detect an 
interaction between ADAR2 and DSS1. Also using an anti Flag antibody directed against 
Flag-DSS1 failed to pull down rADAR2.  
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Fig. 4.39: IP experiment to pull down rADAR2 with Myc-tagged DSS1. The cells transfected with 
appropriate constructs were cultured for 72 hours and afterwards the extracted proteins were used for 
the IP experiment. The Western Blot was performed with anti-Myc antibody detecting hits and anti-Flag 
antibody detecting Flag-tagged rADAR2. Two Blots are shown: the input with additional Hek 293 extract 
to visualize presence of rADAR2 in stable cell lines and output blot with IP results. Although all three 
Myc-tagged polypeptides are visible after the IP, there is no sign of rADAR2 being pulled down along 
with them. 
 
4.4.4 Domain structure of DSS1 
 
To learn whether the full length DSS1 or fractions of it would be sufficient to stimulate 
editing, truncated variants of it were cloned and expressed. Since DSS1 is a small, 70aa long 
protein it was only divided into two halves of 35 amino acids each [Fig. 4.40]. DSS1 contains 
three α-helices and two β-sheets, which nicely overlap with conserved BRCA2 binding sites 
(Yang, Jeffrey et al. 2002). Division of DSS1 into two halves was performed without 
disrupting the protein’s secondary structure. Also Asp/Glu-rich regions, that could take part in 
binding were left intact. 
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Fig. 4.40: The amino acid sequence of DSS1. Shown is the whole sequence of DSS1 and how the protein 
was divided into two shorter N- and C-terminal versions of it for further experiments. Additionally, 
secondary structure of the protein is depicted as well as localization of acidic regions of it. 
 
To test the cellular localization of DSS1, the full length gene was cloned into pCDNA 
vector containing an additional NLS sequence and also into pCDNA (Invitrogen) and pCaggs 
vectors without artificial NLS (BCCM/LMBP plasmid catalogue) (Niwa, Yamamura et al. 
1991). The pCDNA vector carries a Myc-tag N-terminally and pCaggs C-terminally. Also, the 
truncated versions of DSS1 were cloned into these two vectors. The immunostaining has 
shown that DSS1 expressed from the pCDNA vector without NLS sequence still localizes 
predominantly in the nucleus. DSS1 and its truncation variants expressed from the pCaggs 
vector without NLS sequence were also mostly located in the nucleus as well, but the 
cytoplasmic signal was stronger than observed for the N-terminal Myc-tagged DSS1 [Fig. 
4.41]. This might indicate a negative influence of C-terminal Myc-tag on nuclear localization. 
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Fig. 4.41: Immunostaining of HeLa cells transfected with vectors expressing different variants of DSS1. 
The cells transfected with appropriate constructs were cultured for 72 hours and afterwards the 
immunostaining was performed with anti-Myc antibody detecting Myc-tagged DSS1 and Alexa Fluor 568 
antibody for detection. Scale bar: 10µm. 
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The same constructs were tested via FACS for their influence on RNAG editing. Firstly, 
HeLa cells expressing either full-length DSS1 or its truncated variants displayed an increase 
in editing of the RNAG substrate compared to the empty vector control. Secondly, DSS1 and 
its deletion mutants expressed from pCDNA vectors seem to have a stronger influence on 
editing than the ones expressed from pCaggs. This could relate to the reduced nuclear 
localization of C-terminal Myc-tagged DSS1. A similar explanation might hold true for the 
observed weaker effect in case of DSS1 expressed from pCDNA vector without NLS 
sequence. Independent of the vector backbone, all truncated versions of DSS1 have less 
influence on editing than the full-length protein. Of the full-length DSS1 the protein 
expressed from pCDNA with an artificial NLS enhances editing even more efficiently that the 
DSS1 in frame construct. In both cases the C-terminal fragment of DSS1 enhances editing to 
a larger extent than the N-terminal DSS1 fragment, which is nearly comparable to the empty 
vector control [Fig. 4.42]. Although the whole protein is responsible for the enhancing effect, 
it seems that the C-terminal part is more essential in this process. 
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4.4.5 Specific localization of overexpressed DSS1 
 
At the same time the localization of the overexpressed DSS1 was investigated. In 
particular we were interested in whether DSS1 localizes in a specific pattern within the 
nucleus. Indeed, overexpressed DSS1 localizes to nuclear structures while the polypeptide 
expressed from Myc-NLS construct with out-of-frame sequence of DSS1 is homogenously 
dispersed in the whole nucleus. These strongly stained structures are often observed in pairs 
and localize in the vicinity of nucleoli, but mostly do not colocalize with them [Fig.4.43]. 
 
Fig. 4.42: Mean values of the FACS 
results of all tested variants of DSS1. 
On the different graphs the following 
DSS1 variants are shown: out of frame 
and in frame versions of DSS1, full 
version of DSS1 and its truncated 
versions expressed from pCDNA 
vector with or without NLS and the 
same polypeptides expressed from 
NLS-less pCaggs vector. The effect on 
editing is higher in case of the pCDNA 
vector and the  full-length variants 
have the highest impact, followed by 
the C-terminal fragment and then N-
terminal fragment. 
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Fig. 4.43: Immunostaining of Hek A2 10 stable cell line transfected with vectors expressing DSS1 for 
localization studies. The cells transfected with appropriate constructs were cultured for 72 hours and 
afterwards the immunostaining was performed with anti-Flag antibody detecting rADAR2, anti-Myc 
antibody detecting Myc-tagged DSS1 and Alexa Fluor 488 antibody and Alexa Fluor 568 antibodies for 
detection. Scale bar: 10µm . 
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5.1 Regulators of ADAR activity 
 
Although there is a lot known how A to I editing is performed and what might regulate 
the process, the precise picture of ADARs cellular interactions holds many mysteries. Little is 
known about factors that would directly affect the editing activity of ADARs. Direct 
enhancers or inhibitors of editing are yet to be identified. 
In light of the fact that ADARs don’t need any partners to perform editing (Bass 2002; 
Nishikura 2009), this raises the question of whether there is any evidence for the existence of 
molecules interacting with and acting on ADARs? As ADARs are involved in co- and post-
transcriptional processes, this suggests that these enzymes are part of a very complex RNP 
architecture that forms on nascent transcript, which have to be edited, spliced and in the end 
exported. Recently, a direct interaction between ADAR2 and the C-terminal domain (CTD) of 
RNA polymerase II has been shown. The CTD is necessary for ADAR2 to auto-edit its 
transcript (Laurencikiene, Kallman et al. 2006). This would indicate a possible existence of 
factors influencing co-transcriptional RNA editing. A to I editing has recently become a 
factor, that might be involved in controlling important processes, like alternative splicing and 
miRNA biogenesis, the products and efficiency of them both (Higuchi, Maas et al. 2000; 
Schoft, Schopoff et al. 2007; Penn and Greger 2009). Thus, it would be only illogical to 
believe that editing itself is not controlled.  
Our hypothesis is further supported by fact, that many discrepancies between the 
expression levels of ADARs and the editing levels of main substrates, already mentioned 
earlier in this work, have been reported. Although one still cannot sufficiently explain these 
findings, few plausible theories exist. One of the explanation may lay in developmental- and 
tissue-specific expression of the various isoforms and splice variants of ADARs, that possess 
different editing efficiency and substrate specificity. Another explanation may be still highly 
controversial possibility of ADARs to homo- and heterodimerise. Again, different ADAR 
proteins, including ADAR3, could influence their activity by interacting with each other. 
Although both the existence of various splice variants and dimerisation of ADARs may 
even cover all explanations for all discrepancies in ADAR expression and activity, it is hardly 
believable that there are no factors that could affect the enzymatic activity of ADARs in a 
direct or indirect manner. With that in mind we designed and performed a screen in search for 
endogenous molecules that might enhance editing of ADARs. Until now only two attempts to 
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perform similar screens were reported. First, the Peter A. Beal laboratory performed a screen 
in yeast, employing the same principle, as in ours: the editing site is part of a stop codon 
located in front of a reporter gene, in their case a β-galactosidase. This system was used for 
high-throughput screening for mutations in ADAR2 and the substrate that support editing 
(Pokharel and Beal 2006). The laboratory of Stefan Maas has set up a luciferase tissue culture 
assay based on a comparable principle as well (Gommans, McCane et al.). Up to now 
molecules interacting with ADAR have not been reported. 
 
5.2 rADAR2 efficiently edits in yeast system 
 
The basic yeast strain used in the screen was a mutant strain, in which an auxotrophy 
gene, preceded by an editing site, was expressed as a marker. It was based on the idea that 
editing of an adenosine, which was a part of a stop codon, would allow this gene to be 
expressed and therefore let this strain to grow on selective medium. The advantage of using 
yeast for our screen over a mammalian system was a rather quick and inexpensive way to 
screen millions of genes in various cDNA libraries. The possibility of having such a library 
pretransformed in a opposite mating type yeast strain also helped to get rid of tiresome 
transformation efficiency problems that one faces when working with mammalian cells. 
Additional convenience of this model system was the absence of endogenous ADAR 
homologues, which helped to avoid possible redundancy. Each of this advantage had 
unfortunately its dark side. Using Saccharomyces cerevisiae as a model would help to quickly 
screen a high number of genes, but these genes had to be later confirmed in the mammalian 
system to avoid yeast-borne false positives. Also, the absence of ADAR meant a possible 
absence of other molecules interacting with them posing a threat, that even a true ADAR 
interactor, expressed in this screen, could remain undetectable. Despite all these drawbacks 
and knowing that no system is perfect and able to detect everything, we decided to proceed. 
The editing screen was based on a common two-hybrid mating assay screen. The goal 
was to adapt it in purpose to detect differences in editing via increase in growth rate of the 
prepared editing yeast strain. This aspect already turned out to be difficult showing  
discrepancies in growth rates between obtained yeast, which were sometimes hard to explain. 
One had to learn to cope with contamination, differences in growth rate depending on age of 
the plates the single colonies were picked from or growth conditions, which all would have an 
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impact on editing levels. Even transforming the W303 yeast strain with two different 
constructs (HIS3amber or URA3amber), which were integrated into its genome, repeatedly 
resulted in strains of a different growth rate. The strain carrying URA3amber was always the 
one growing faster and after rADAR2 transformation this strain accumulated inosines slower 
[Fig. 4.9, 4.10, 4.13 and 4.16]. This could be the result of a faster synthesis of Ura3 or of a 
less structured mRNA this gene. In brief, the yeast metabolism is still quite complex and with 
a screen based on most basic and essential functions like cell growth and proliferation, these 
kind of problems may not be trivial. One had to understand that some of the screen results 
may be false positives, since there would be a heavy pressure on the cell to promote the cells 
boosting up cell cycle and counteracting the selection. Additionally, because the screen was 
not based on protein-protein interaction, there was no fail-safe control ensuring that all 
positives are the result of such an interaction. 
Out of three substrates, which were based on the GluR-B R/G, Gabra-3 I/M and 
hepatitis delta type 1 amber/W sites, only the first one was edited in yeast. These substrates 
have been chosen because all of them were proven to be edited by both ADAR1 and ADAR2 
(Sato, Wong et al. 2001; Wong, Sato et al. 2001; Ohlson, Pedersen et al. 2007). There are 
numerous reasons that might explain for the lack of editing of the other substrates. It is 
possible that a yeast cell presenting still a good environment for GluR-B R/G editing wasn’t 
so favorable for others. On the other hand, it is also possible the mRNA molecules weren’t in 
fact folding in vivo according to the predictions made in silico. Also, additional cofactors 
might be needed for these substrates. Lastly, an undesired signal for NMD might have been 
created. A definitive answer cannot be provided, since these substrates were not investigated 
further. Additionally, a shortened version of GluR-B R/G based substrate was prepared. This 
substrate was not edited, which is in line with the later finding that each part of GluR-B R/G 
stem-loop structure is necessary for proper ADAR2 binding, since both dsRBDs of ADAR2 
bind to its distinctly different motifs (Stefl, Xu et al. 2006). This might also be the case for 
ADAR1.  
In this investigation attempts to use both ADAR1 and ADAR2 were made. As more or 
less expected, it was only possible to succeed in case of ADAR2. It is known in A to I editing 
field that ADAR1 is the one of these two causing the most problems. ADAR1 is the much 
larger and more complex protein. All crystalographical studies were made on ADAR2 for a 
reason (Macbeth, Schubert et al. 2005; Stefl, Xu et al. 2006). Also, large-scale expression of 
ADAR1 has proven to be difficult. Only low yield ADAR1 expression from Pichia pastoris 
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and only of ADAR2 from Saccharomyces cerevisiae were reported (Keegan, Rosenthal et al. 
2007; Macbeth and Bass 2007). Also, another yeast screen based on the similar principle was 
performed also only with human ADAR2 (Pokharel and Beal 2006). In this case the 
expression of hsADAR1 seemed to be successful judging from the presence of hsADAR1 
mRNA and Western Blot detection, although it wasn’t as strong as in case of expressed 
rADAR2 [Fig. 4.4 and Fig. 4.5]. Also, functional protein was expressed from the original 
vector encoding hsADAR1 and edited a GluR-B R/G-derived substrate in tissue culture 
experiments [Fig. 4.30]. This could only suggest that either the hsADAR1 expressed in 
Saccharomyces was inactive, not in sufficient amount, or the yeast cellular environment 
wasn’t the right one for proper editing. 
The expression system used for rADAR2 expression was a tetracycline inducible one. 
For the purpose of the screen, which is the identification of enhancers of ADAR editing 
activity, a low basal ADAR expression was essential. This was achieved by a controlled DOX 
induction of rADAR expression. To my surprise, a very tight system in mammalian cells has 
proven to be leaky in yeast. The levels of the leakiness were above acceptable ones, as growth 
and editing levels of uninduced and induced yeast cultures were comparable. Unfortunately, 
all attempts to reduce the leaky expression, such as reducing the number of TetO boxes and 
coexpression of a repressor, were unsuccessful. To increase the stringency of the screen, it 
was performed in presence of 3-amino-1,2,4-triazole (3-AT), a competitive inhibitor of the 
product of the HIS3 gene. In order to achieve a better control over ADAR expression in the 
future, a different expression system would have to be employed. 
 
5.3 The screen gives rise to enhancers of rADAR2 activity 
 
For the screen a yeast strain already pretransformed with human fetal brain cDNA 
library was used. This kind of library was used knowing that ADARs are predominantly 
expressed in the CNS. The performed screen has covered 3.33x10
6
 clones of the cDNA 
library, which was roughly the amount of the clones in the library. Since the manufacturer 
suggested to double the number of library clones, this result could prevent the screen from 
efficiently covering of the whole library. In the end 61 clones, which were showing the 
highest growth rate, were retrieved. All these clones were still expressing His3 and rADAR2 
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and removal of rADAR2 bearing vector caused lack of growth on histidine deficient medium. 
All this indicated that the system went through the mating procedure successfully. 
Sequencing of the candidates has brought many surprises. Firstly, among the candidates, 
there were no striking candidates, that would immediately fit in one ADAR regulation theory. 
Also, the fact that none of the hits was enriched, was discouraging. An explanation for this 
observation could be the lack of proper cDNA library coverage. In this case only part of the 
genome that is expressed in the human brain would be covered and many of maybe essential 
genes would be missed in the process. Also, duplicates of genes having an effect on editing 
would be rarer. One should also not underestimate the bias created by using GluR-B R/G-
derived editing substrate and expression of rADAR2. Although ADARs are able to edit this 
site by themselves, purely hypothetically, some of the factors affecting ADAR activity might 
be also site-specific, discriminating against those that cannot bind the site. Also, many 
binding studies were made on ADAR1 and may not apply to the obtained rADAR2 results. 
The second surprise was an abundance of 3’UTR fragments and not annotable 
sequences among obtained candidates. Also, coding sequences were found to be expressed 
from the yeast vector out of the coding frame. This situation shouldn’t be a surprise 
concerning the way this Matchmaker cDNA library was cloned, by random, not reading frame 
dependent, amplification. It would still leave 1/3 of the clones that should be expressed in 
frame, but this was not the case. A possible explanation would be that many human proteins 
lack a yeast ortholog and might thus act in a destabilizing, toxic way on the yeast metabolism 
and decrease the ‘in frame’ pool to a minimum. This still doesn’t answer the question why 
these candidates emerged from the screen and what made them grow faster. It may be 
possible that the screen failed, but several other explanations exist as well. For example, the 
RNA component, mRNA and hidden repetitive element in it, may be responsible for the 
increase in editing and therefore in yeast growth. Overexpression of another binding platform 
for rADAR2 could have been a reason for concentrating the protein and rendering the editing 
process more efficient. Alternatively, the proteins are in fact still expressed correctly. 
However, most of the expressed genes were found to be out of frame, there are processes in 
eukaryotic organisms that allow the expression of a protein not from the first start codon. One 
of these processes is reinitiation, where translation starts at a start codon downstream of the 
preliminary stop codon. Although these processes are not common in higher eukaryotes, yeast 
is known to allow more flexibility in protein expression (Kozak 1999). Also, experience 
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gathered in our laboratory led us to think that this may be happening. Perhaps a low 
expression of the protein was needed to enhance editing. 
In order to confirm results on editing level, a comparison of editing of HIS3amber 
fragment via bulk sequencing was performed. This method was chosen over single clone 
sequence comparison due to less time invested in it. A more time- and work-consuming 
method wouldn’t be applicable with this amount of candidates. A big drawback of bulk 
sequencing emerged while performing it: the obtained results varied significantly for the same 
candidate. Although initially few independent repeats of the same clone have shown a 
relatively high standard deviation, the overall trend did however not change for the individual 
candidates. Afterwards the editing level for all candidates was measured twice, showing two 
different results in many cases. It has only shown that bulk sequencing, which may be a great 
method to study editing levels in tissues, may not be the perfect one for the yeast, the 
metabolism of which is less stable and highly depends on given conditions. In the end, the 
bulk sequencing runs of all candidates confirmed that the screen was a success. Most of the 
candidates displayed elevated editing levels and indicating a few candidates that should be 
further characterized in mammalian tissue culture. 
 
5.4 DSS1 is an enhancer of A to I editing 
 
The chosen candidates were confirmed to enhance editing activity of ADAR in 
mammalian system as well. A red and green fluorescent protein with GluR-B R/G-derived 
editing site in between was utilised and measured via FACS. This method was used to obtain 
statistical data about the influence of chosen candidates on editing in a very fast way. 
Although the FACS reporter system has proven to be a nice tool to distinguish between 
candidates influencing editing, a few drawbacks of this method have emerged. Firstly, it was 
highly dependent on transfection efficiency, and even with stable transfection rate of 30-50% 
many candidates could have been lost in this way. Transfection rate of DSS1 expressing 
vector below 20-30% equalled mostly no detectible difference of editing level in bulk 
sequencing. [data not shown] Also, the discrepancy between the FACS results and bulk 
sequencing data had to be taken into consideration. The enhancement of editing was better 
visible in case of FACS graphs than in case of bulk sequencing of RNAG construct or CyFip2 
mRNA. In case of DSS1 an increase in relative fluorescence ranging from 20% up to 100% 
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depending on a gate was measured, while only a 5-8% increase in bulk sequencing of RNAG 
mRNA was detected [Fig. 4.33 and 4.34]. Also, as for Hek 293 stably expressing rADAR2 
clone #10 nearly all cells were found on the diagonal axis of the FACS plot suggesting 
complete editing of the substrate, but only 66% editing of CyFip2 K/E editing site was 
determined by sequencing [Fig. 4.35 and 4.36]. The lack of a precise correlation between 
these two experimental strategies may be due to a different pool of cells taking part in both 
experiments or less copies of GFP needed to saturate the FACS system. Also in case of 
RNAG and CyFip2 substrates one has to take into consideration the differences in editing 
between them and possible role of ADAR1 in HeLa-based FACS system, that does not edit 
CyFip2 site. These results show that both methods are not fully proportional and candidates 
that show lower effect in FACS reporter system would not be detected by bulk sequencing of 
CyFip2 K/E editing site. 
As a result only one strong candidate, DSS1, emerged and was studied further. 
Additional two possible ones; FABP7, a transport protein and 3’UTR of DYRK2, a tyrosine 
kinase, presented a lot lower effect but may still be interested to investigate in the future. One 
out of fifteen surprises at first glance but it was expected that some of the candidates from 
yeast screens are indeed artefacts and have no influence on editing. Additionally, from the 
reasons mentioned above some of the candidates may be true enhancers of editing, but these 
weren’t detected in the mammalian system due to the low sensitivity of FACS reporter 
system. Moreover, even if they were showing lower enhancement in editing, bulk sequencing 
wouldn’t detect it most probably, considering the data obtained for DSS1. A way to improve 
the sensitivity of FACS system would be increasing the transfection efficiency by using a 
more efficient method. Applying such a solution could help in testing candidates, that have 
shown a lesser effect. 
Studying DSS1 in a mammalian system directly confirmed that DSS1 enhances editing 
by rADAR2. Comparing the editing levels of the RNAG and CyFip2 substrates has shown 
that DSS1 increases editing of both substrates by rADAR [Fig. 4.34 and 4.38]. Since the 
studies concentrated on stable expression of rADAR2 to prove the influence of DSS1 on the 
protein activity, one cannot say much about the possible influence of ADAR1, which could 
also contribute in FACS results. Additionally, different DSS1 variants were analyzed for their 
cellular localization and their ability to enhance editing, enabling us to gain a few interesting 
insights. Although DSS1 is a very small protein, the editing enhancing function of it seems to 
be localized at its C-terminus, as the C-terminal fragment showed a notable enhancement of 
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editing [Fig. 4.41]. Also, nuclear localization of the protein seems to be important. 
Overexpressed DSS1 localizes to nuclear structures, which don’t colocalize with nucleoli 
where most of ADAR2 resides, but stay in their vicinity [Fig. 4.43]. This observation could 
already suggest that both these proteins do not form any physical contact although it doesn’t 
discriminate this possibility considering the pool of both proteins present in the rest of the 
nucleus. 
The question that still remains open is the role that DSS1 plays in RNA editing. It’s not 
easy to answer, since DSS1 is an abundant protein taking part in many cellular processes, but 
one can speculate. DSS1 is a very small, acidic and aromatic in content protein, and is 
therefore predicted to rather bind as a cofactor to other proteins than to RNA. Although one 
cannot discard the thought of DSS1 binding next to editing site and recruiting ADAR, it 
would be more likely to believe that it binds to ADAR changing its properities, like it was 
shown in case of BRCA2, where DSS1 facilitates ssDNA binding affinity of the protein 
(Yang, Jeffrey et al. 2002). Unfortunately, the lack of success in proving a direct interaction 
between DSS1 and rADAR2 disproves this theory [Fig. 4.39]. It’s possible that DSS1 binds 
in a weak manner or, what is more likely, affects editing via binding to another protein 
interacting with ADAR/RNA or affecting yet another process controlling A to I editing. 
At first sight from all reports about DSS1 function, the less likely fitting our scenario is 
about DSS1 being a part of 26S proteasome particle, where it regulates the proteasome 
interactions and utilizes a specific subset of poly-ubiquittinated p53 protein as a substrate 
(Coux, Tanaka et al. 1996; Funakoshi, Li et al. 2004; Krogan, Lam et al. 2004; Sone, Saeki et 
al. 2004; Gudmundsdottir, Lord et al. 2007; Wei, Williams et al. 2008). Although one could 
imagine an inhibitor of RNA editing, the proteolysis of which would be promoted by DSS1, 
like in case of p53. This theory, however, is still far-fetched and hard to prove or disprove 
without knowing such an inhibitor. 
More promising are reports from fission yeast, where the homologue of DSS1, Sem-1, 
was shown to be involved in splicing and in TREX-2 mRNA export pathway, which is 
already closer to what we know about ADARs (Thakurta, Gopal et al. 2005; Mannen, Andoh 
et al. 2008; Wilmes, Bergkessel et al. 2008; Faza, Kemmler et al. 2009). Since ADARs are a 
part of mRNP, intertwined in splicing and transport of mRNA, one could postulate a theory 
connecting both proteins. Maybe DSS1 is an essential factor needed for proper architecture of 
mRNP and therefore helping ADAR to take its proper place on mRNA particle and perform 
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its task. On the other hand the lack of DSS1 may also inhibit export of mRNA and lead 
export-impaired mRNPs for destruction. 
Also reports from Caenorhabditis are promising. Quite a severe phenotype of dss-1 
knock out was very similar to phenotype of kgb-1 mutant worms. The kgb-1 knockout leads to 
increased levels of the GLH-1 RNA helicase. In dss-1 mutants GLH-1 levels were normal, but 
there is a chance that a similar protein to GLH-1 is also regulated by DSS-1 (Orsborn, Li et al. 
2007; Pispa, Palmen et al. 2008). It would be possible that this helicase unwinds A to I editing 
substrates, thereby inhibiting editing. Surprisingly, that brings us again to proteasome with 
DSS-1 and KGB-1, both being a part of it. Therefore, DSS-1 at the proteasome could indeed 
control abundance of this hypothetical helicase that acts as a inhibitor of ADARs. 
Although it was shown in this study, that DSS1 is enhancing rADAR2 activity a mode 
of action of this process remains yet to be uncovered. 
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